CA3130405A1 - Compounds for treating and preventing net associated complications - Google Patents
Compounds for treating and preventing net associated complications Download PDFInfo
- Publication number
- CA3130405A1 CA3130405A1 CA3130405A CA3130405A CA3130405A1 CA 3130405 A1 CA3130405 A1 CA 3130405A1 CA 3130405 A CA3130405 A CA 3130405A CA 3130405 A CA3130405 A CA 3130405A CA 3130405 A1 CA3130405 A1 CA 3130405A1
- Authority
- CA
- Canada
- Prior art keywords
- sepsis
- subject
- iri
- sirs
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 232
- 238000000034 method Methods 0.000 claims abstract description 141
- 206010040047 Sepsis Diseases 0.000 claims abstract description 136
- 150000003839 salts Chemical class 0.000 claims abstract description 66
- 230000001404 mediated effect Effects 0.000 claims abstract description 60
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 55
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims description 119
- 125000001424 substituent group Chemical group 0.000 claims description 116
- 239000000203 mixture Substances 0.000 claims description 112
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 91
- 201000010099 disease Diseases 0.000 claims description 79
- 230000001225 therapeutic effect Effects 0.000 claims description 53
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 44
- 239000013543 active substance Substances 0.000 claims description 42
- 230000001472 cytotoxic effect Effects 0.000 claims description 42
- 208000014674 injury Diseases 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 41
- 239000011734 sodium Substances 0.000 claims description 40
- 230000007170 pathology Effects 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 230000006378 damage Effects 0.000 claims description 38
- 208000015181 infectious disease Diseases 0.000 claims description 37
- 206010061218 Inflammation Diseases 0.000 claims description 31
- 230000004054 inflammatory process Effects 0.000 claims description 31
- 210000001519 tissue Anatomy 0.000 claims description 29
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 24
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 24
- 230000008733 trauma Effects 0.000 claims description 24
- 230000015271 coagulation Effects 0.000 claims description 20
- 238000005345 coagulation Methods 0.000 claims description 20
- 206010012601 diabetes mellitus Diseases 0.000 claims description 18
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 17
- 238000001356 surgical procedure Methods 0.000 claims description 17
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 16
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 239000003429 antifungal agent Substances 0.000 claims description 15
- 229940121375 antifungal agent Drugs 0.000 claims description 15
- 230000002458 infectious effect Effects 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 15
- 206010033645 Pancreatitis Diseases 0.000 claims description 14
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 14
- 239000003443 antiviral agent Substances 0.000 claims description 14
- 208000023275 Autoimmune disease Diseases 0.000 claims description 13
- 206010016654 Fibrosis Diseases 0.000 claims description 13
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 13
- 201000003229 acute pancreatitis Diseases 0.000 claims description 13
- 231100000433 cytotoxic Toxicity 0.000 claims description 13
- 230000004761 fibrosis Effects 0.000 claims description 13
- 208000037816 tissue injury Diseases 0.000 claims description 13
- 208000032843 Hemorrhage Diseases 0.000 claims description 12
- 208000007536 Thrombosis Diseases 0.000 claims description 12
- 208000007502 anemia Diseases 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 12
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 11
- 206010047249 Venous thrombosis Diseases 0.000 claims description 11
- 208000015114 central nervous system disease Diseases 0.000 claims description 11
- 208000027866 inflammatory disease Diseases 0.000 claims description 11
- 210000003038 endothelium Anatomy 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 8
- 206010021143 Hypoxia Diseases 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 230000008694 endothelial dysfunction Effects 0.000 claims description 7
- 230000007954 hypoxia Effects 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 230000000747 cardiac effect Effects 0.000 claims description 5
- 230000023597 hemostasis Effects 0.000 claims description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 230000008718 systemic inflammatory response Effects 0.000 claims description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 206010003253 Arthritis enteropathic Diseases 0.000 claims description 4
- 206010003267 Arthritis reactive Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 208000033626 Renal failure acute Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 201000011040 acute kidney failure Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 210000001367 artery Anatomy 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 230000028709 inflammatory response Effects 0.000 claims description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000002574 reactive arthritis Diseases 0.000 claims description 4
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 4
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 3
- 206010003274 Arthritis viral Diseases 0.000 claims description 3
- 206010007617 Cardio-respiratory arrest Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010013647 Drowning Diseases 0.000 claims description 3
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 3
- 102000029797 Prion Human genes 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 208000034713 Spontaneous Rupture Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 3
- 230000001086 cytosolic effect Effects 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 206010063344 microscopic polyangiitis Diseases 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 230000000472 traumatic effect Effects 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 abstract description 59
- 208000012947 ischemia reperfusion injury Diseases 0.000 abstract description 49
- 239000000126 substance Substances 0.000 abstract description 41
- 238000002560 therapeutic procedure Methods 0.000 abstract description 25
- 230000009885 systemic effect Effects 0.000 abstract description 10
- 230000001575 pathological effect Effects 0.000 abstract description 6
- 208000011580 syndromic disease Diseases 0.000 abstract description 5
- 230000028993 immune response Effects 0.000 abstract description 4
- 108010033040 Histones Proteins 0.000 description 109
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 85
- 229920000447 polyanionic polymer Polymers 0.000 description 66
- 235000002639 sodium chloride Nutrition 0.000 description 65
- 102000006947 Histones Human genes 0.000 description 59
- 210000003743 erythrocyte Anatomy 0.000 description 47
- 239000008280 blood Substances 0.000 description 42
- 210000004369 blood Anatomy 0.000 description 41
- 239000003795 chemical substances by application Substances 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 29
- 159000000000 sodium salts Chemical class 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 208000027418 Wounds and injury Diseases 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 241000282414 Homo sapiens Species 0.000 description 21
- 238000002821 scintillation proximity assay Methods 0.000 description 21
- 241000700159 Rattus Species 0.000 description 19
- -1 citric Chemical class 0.000 description 19
- 231100000331 toxic Toxicity 0.000 description 18
- 230000002588 toxic effect Effects 0.000 description 18
- 238000002203 pretreatment Methods 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 230000003013 cytotoxicity Effects 0.000 description 15
- 231100000135 cytotoxicity Toxicity 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 14
- 230000002776 aggregation Effects 0.000 description 14
- 238000004220 aggregation Methods 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 230000010410 reperfusion Effects 0.000 description 14
- 230000001988 toxicity Effects 0.000 description 14
- 231100000419 toxicity Toxicity 0.000 description 14
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 12
- 239000000232 Lipid Bilayer Substances 0.000 description 12
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 11
- 230000003115 biocidal effect Effects 0.000 description 11
- 229910001424 calcium ion Inorganic materials 0.000 description 11
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 11
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 208000028867 ischemia Diseases 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 229960003105 metformin Drugs 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000029663 wound healing Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 8
- 230000001363 autoimmune Effects 0.000 description 8
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 206010040070 Septic Shock Diseases 0.000 description 6
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000001028 anti-proliverative effect Effects 0.000 description 6
- 230000003185 calcium uptake Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000005240 left ventricle Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 6
- 238000011275 oncology therapy Methods 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000036303 septic shock Effects 0.000 description 6
- 210000001631 vena cava inferior Anatomy 0.000 description 6
- 241000416162 Astragalus gummifer Species 0.000 description 5
- 108010077544 Chromatin Proteins 0.000 description 5
- 208000001953 Hypotension Diseases 0.000 description 5
- 235000019483 Peanut oil Nutrition 0.000 description 5
- 229920001615 Tragacanth Polymers 0.000 description 5
- 208000007587 Transfusion-Related Acute Lung Injury Diseases 0.000 description 5
- 230000003466 anti-cipated effect Effects 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 210000003483 chromatin Anatomy 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000004768 organ dysfunction Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000312 peanut oil Substances 0.000 description 5
- 229960005095 pioglitazone Drugs 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 206010043089 tachypnoea Diseases 0.000 description 5
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 4
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 208000010718 Multiple Organ Failure Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 4
- 102000014813 Ryanodine receptor 1 Human genes 0.000 description 4
- 235000019485 Safflower oil Nutrition 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 229940123464 Thiazolidinedione Drugs 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229960004580 glibenclamide Drugs 0.000 description 4
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 230000000266 injurious effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 235000005713 safflower oil Nutrition 0.000 description 4
- 239000003813 safflower oil Substances 0.000 description 4
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 4
- 108010033693 saxagliptin Proteins 0.000 description 4
- 235000011803 sesame oil Nutrition 0.000 description 4
- 239000008159 sesame oil Substances 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 150000001467 thiazolidinediones Chemical class 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 231100000827 tissue damage Toxicity 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- 235000006491 Acacia senegal Nutrition 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 3
- 206010053159 Organ failure Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010093894 Xanthine oxidase Proteins 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 239000002385 cottonseed oil Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229960004346 glimepiride Drugs 0.000 description 3
- 229960001381 glipizide Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000011201 multiple comparisons test Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 210000004738 parenchymal cell Anatomy 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000018127 platelet degranulation Effects 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229960002354 repaglinide Drugs 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960004937 saxagliptin Drugs 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 229960004034 sitagliptin Drugs 0.000 description 3
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 206010006802 Burns second degree Diseases 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 229920002905 Colesevelam Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102100022317 Dihydropteridine reductase Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010051814 Eschar Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 206010023424 Kidney infection Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 108010028275 Leukocyte Elastase Proteins 0.000 description 2
- 102000016799 Leukocyte elastase Human genes 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010027417 Metabolic acidosis Diseases 0.000 description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 102000003896 Myeloperoxidases Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 108010047956 Nucleosomes Proteins 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 101710088929 Voltage-dependent L-type calcium channel subunit alpha-1S Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- CAWBRCOBJNWRLK-UHFFFAOYSA-N acetyloxymethyl 2-[4-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-3-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-5-methylphenoxy]ethoxy]phenyl]-1h-indole-6-carboxylate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C=2NC3=CC(=CC=C3C=2)C(=O)OCOC(C)=O)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O CAWBRCOBJNWRLK-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940124446 critical care medicine Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 231100000333 eschar Toxicity 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 229940093476 ethylene glycol Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002338 glycosides Chemical group 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 208000037806 kidney injury Diseases 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 229960002397 linagliptin Drugs 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229950004994 meglitinide Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 210000001623 nucleosome Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000036581 peripheral resistance Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 229920000155 polyglutamine Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- OLTAWOVKGWWERU-UHFFFAOYSA-N proxazole Chemical compound C=1C=CC=CC=1C(CC)C1=NOC(CCN(CC)CC)=N1 OLTAWOVKGWWERU-UHFFFAOYSA-N 0.000 description 2
- 229960001801 proxazole Drugs 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 229960003676 tenidap Drugs 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- RJNRORZRFGUAKL-ADMBVFOFSA-N (1r)-1-[(3ar,5r,6s,6ar)-6-[3-(dimethylamino)propoxy]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol;hydrochloride Chemical compound Cl.O1C(C)(C)O[C@@H]2[C@@H](OCCCN(C)C)[C@@H]([C@H](O)CO)O[C@@H]21 RJNRORZRFGUAKL-ADMBVFOFSA-N 0.000 description 1
- QUKZWYNGKYRRKE-RIKNOMPASA-N (1r,3r)-2-[(2r)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile;3-(diaminomethylidene)-1,1-dimethylguanidine Chemical compound CN(C)C(=N)N=C(N)N.C1C(C2)CC(C3)CC2(O)CC13[C@@H](N)C(=O)N1[C@@H](C#N)CC2C[C@H]21 QUKZWYNGKYRRKE-RIKNOMPASA-N 0.000 description 1
- OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- VYPKEODFNOEZGS-VIFPVBQESA-N (2r)-2-acetamido-3-(2-hydroxybenzoyl)sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)C1=CC=CC=C1O VYPKEODFNOEZGS-VIFPVBQESA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- AUDFHJLSHQWFQQ-SFHVURJKSA-N (2s)-2-[[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]amino]-3-hydroxypropanoic acid Chemical compound CC1=C(CC(=O)N[C@@H](CO)C(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 AUDFHJLSHQWFQQ-SFHVURJKSA-N 0.000 description 1
- XYRIRLDHOQSNLW-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound CC1=C(CC(=O)OC2C3=CC=CC=C3C(=O)O2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 XYRIRLDHOQSNLW-UHFFFAOYSA-N 0.000 description 1
- SHCYQUDTKWHARF-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1C2=CC=CC=C2C(=O)O1 SHCYQUDTKWHARF-UHFFFAOYSA-N 0.000 description 1
- GQPYTJVDPQTBQC-KLQYNRQASA-N (3r)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F GQPYTJVDPQTBQC-KLQYNRQASA-N 0.000 description 1
- ZDHHGGFQZRPUSN-UHFFFAOYSA-N (4-chlorophenyl)-[3-(2h-tetrazol-5-ylmethyl)indol-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C2=CC=CC=C2C(CC2=NNN=N2)=C1 ZDHHGGFQZRPUSN-UHFFFAOYSA-N 0.000 description 1
- PPQZABOURJVKNI-UHFFFAOYSA-N (4-fluorophenyl)-[4-(4-fluorophenyl)-4-hydroxy-1-methylpiperidin-3-yl]methanone Chemical compound C1N(C)CCC(O)(C=2C=CC(F)=CC=2)C1C(=O)C1=CC=C(F)C=C1 PPQZABOURJVKNI-UHFFFAOYSA-N 0.000 description 1
- JFTOCKFCHJCDDX-UVTDQMKNSA-N (4z)-4-benzylidene-5,6,7,8-tetrahydroisoquinoline-1,3-dione Chemical compound C1CCCC2=C1C(=O)NC(=O)\C2=C/C1=CC=CC=C1 JFTOCKFCHJCDDX-UVTDQMKNSA-N 0.000 description 1
- VDNZZIYSCXESNI-ILSZZQPISA-N (6s,8s,9s,10r,11s,13s,14s,17s)-17-acetyl-11-hydroxy-6,10,13-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 VDNZZIYSCXESNI-ILSZZQPISA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- ZHXUEUKVDMWSKV-UHFFFAOYSA-N 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one Chemical compound CC(C)(C)C1=CC(C(=O)CCCC#C)=CC(C(C)(C)C)=C1O ZHXUEUKVDMWSKV-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- YETULFFXNIHQLK-UHFFFAOYSA-N 1-ethynyl-4-(2-fluorophenyl)benzene Chemical compound FC1=CC=CC=C1C1=CC=C(C#C)C=C1 YETULFFXNIHQLK-UHFFFAOYSA-N 0.000 description 1
- ULIDRMKBVYYVIQ-UHFFFAOYSA-N 1-phenyltetrazol-5-amine Chemical compound NC1=NN=NN1C1=CC=CC=C1 ULIDRMKBVYYVIQ-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- SRETXDDCKMOQNE-UHFFFAOYSA-N 2,3-bis(4-methoxyphenyl)-1h-indole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)C2=CC=CC=C2N1 SRETXDDCKMOQNE-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- IZGMROSLQHXRDZ-UHFFFAOYSA-N 2-(1-propyl-4,9-dihydro-3h-pyrano[3,4-b]indol-1-yl)acetic acid Chemical compound N1C2=CC=CC=C2C2=C1C(CCC)(CC(O)=O)OCC2 IZGMROSLQHXRDZ-UHFFFAOYSA-N 0.000 description 1
- KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 description 1
- ODZUWQAFWMLWCF-UHFFFAOYSA-N 2-(3-phenyl-1-benzofuran-7-yl)propanoic acid Chemical compound C=1OC=2C(C(C(O)=O)C)=CC=CC=2C=1C1=CC=CC=C1 ODZUWQAFWMLWCF-UHFFFAOYSA-N 0.000 description 1
- LRXFKKPEBXIPMW-UHFFFAOYSA-N 2-(9h-fluoren-2-yl)propanoic acid Chemical compound C1=CC=C2C3=CC=C(C(C(O)=O)C)C=C3CC2=C1 LRXFKKPEBXIPMW-UHFFFAOYSA-N 0.000 description 1
- DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 1
- IDCAZKFFVIMCCS-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)-4-imino-2-oxoimidazolidin-1-yl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1N1C(=O)N(CC#N)CC1=N IDCAZKFFVIMCCS-UHFFFAOYSA-N 0.000 description 1
- ANMLJLFWUCQGKZ-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]-3-pyridinecarboxylic acid (3-oxo-1H-isobenzofuran-1-yl) ester Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OC2C3=CC=CC=C3C(=O)O2)=C1 ANMLJLFWUCQGKZ-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- NLGUJWNOGYWZBI-UHFFFAOYSA-N 2-[3-chloro-4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 NLGUJWNOGYWZBI-UHFFFAOYSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- QKKLKGVIECOSRM-CODXZCKSSA-N 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol;4-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 QKKLKGVIECOSRM-CODXZCKSSA-N 0.000 description 1
- LNXXSBRGLBOASF-UHFFFAOYSA-N 2-[[2-(4-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methoxy]-2-methylpropanoic acid Chemical compound O1C(COC(C)(C)C(O)=O)=C(C)N=C1C1=CC=C(Cl)C=C1 LNXXSBRGLBOASF-UHFFFAOYSA-N 0.000 description 1
- GXEUNRBWEAIPCN-UHFFFAOYSA-N 2-chloro-2-(3-chloro-4-cyclohexylphenyl)acetic acid Chemical compound ClC1=CC(C(Cl)C(=O)O)=CC=C1C1CCCCC1 GXEUNRBWEAIPCN-UHFFFAOYSA-N 0.000 description 1
- PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 1
- PLZMRGRLCWCLFW-UHFFFAOYSA-N 3-[5-(3-bromophenyl)tetrazol-2-yl]-1-piperidin-1-ylpropan-1-one Chemical compound BrC1=CC=CC(C2=NN(CCC(=O)N3CCCCC3)N=N2)=C1 PLZMRGRLCWCLFW-UHFFFAOYSA-N 0.000 description 1
- YLJRTDTWWRXOFG-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)furan-2-yl]-3-hydroxypropanoic acid Chemical compound O1C(C(CC(O)=O)O)=CC=C1C1=CC=C(Cl)C=C1 YLJRTDTWWRXOFG-UHFFFAOYSA-N 0.000 description 1
- YUORBURTMIUPMW-UHFFFAOYSA-N 3-methyl-5-[2-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)ethyl]-1,3-oxazolidin-2-one Chemical compound O1C(=O)N(C)CC1CCN1CC=C(C=2C=CC=CC=2)CC1 YUORBURTMIUPMW-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- PIAMNHTVFPWVHG-UHFFFAOYSA-N 4-(4-chlorophenyl)-5-methyl-1h-imidazole;hydrochloride Chemical compound Cl.N1C=NC(C=2C=CC(Cl)=CC=2)=C1C PIAMNHTVFPWVHG-UHFFFAOYSA-N 0.000 description 1
- INDZCVYWKNWKIQ-UHFFFAOYSA-N 4-(fluoren-9-ylidenemethyl)benzenecarboximidamide;hydrochloride Chemical compound Cl.C1=CC(C(=N)N)=CC=C1C=C1C2=CC=CC=C2C2=CC=CC=C21 INDZCVYWKNWKIQ-UHFFFAOYSA-N 0.000 description 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- LQVMQEYROPXMQH-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)CCC(=O)O)=CC=C3OC2=C1 LQVMQEYROPXMQH-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- CXSJGNHRBWJXEA-UHFFFAOYSA-N 5,12-dihydrophthalazino[3,2-b]phthalazine-7,14-dione Chemical compound C1C2=CC=CC=C2C(=O)N2N1C(=O)C1=CC=CC=C1C2 CXSJGNHRBWJXEA-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- HEOZYYOUKGGSBJ-UHFFFAOYSA-N 5-(4-methoxybenzoyl)-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=C2N1CCC2C(O)=O HEOZYYOUKGGSBJ-UHFFFAOYSA-N 0.000 description 1
- HCEQQASHRRPQFE-UHFFFAOYSA-N 5-chloro-n-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide;3-(diaminomethylidene)-1,1-dimethylguanidine;hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N.COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 HCEQQASHRRPQFE-UHFFFAOYSA-N 0.000 description 1
- OAIZNWQBWDHNIH-UHFFFAOYSA-N 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)quinazolin-2-one Chemical compound N=1C(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 OAIZNWQBWDHNIH-UHFFFAOYSA-N 0.000 description 1
- XWXVKXXKKLBDDJ-UHFFFAOYSA-N 7-chloro-3,3a-dihydro-2h-[1,2]oxazolo[3,2-b][1,3]benzoxazin-9-one Chemical compound O1C2CCON2C(=O)C2=CC(Cl)=CC=C21 XWXVKXXKKLBDDJ-UHFFFAOYSA-N 0.000 description 1
- HCKFPALGXKOOBK-NRYMJLQJSA-N 7332-27-6 Chemical compound C1([C@]2(O[C@]3([C@@]4(C)C[C@H](O)[C@]5(F)[C@@]6(C)C=CC(=O)C=C6CC[C@H]5[C@@H]4C[C@H]3O2)C(=O)CO)C)=CC=CC=C1 HCKFPALGXKOOBK-NRYMJLQJSA-N 0.000 description 1
- ZOCUOMKMBMEYQV-GSLJADNHSA-N 9alpha-Fluoro-11beta,17alpha,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ZOCUOMKMBMEYQV-GSLJADNHSA-N 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 206010006797 Burns first degree Diseases 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- HPWIKAVXRHCHPE-BQAIUKQQSA-N CN(C)C(=N)N=C(N)N.C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 Chemical compound CN(C)C(=N)N=C(N)N.C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 HPWIKAVXRHCHPE-BQAIUKQQSA-N 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 102000004173 Cathepsin G Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 108010014754 Chrono-lume Proteins 0.000 description 1
- KATBVKFXGKGUFE-UHFFFAOYSA-N Cintazone Chemical compound C12=CC=CC=C2N2C(=O)C(CCCCC)C(=O)N2C=C1C1=CC=CC=C1 KATBVKFXGKGUFE-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- YXKFATPOEMHNMJ-KJEYTGHBSA-N Cormethasone acetate Chemical compound C1C(F)(F)C2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O YXKFATPOEMHNMJ-KJEYTGHBSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- 125000001711 D-phenylalanine group Chemical class [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 108010049047 Echinocandins Proteins 0.000 description 1
- 241000223933 Eimeria bovis Species 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010043222 Exubera Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- HNSCCNJWTJUGNQ-UHFFFAOYSA-N Glyclopyramide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC(=O)NN1CCCC1 HNSCCNJWTJUGNQ-UHFFFAOYSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- YCISZOVUHXIOFY-HKXOFBAYSA-N Halopredone acetate Chemical compound C1([C@H](F)C2)=CC(=O)C(Br)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@](OC(C)=O)(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O YCISZOVUHXIOFY-HKXOFBAYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101000923328 Homo sapiens Phospholipid-transporting ATPase IG Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010073961 Insulin Aspart Proteins 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000222724 Leishmania amazonensis Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- HUXCOHMTWUSXGY-GAPIFECDSA-N Meclorisone dibutyrate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CCC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2Cl HUXCOHMTWUSXGY-GAPIFECDSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101150094373 Padi4 gene Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034246 Pelvic fractures Diseases 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100032660 Phospholipid-transporting ATPase IG Human genes 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 description 1
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 1
- 102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 description 1
- 101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000244177 Strongyloides stercoralis Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- MVLBCBPGBUAVJQ-CENSZEJFSA-N [(6s,8s,9r,10s,11s,13s,14s,16r,17r)-17-(chloromethylsulfanylcarbonyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O MVLBCBPGBUAVJQ-CENSZEJFSA-N 0.000 description 1
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229940052808 actoplus met Drugs 0.000 description 1
- 229940062328 actos Drugs 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 229960004229 alclometasone dipropionate Drugs 0.000 description 1
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 description 1
- DAYKLWSKQJBGCS-NRFANRHFSA-N aleglitazar Chemical compound C1=2C=CSC=2C(C[C@H](OC)C(O)=O)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 DAYKLWSKQJBGCS-NRFANRHFSA-N 0.000 description 1
- 229950010157 aleglitazar Drugs 0.000 description 1
- LSWBQIAZNGURQV-WTBIUSKOSA-N algestone acetonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)C)[C@@]1(C)CC2 LSWBQIAZNGURQV-WTBIUSKOSA-N 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940000806 amaryl Drugs 0.000 description 1
- NSZFBGIRFCHKOE-LFZVSNMSSA-N amcinafal Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(CC)(CC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O NSZFBGIRFCHKOE-LFZVSNMSSA-N 0.000 description 1
- 229950004850 amcinafal Drugs 0.000 description 1
- 229950003408 amcinafide Drugs 0.000 description 1
- QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229950004699 anirolac Drugs 0.000 description 1
- HDNJXZZJFPCFHG-UHFFFAOYSA-N anitrazafen Chemical compound C1=CC(OC)=CC=C1C1=NN=C(C)N=C1C1=CC=C(OC)C=C1 HDNJXZZJFPCFHG-UHFFFAOYSA-N 0.000 description 1
- 229950002412 anitrazafen Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002583 anti-histone Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960000560 balsalazide disodium Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- 229960001264 benfluorex Drugs 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- CJAVTWRYCDNHSM-UHFFFAOYSA-N benzoic acid 2-[1-[3-(trifluoromethyl)phenyl]propan-2-ylamino]ethyl ester Chemical compound C=1C=CC=CC=1C(=O)OCCNC(C)CC1=CC=CC(C(F)(F)F)=C1 CJAVTWRYCDNHSM-UHFFFAOYSA-N 0.000 description 1
- 229960001689 benzydamine hydrochloride Drugs 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- UIDLJTHRRPMIQP-UHFFFAOYSA-L bis[2-[4-(2-methylpropyl)phenyl]propanoyloxy]aluminum;hydrate Chemical compound O.C1=CC(CC(C)C)=CC=C1C(C)C(=O)O[Al]OC(=O)C(C)C1=CC=C(CC(C)C)C=C1 UIDLJTHRRPMIQP-UHFFFAOYSA-L 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960001780 bromelains Drugs 0.000 description 1
- 229950011622 broperamole Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- WIKQEUJFZPCFNJ-UHFFFAOYSA-N carbonic acid;silver Chemical compound [Ag].[Ag].OC(O)=O WIKQEUJFZPCFNJ-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960003362 carbutamide Drugs 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- CKMOQBVBEGCJGW-UHFFFAOYSA-L chembl1200760 Chemical compound [Na+].[Na+].C1=C(C([O-])=O)C(O)=CC=C1N=NC1=CC=C(C(=O)NCCC([O-])=O)C=C1 CKMOQBVBEGCJGW-UHFFFAOYSA-L 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229950002545 cicloprofen Drugs 0.000 description 1
- GPUVGQIASQNZET-CCEZHUSRSA-N cinnoxicam Chemical compound C=1C=CC=CC=1/C=C/C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 GPUVGQIASQNZET-CCEZHUSRSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229950005384 cliprofen Drugs 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960005465 clobetasone butyrate Drugs 0.000 description 1
- SJCRQMUYEQHNTC-UHFFFAOYSA-N clopirac Chemical compound CC1=CC(CC(O)=O)=C(C)N1C1=CC=C(Cl)C=C1 SJCRQMUYEQHNTC-UHFFFAOYSA-N 0.000 description 1
- 229950009185 clopirac Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229950002276 cortodoxone Drugs 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- ZHPBLHYKDKSZCQ-UHFFFAOYSA-N cyclooctylmethanol Chemical compound OCC1CCCCCCC1 ZHPBLHYKDKSZCQ-UHFFFAOYSA-N 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- CIWBQSYVNNPZIQ-PKWREOPISA-N dexamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-PKWREOPISA-N 0.000 description 1
- 229950000250 dexamethasone dipropionate Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940089126 diabeta Drugs 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229960004515 diclofenac potassium Drugs 0.000 description 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960002124 diflorasone diacetate Drugs 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- 229950007956 diftalone Drugs 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- GZBONOYGBJSTHF-QLRNAMTQSA-N drocinonide Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O GZBONOYGBJSTHF-QLRNAMTQSA-N 0.000 description 1
- 229950006082 drocinonide Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940127257 dual PPAR agonist Drugs 0.000 description 1
- 229940012584 duetact Drugs 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229950002798 enlimomab Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002815 epigastric artery Anatomy 0.000 description 1
- 229950003801 epirizole Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- ULANGSAJTINEBA-UHFFFAOYSA-N ethyl n-(3-benzoylphenyl)-n-(trifluoromethylsulfonyl)carbamate Chemical compound CCOC(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 ULANGSAJTINEBA-UHFFFAOYSA-N 0.000 description 1
- HXQVQGWHFRNKMS-UHFFFAOYSA-M ethylmercurithiosalicylic acid Chemical compound CC[Hg]SC1=CC=CC=C1C(O)=O HXQVQGWHFRNKMS-UHFFFAOYSA-M 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229940012151 exubera Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229950003579 fenamole Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
- 229950006236 fenclofenac Drugs 0.000 description 1
- 229950003537 fenclorac Drugs 0.000 description 1
- HAWWPSYXSLJRBO-UHFFFAOYSA-N fendosal Chemical compound C1=C(O)C(C(=O)O)=CC(N2C(=CC=3C4=CC=CC=C4CCC=32)C=2C=CC=CC=2)=C1 HAWWPSYXSLJRBO-UHFFFAOYSA-N 0.000 description 1
- 229950005416 fendosal Drugs 0.000 description 1
- 229950002296 fenpipalone Drugs 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229950004322 flazalone Drugs 0.000 description 1
- BYZCJOHDXLROEC-RBWIMXSLSA-N fluazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O BYZCJOHDXLROEC-RBWIMXSLSA-N 0.000 description 1
- 229950002335 fluazacort Drugs 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- OPYFPDBMMYUPME-UHFFFAOYSA-N flumizole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)NC(C(F)(F)F)=N1 OPYFPDBMMYUPME-UHFFFAOYSA-N 0.000 description 1
- 229950005288 flumizole Drugs 0.000 description 1
- WEGNFRKBIKYVLC-XTLNBZDDSA-N flunisolide acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WEGNFRKBIKYVLC-XTLNBZDDSA-N 0.000 description 1
- 229960000588 flunixin Drugs 0.000 description 1
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 1
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 1
- 229960000469 flunixin meglumine Drugs 0.000 description 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 description 1
- 229950008509 fluocortin butyl Drugs 0.000 description 1
- 229960001629 fluorometholone acetate Drugs 0.000 description 1
- YRFXGQHBPBMFHW-SBTZIJSASA-N fluorometholone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 YRFXGQHBPBMFHW-SBTZIJSASA-N 0.000 description 1
- 229950007253 fluquazone Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229950003750 fluretofen Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 108010006620 fodrin Proteins 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940027775 fortamet Drugs 0.000 description 1
- 229950008156 furaprofen Drugs 0.000 description 1
- 229950006099 furobufen Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- 229940088991 glucotrol Drugs 0.000 description 1
- 229940112611 glucovance Drugs 0.000 description 1
- 229940093617 glumetza Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229950002888 glyclopyramide Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940120105 glynase Drugs 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229950004611 halopredone acetate Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229950005954 ibuprofen piconol Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004260 indomethacin sodium Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 229950008443 indoxole Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 229960004717 insulin aspart Drugs 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 229950004204 intrazole Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000004171 ischemic cascade Effects 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 229960003317 isoflupredone acetate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- 229950011455 isoxepac Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 229940103445 janumet Drugs 0.000 description 1
- 229940090473 januvia Drugs 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229940103444 kombiglyze Drugs 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 208000001921 latent autoimmune diabetes in adults Diseases 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 1
- 229960003744 loteprednol etabonate Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- GQVWFGYYMWLERN-UHFFFAOYSA-J magnesium;2-carboxyphenolate;2-hydroxyethyl(trimethyl)azanium;sulfate;tetrahydrate Chemical compound O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O.C[N+](C)(C)CCO.C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O GQVWFGYYMWLERN-UHFFFAOYSA-J 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- OJGJQQNLRVNIKE-UHFFFAOYSA-N meseclazone Chemical compound O1C2=CC=C(Cl)C=C2C(=O)N2C1CC(C)O2 OJGJQQNLRVNIKE-UHFFFAOYSA-N 0.000 description 1
- 229950000701 meseclazone Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940054183 metaglip Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- CDMLLMOLWUKNEK-AOHDELFNSA-M methylprednisolone suleptanate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS([O-])(=O)=O)CC[C@H]21 CDMLLMOLWUKNEK-AOHDELFNSA-M 0.000 description 1
- 229950010796 methylprednisolone suleptanate Drugs 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229940084921 micronized glyburide Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960003365 mitiglinide Drugs 0.000 description 1
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical class [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 229960003251 morniflumate Drugs 0.000 description 1
- LDXSPUSKBDTEKA-UHFFFAOYSA-N morniflumate Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OCCN2CCOCC2)=C1 LDXSPUSKBDTEKA-UHFFFAOYSA-N 0.000 description 1
- 229950001135 muraglitazar Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- NKDJNEGDJVXHKM-UHFFFAOYSA-N n,2-dimethyl-4,5,6,7-tetrahydroindazol-3-amine Chemical compound C1CCCC2=NN(C)C(NC)=C21 NKDJNEGDJVXHKM-UHFFFAOYSA-N 0.000 description 1
- HWCORKBTTGTRDY-UHFFFAOYSA-N n-(4-chlorophenyl)-1,3-dioxo-4h-isoquinoline-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1C2=CC=CC=C2C(=O)NC1=O HWCORKBTTGTRDY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- LTRANDSQVZFZDG-SNVBAGLBSA-N naproxol Chemical compound C1=C([C@H](C)CO)C=CC2=CC(OC)=CC=C21 LTRANDSQVZFZDG-SNVBAGLBSA-N 0.000 description 1
- 229950006890 naproxol Drugs 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 229950006046 nimazone Drugs 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960004364 olsalazine sodium Drugs 0.000 description 1
- 229940001450 onglyza Drugs 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960004534 orgotein Drugs 0.000 description 1
- 108010070915 orgotein Proteins 0.000 description 1
- 229950003655 orpanoxin Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- 229960001369 piroxicam cinnamate Drugs 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 238000003615 platelet activation assay Methods 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 229940103420 prandimet Drugs 0.000 description 1
- 229940096058 prandin Drugs 0.000 description 1
- 229940095885 precose Drugs 0.000 description 1
- 229950008421 prednazate Drugs 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- WAAVMZLJRXYRMA-UHFFFAOYSA-N prifelone Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C(=O)C=2SC=CC=2)=C1 WAAVMZLJRXYRMA-UHFFFAOYSA-N 0.000 description 1
- 229950004465 prifelone Drugs 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229950003795 prodolic acid Drugs 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960002466 proquazone Drugs 0.000 description 1
- JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 229940126844 remogliflozin Drugs 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- 229940034379 riomet Drugs 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229950010764 rivoglitazone Drugs 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229950001166 romazarit Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229950000125 salcolex Drugs 0.000 description 1
- 229950009768 salnacedin Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- GIZKAXHWLRYMLE-UHFFFAOYSA-M sanguinarium chloride Chemical compound [Cl-].C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 GIZKAXHWLRYMLE-UHFFFAOYSA-M 0.000 description 1
- 229950011197 sanguinarium chloride Drugs 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 229950002093 seclazone Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- HFLCZNNDZKKXCS-OUUBHVDSSA-N sergliflozin Chemical compound C1=CC(OC)=CC=C1CC1=CC=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HFLCZNNDZKKXCS-OUUBHVDSSA-N 0.000 description 1
- 229940126842 sergliflozin Drugs 0.000 description 1
- 229950006250 sermetacin Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- KQTXIZHBFFWWFW-UHFFFAOYSA-L silver(I) carbonate Inorganic materials [Ag]OC(=O)O[Ag] KQTXIZHBFFWWFW-UHFFFAOYSA-L 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HVBBVDWXAWJQSV-UHFFFAOYSA-N sodium;(3-benzoylphenyl)-(difluoromethylsulfonyl)azanide Chemical compound [Na+].FC(F)S(=O)(=O)[N-]C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 HVBBVDWXAWJQSV-UHFFFAOYSA-N 0.000 description 1
- VCSAHSDZAKGXAT-AFEZEDKISA-M sodium;(z)-(1-carbamoyl-5-chloro-2-oxoindol-3-ylidene)-thiophen-2-ylmethanolate Chemical compound [Na+].C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/[O-])C1=CC=CS1 VCSAHSDZAKGXAT-AFEZEDKISA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- JMHRGKDWGWORNU-UHFFFAOYSA-M sodium;2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound [Na+].CC1=C(CC([O-])=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 JMHRGKDWGWORNU-UHFFFAOYSA-M 0.000 description 1
- SEEXPXUCHVGZGU-UHFFFAOYSA-M sodium;2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetate Chemical compound [Na+].C1=C(CC([O-])=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C SEEXPXUCHVGZGU-UHFFFAOYSA-M 0.000 description 1
- TVGNJNYKOTWAJQ-UHFFFAOYSA-M sodium;4-butyl-5-oxo-1,2-diphenylpyrazol-3-olate;propane-1,2,3-triol Chemical compound [Na+].OCC(O)CO.C=1C=CC=CC=1N1C(=O)C(CCCC)=C([O-])N1C1=CC=CC=C1 TVGNJNYKOTWAJQ-UHFFFAOYSA-M 0.000 description 1
- AVERBMQHYOZACV-UHFFFAOYSA-M sodium;7-chloro-4-[(3,4-dichlorophenyl)carbamoyl]-1,1-dioxo-2,3-dihydro-1$l^{6}-benzothiepin-5-olate;hydrate Chemical compound O.[Na+].C1CS(=O)(=O)C2=CC=C(Cl)C=C2C([O-])=C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 AVERBMQHYOZACV-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 229950005100 talmetacin Drugs 0.000 description 1
- 229960005262 talniflumate Drugs 0.000 description 1
- 229950005400 talosalate Drugs 0.000 description 1
- 229950003441 tebufelone Drugs 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 1
- 229950004704 tesaglitazar Drugs 0.000 description 1
- 229950007324 tesicam Drugs 0.000 description 1
- 229950000997 tesimide Drugs 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229950002345 tiopinac Drugs 0.000 description 1
- BISFDZNIUZIKJD-XDANTLIUSA-N tixocortol pivalate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)C(C)(C)C)(O)[C@@]1(C)C[C@@H]2O BISFDZNIUZIKJD-XDANTLIUSA-N 0.000 description 1
- 229960003114 tixocortol pivalate Drugs 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960002044 tolmetin sodium Drugs 0.000 description 1
- 229960003069 tolrestat Drugs 0.000 description 1
- LUBHDINQXIHVLS-UHFFFAOYSA-N tolrestat Chemical compound OC(=O)CN(C)C(=S)C1=CC=CC2=C(C(F)(F)F)C(OC)=CC=C21 LUBHDINQXIHVLS-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 229940049667 tradjenta Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- VSVSLEMVVAYTQW-VSXGLTOVSA-N triclonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]2(C)C[C@@H]1Cl VSVSLEMVVAYTQW-VSXGLTOVSA-N 0.000 description 1
- 229950008073 triclonide Drugs 0.000 description 1
- 229950000451 triflumidate Drugs 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229950008396 ulobetasol propionate Drugs 0.000 description 1
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940111503 welchol Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
- 229950007802 zidometacin Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229960003516 zomepirac sodium Drugs 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of ß-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of NET mediated ailments in subjects.
Description
PCT/AU2019:050156 Received 2402,2021 COMPOUNDS FOR TREATING AND PREVENTING
NET ASSOCIATED COMPLICATIONS
TECHNICAL FIELD
[0001] The present invention relates to compounds and methods for inhibiting the pathological activity of neutrophil extracellular traps (NETs) in a subject.
In particular, the invention relates to compounds, uses and methods for inhibiting or ameliorating NET
mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRO). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside. Preferably, the polyanionic sulfated cellobioside is modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of cellobioside sulfate (CBS), 13-0-methyl cellobioside sulfate (mCBS) IS or a pharmaceutically acceptable salt thereof, in the therapy of a range of NET mediated ailments in subjects.
BACKGROUND
NET ASSOCIATED COMPLICATIONS
TECHNICAL FIELD
[0001] The present invention relates to compounds and methods for inhibiting the pathological activity of neutrophil extracellular traps (NETs) in a subject.
In particular, the invention relates to compounds, uses and methods for inhibiting or ameliorating NET
mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRO). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside. Preferably, the polyanionic sulfated cellobioside is modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of cellobioside sulfate (CBS), 13-0-methyl cellobioside sulfate (mCBS) IS or a pharmaceutically acceptable salt thereof, in the therapy of a range of NET mediated ailments in subjects.
BACKGROUND
[0002] Neutrophils are innate immune granulocytes (most abundant white blood cells) that have a central role in pathogen clearance, immune regulation and disease pathology.
They eliminate infectious agents by mechanisms such as phagocytosis, reactive oxygen species' (ROS) generation and the release of microbicidal molecules from neutrophilic granules (degranulation).
They eliminate infectious agents by mechanisms such as phagocytosis, reactive oxygen species' (ROS) generation and the release of microbicidal molecules from neutrophilic granules (degranulation).
[0003] Neutrophils also extrude a meshwork of chromatin fibres that are decorated with granule-derived antimicrobial peptides and enzymes such as neutrophil elastase (NE), cathepsin G, and myeloperoxidase (MPO). These extruded structures are called neutrophil extracellular traps (NETs).
[0004] A purpose for NETs is to disarm pathogens using their high local concentration of antimicrobial components. As such, NETs represent an important strategy to AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 immobilize and kill invading organisms. NET scaffolds consist of web-like chromatin fibres with a diameter of 15-17 nm; DNA and histones represent the major NET
constituents.
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 immobilize and kill invading organisms. NET scaffolds consist of web-like chromatin fibres with a diameter of 15-17 nm; DNA and histones represent the major NET
constituents.
[0005] In addition to their antimicrobial properties, NETs serve as a physical barrier that prevents spread of pathogens and potentially injurious proteins. For example, absorption of granule proteins into NETs can keep potentially injurious proteins, like proteases, from diffusing away from an injury where they can induce damage in tissue adjacent to a site of inflammation.
[0006] NET formation and release is thought to arise in two possible situations:
a. NETosis, a distinct form of active cell death that is characterized by release of decondensed chromatin and granular contents to the extracellular space.
During NETosis, nuclear and granular membranes dissolve, and nuclear contents decondense into the cytoplasm. This is followed by plasma membrane rupture and release of chromatin decorated with granular proteins into the extracellular space;
b. a DNA/serine protease extrusion mechanism from intact neutrophils, where mitochondrial DNA release is apparently not associated with cell death.
a. NETosis, a distinct form of active cell death that is characterized by release of decondensed chromatin and granular contents to the extracellular space.
During NETosis, nuclear and granular membranes dissolve, and nuclear contents decondense into the cytoplasm. This is followed by plasma membrane rupture and release of chromatin decorated with granular proteins into the extracellular space;
b. a DNA/serine protease extrusion mechanism from intact neutrophils, where mitochondrial DNA release is apparently not associated with cell death.
[0007] NETosis is largely induced in response to microbial cues and endogenous danger signals, including proinflammatory cytokines (TNF-a, IL-8), platelets, activated endothelial cells (ECs), nitric oxide, monosodium urate crystals, and various autoantibodies. Ordinarily, this process is tightly regulated to prevent excessive tissue damage during acute inflammation or chronic inflammatory and autoimmune disease.
[0008] Although NET formation is integral to the innate immune response providing a beneficial strategy for combatting disease, NETs also figure prominently at the centre of various infectious and non-infectious pathologic states such as hypoxia or sterile inflammation. In this respect, NETs because of their construct and nature are putative sources of molecules with immune effector and proinflammatory roles that, in susceptible individuals, can promote a range of infectious and non-infectious diseases, inflammation, tissue damage and autoimmunity. When they form in excessive amounts NETs can be AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 injurious to the endothelium and underlying tissue. Such injury often results from NET
degradation by both endogenous and microbial-derived nucleases. When NETs degrade, they release histones that are cytotoxic for not only microbes but also for host epithelial and endothelial cells.
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 injurious to the endothelium and underlying tissue. Such injury often results from NET
degradation by both endogenous and microbial-derived nucleases. When NETs degrade, they release histones that are cytotoxic for not only microbes but also for host epithelial and endothelial cells.
[0009] NETs have been directly implicated in a range of medical conditions including or associated with, for example and only by way of illustration: hyper-inflammatory responses to infection (including, bacterial, viral and parasitic), during sepsis, preeclampsia, colon mucosa of patients with the inflammatory bowel disease ulcerative colitis and associated with the production of IgG antinuclear double stranded DNA
antibodies in children infected with P. falciparum (malaria); fibrosis where functional parenchymal organ tissue is replaced by fibrotic tissue, which can severely diminish organ function, transfusion-related acute lung injury, deep vein thrombosis and cancer.
antibodies in children infected with P. falciparum (malaria); fibrosis where functional parenchymal organ tissue is replaced by fibrotic tissue, which can severely diminish organ function, transfusion-related acute lung injury, deep vein thrombosis and cancer.
[0010] Despite the clinical use of modern antibiotics, there remains a significant level of morbidity and mortality due to ineffective treatment of NET related ailments.
Accordingly, there is an urgent need for drugs that neutralise the damaging effects of excessive levels of NETs, without impeding the beneficial effects of neutrophils. .
Accordingly, there is an urgent need for drugs that neutralise the damaging effects of excessive levels of NETs, without impeding the beneficial effects of neutrophils. .
[0011] To date there exists a dearth of compounds that present a treatment for NET
induced ailments. It is against this background and the growing recognition of the role of NETs in multiple diseases that the present invention has been developed.
SUMMARY OF INVENTION
induced ailments. It is against this background and the growing recognition of the role of NETs in multiple diseases that the present invention has been developed.
SUMMARY OF INVENTION
[0012] The present invention is predicated on the finding that certain anti-NET
polyanionic compounds, as described herein, interact electrostatically with NETs in the circulation of animals to neutralise the cytopathic properties of NETs.
Complexing of such polyanionic molecules with NETs in the circulation of a living animal provides a means to at least ameliorate the cytotoxic activity of NETs.
polyanionic compounds, as described herein, interact electrostatically with NETs in the circulation of animals to neutralise the cytopathic properties of NETs.
Complexing of such polyanionic molecules with NETs in the circulation of a living animal provides a means to at least ameliorate the cytotoxic activity of NETs.
[0013] In particular, the inventors have identified that certain sulfated disaccharides are effective at neutralizing the pathological effects of NETs. For example, a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 its reducing terminus provides a chemically stable polyanion that is able to provide highly effective treatment for NET associated complication (such as, for example, sepsis, SIRS
and IRI and at least ameliorate those conditions in patients).
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 its reducing terminus provides a chemically stable polyanion that is able to provide highly effective treatment for NET associated complication (such as, for example, sepsis, SIRS
and IRI and at least ameliorate those conditions in patients).
[0014] Use of a sulfated cellobioside modified with a small uncharged substituent at its .. reducing terminus, with resultant chemical stability, presents or provides a new general principal of application in the field of treating patients suffering from NET
associated complications and/or preventing NET associated complications from occurring in at risk patients.
associated complications and/or preventing NET associated complications from occurring in at risk patients.
[0015] In a first aspect of the invention, there is provided a compound for use in the treatment or prevention of at least a NET associated complication in a subject, wherein the compound comprises: a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0016] Preferably, where the polyanionic sulfated cellobioside is modified it desirably IS posseses a small uncharged glycosidically linked substituent at the reducing terminus of the polyanionic sulfated cellobioside. This preferably improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus.
[0017] Compounds of the invention when present in a therapeutically or pharmaceutically effective amount provide a means for ameliorating, treating or preventing NET associated complications.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021
[0018] In an embodiment of the invention, the modified polyanionic sulfated cellobioside, has the general structure:
RI
wherein:
is a sulfate group or a small uncharged glycosidically linked substituent, for example, 0- or S-(C1-6)alkyl; and R2 to R8 are each selected from: (i) a small uncharged 0-linked substituent or (ii) a sulfate group.
RI
wherein:
is a sulfate group or a small uncharged glycosidically linked substituent, for example, 0- or S-(C1-6)alkyl; and R2 to R8 are each selected from: (i) a small uncharged 0-linked substituent or (ii) a sulfate group.
[0019]
Preferably, R1 is 0- or S-(C1_6)alkyl. When R1 is 0- or S-(C1_6)alkyl, the substituent preferably improves the chemical stability of the polyanion, compared to the same polyanion with a sulfate group at R1.
Preferably, R1 is 0- or S-(C1_6)alkyl. When R1 is 0- or S-(C1_6)alkyl, the substituent preferably improves the chemical stability of the polyanion, compared to the same polyanion with a sulfate group at R1.
[0020] Preferably, R2 to R8 are each selected from: (a) an unmodified hydroxyl group;
or (b) a sulfate group.
or (b) a sulfate group.
[0021] More preferably, R1 is a methoxy or ethoxy group and R2 to R8 are each a sulfate group.
[0022]
Desirably, the class of compound has a high net negative charge, i.e. it is a polyanion.
Desirably, the class of compound has a high net negative charge, i.e. it is a polyanion.
[0023] The anomeric configuration of the small uncharged glycoside substituent (R1) can be in either of the a or 13 position. Preferably, the small uncharged substituent is in the 13 configuration.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021
[0024] In a highly-preferred form of the invention, the compound is CBS, mCBS
or a pharmaceutically acceptable salt thereof, wherein when the compound is mCBS it is desirably a sulfated 6-0-methyl cellobioside disaccharide. By way of illustration, when the compound is mCBS it is desirably the sodium salt of 6-0-Methyl Cellobioside Sulfate, viz Sodium p-O-Methyl Cellobioside Sulfate (mCBS.Na).
or a pharmaceutically acceptable salt thereof, wherein when the compound is mCBS it is desirably a sulfated 6-0-methyl cellobioside disaccharide. By way of illustration, when the compound is mCBS it is desirably the sodium salt of 6-0-Methyl Cellobioside Sulfate, viz Sodium p-O-Methyl Cellobioside Sulfate (mCBS.Na).
[0025] mCBS is preferred as it is highly stable relative to CBS and well tolerated at high concentrations.
[0026] In a second aspect of the invention, there is provided a method for treating (either therapeutically or preventively) a medical condition, ailment or disease involving NETs in a subject, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0027] In a third aspect of the invention, there is provided a method for ameliorating IS NET accumulation in a subject, said method comprising the step of:
administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0028] In an embodiment of the second or third aspect of the invention the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated 8-0-methyl cellobioside disaccharide or a sodium salt of 6-0-Methyl Cellobioside Sulfate, viz mCBS.Na.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021
[0029] For example, in an embodiment of the second or third aspect of the invention, the method is used to treat or prevent a condition or ailment associated with an NET
associated complication such as, for example, sepsis, SIRS or IRI.
associated complication such as, for example, sepsis, SIRS or IRI.
[0030] In certain exemplary embodiments according to the second or third aspects of the invention, the identified methods can further comprise the step of:
administering to the subject, together with or concomitantly with the modified sulfated cellobioside, a therapeutically or pharmaceutically effective amount of a second active agent, compound or composition selected from: one or more of anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents and/or any other form of pharmaceutical composition that treats one or more condition that a subject is afflicted with or at risk of being afflicted with.
administering to the subject, together with or concomitantly with the modified sulfated cellobioside, a therapeutically or pharmaceutically effective amount of a second active agent, compound or composition selected from: one or more of anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents and/or any other form of pharmaceutical composition that treats one or more condition that a subject is afflicted with or at risk of being afflicted with.
[0031] According to this embodiment, the second active agent, compound or composition provides an adjunct treatment to the treatment directed to the NET
associated complication (such as, for example, sepsis, SIRS or IRI) and/or for medical conditions or diseases associated with such complications. Preferably, the second active agent, compound or composition comprises one or more of anti-inflammatory agents.
associated complication (such as, for example, sepsis, SIRS or IRI) and/or for medical conditions or diseases associated with such complications. Preferably, the second active agent, compound or composition comprises one or more of anti-inflammatory agents.
[0032] Preferably, the second active agent presents a means for medical intervention of a disease that a patient is afflicted with that is related to or distinct from the medical ailment treated by the compounds of this invention, said second active agent providing an adjunct treatment for the patient.
[0033] In a fourth aspect of the invention, there is provided a method for treating or preventing a medical condition or disease associated with NET cytotoxicity in a subject, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0034] In an embodiment of the fourth aspect of the invention the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0035] In one preferred example of the fourth aspect of the invention, the method is used to neutralise NETs that (i) are cytotoxic towards the endothelium in a subject and/or (ii) contribute to endothelial dysfunction in a subject.
[0036] In addition, or alternatively, the method is used to treat a septic or SIRS
condition or an IRI or a disease associated with sepsis, SIRS or an IRI that is, caused by or mediated by a release of NETs in a subject following infection, inflammation or hypoxia or any infection, inflammatory or hypoxia response in a subject.
condition or an IRI or a disease associated with sepsis, SIRS or an IRI that is, caused by or mediated by a release of NETs in a subject following infection, inflammation or hypoxia or any infection, inflammatory or hypoxia response in a subject.
[0037] In a fifth aspect of the invention, there is provided a therapeutic or pharmaceutical composition for use in treating an NET associated complication comprising: at least a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0038] In an embodiment of the fifth aspect of the invention the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0039] Preferably, the compound is present in a therapeutically or pharmaceutically effective amount in the therapeutic or pharmaceutical composition. The composition can also include a therapeutically or pharmaceutically acceptable carrier, excipient and/or diluent. The compound in the therapeutic or pharmaceutic is either in a neutral free base AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 form or salt form. Preferably, the polyanionic sulfated cellobioside compound is mCBS or more particularly is the sodium salt of p-O-Methyl Cellobioside Sulfate.
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 form or salt form. Preferably, the polyanionic sulfated cellobioside compound is mCBS or more particularly is the sodium salt of p-O-Methyl Cellobioside Sulfate.
[0040] In certain exemplary embodiments, according to the fifth aspect of the invention, the identified composition can also comprise a second active agent, compound or composition selected from: one or more of anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents and/or any other form of therapeutic or pharmaceutical compound that treats one or more conditions that the subject is afflicted with.
[0041] According to this embodiment, the second active agent, compound or composition desirably provides an adjunct therapy for sepsis, SIRS or an IRI
or for a medical condition or disease associated with sepsis, SIRS or an IRI.
Preferably, the second active agent, compound or composition comprises one or more of anti-inflammatory agents.
or for a medical condition or disease associated with sepsis, SIRS or an IRI.
Preferably, the second active agent, compound or composition comprises one or more of anti-inflammatory agents.
[0042] In a sixth aspect of the invention, there is provided a use of a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a medical condition, ailment or disease involving NETs.
[0043] In an embodiment of the sixth aspect of the invention the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0044] For example, in an embodiment of the sixth aspect of the invention, there is provided a use of a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of sepsis, SIRS or an IRI or a medical condition or disease associated with sepsis, SIRS or an IRI in a subject. Preferably, the modified sulfated cellobioside is mCBS
or more particularly is a pharmaceutically acceptable salt thereof such as mCBS.Na.
5 [0045] In one embodiment of such use, the medicament is for the treatment of sepsis, or SIRS or a medical condition or disease associated with sepsis or SIRS in a subject, wherein said treatment ameliorates or inhibits said sepsis or SIRS or said condition or disease associated with said sepsis or SIRS.
[0046] In another embodiment of such use, the medicament is for the treatment of an 10 IRI or of a medical condition or disease associated with an IRI in a subject, wherein said treatment ameliorates or inhibits said IRI or said condition or disease associated with said injury.
[0047] In yet another embodiment of such use, the medicament is used to neutralise NETs that (i) are cytotoxic towards the endothelium in a subject, or (ii) contribute to endothelial dysfunction in a subject, or (iii) initiate coagulation by activating platelets in a subject, or (iv) induce red cell fragility and resultant anaemia in a subject.
[0048] In yet another embodiment, the manufactured medicament may also include a therapeutic or pharmaceutically effective amount of a second active agent, compound or composition. According to this embodiment, the second active agent, compound or composition provides an adjunct therapy for treating a medical condition, ailment or disease involving NETs. Desirably, the second active agent, compound or composition provides an adjunct therapy for the treatment of sepsis, SIRS or an IRI or for a medical condition or disease associated with sepsis, SIRS or an IRI. Preferably, the second active agent is selected from: one or more of anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents and/or any other form of therapeutic or pharmaceutical compound that treats one or more conditions that the subject is afflicted with. More preferably, the second active agent, compound or composition comprises one or more of anti-inflammatory agents.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 [0049] When the modified sulfated cellobioside compound is used in any of the methods of the invention the compound can be administered or formulated for administration to the subject in need thereof, in a single dose of formulation. In certain alternative embodiments, the modified sulfated cellobioside compound is administered, or formulated for administration to the subject in need thereof, as a multi-dose formulation.
[0050] Additional objectives, advantages and novel features will be set forth in the description which follows or will become apparent to those skilled in the art upon examination of the drawings and the ensuing detailed description of several non-limiting embodiments which follows.
.. BRIEF DESCRIPTION OF THE DRAWINGS
[0051]
The disclosure will provide details in the following description of preferred embodiments with reference to the following figures wherein:
Figure 1 Chemical structures of compounds selected.
Figure 2 Minimal structural requirements for polyanions to be as potent as heparin at inhibiting histone-mediated pathologies. a, Inhibition curves showing that the sulfated disaccharide, mCBS, and the sulfated trisaccharide, MTS, are as effective as heparin at inhibiting histone-mediated cytotoxicity for HMEC-1, whereas the sulfated monosaccharides, glucose per-O-sulfate and methyl p-glucoside per-O-sulfate, exhibit little or no inhibitory activity. b, Similar results obtained when examining inhibition of histone-induced erythrocyte fragility. Data are mean s.e.m. (n=3 biological replicates).
Figure 3 Histones promote erythrocyte aggregation and reduce erythrocyte deformability, processes that are completely inhibited by SPAs. Human erythrocytes (RBC) were incubated for 1 h at 37 C alone (Saline' control) or in the presence of histones (400 1.1g m1-1) with or without mCBS (200 pg m1-1).
a, Percentage of RBC aggregation measured by flow cytometry based on forward (FSC) and side (SSC) scatter parameters and an appropriate gating strategy to discriminate aggregated from normal (non-aggregated) RBC. b, Scanning AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 electron micrographs depicting level of RBC aggregation at low and high magnification following the three treatments depicted in (a). c, Concentration dependent inhibition of histone-mediated RBC aggregation by mCBS and MTS, in this case RBC aggregation being calculated by flow cytometry as fold increase in RBC auto-fluorescence relative to RBC in the absence of histones. The fold increase values also provide an estimate of the number of RBC in each aggregate. d, Retention of RBC in an artificial spleen that measures RBC
deformability. RBC were incubated with increasing concentrations of histones for 1 h and, at the highest concentration used (400 jig m1-1), also incubated with either mCBS or MTS (100 and 200 jig m1-1), prior to passage through the artificial spleen. Data are mean s.e.m. (n=3 biological replicates). ***P<0.001, ****P<0.0001 (one way ANOVA with Dunnett's multiple comparisons test).
Figure 4 SPAs inhibit histone-induced platelet aggregation and degranulation. a, Histone-induced aggregation of isolated platelets. b, SPA
inhibition of histone (HIS)(150 pg/mL) induced platelet aggregation. c, Histone-induced degranulation of platelets in whole blood, as measured by ATP release.
Dotted line ATP release from thrombin-activated platelets. d, SPA inhibition of histone-induced platelet degranulation. Data in (a,b) are mean s.e.m (n=3 biological replicates). Data in (c,d) representative of one of three experiments.
Figure 5 Histones disrupt lipid bilayers and induce a cellular Ca2+ flux, processes blocked by SPAs. a, Lifetime of artificial lipid bilayers exposed to histones (HIS)(1 pm) alone (n=47) or in the presence of the SPAs CBS (n=52) or MTS (n=40)(10 pM). Control bilayers (n=125) contained the R7R1 ion channel protein (n=biological replicates). Data are mean s.e.m. P values calculated using non-parametric Kruskal-Wallis test. b, Representative flow cytometry plots, using Ca2+ sensitive dye lndo-1, showing Ca2+ fluxing HMEC-1 1 min following histone addition (100 jig m1-1). c, Time course of effect of CBS and MTS (100 jig m1-1) on histone-induced Ca2+ flux by HMEC-1. Data in (c) from one of two separate experiments and mean of two biological replicates.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 Figure 6 In Vivo SPAs inhibit histone-induced tissue injury, thrombocytopenia, anaemia and DVT. a, Mice (n=5-28/group), injected i.p. with SPA doses (as indicated) 10 min prior to i.v. injection of histones (50 mg kg-1), had their blood collected 4 h post-histones for assessment of liver (alanine aminotransferase, ALT), kidney (creatinine, Crea) and general tissue (lactate dehydrogenase, LDH) damage. Data pooled from 10 separate experiments, with n=5-28 mice/treatment. b, Mice (n=5/group), treated as above but receiving one SPA dosage (100 mg kg-1), had their blood and spleens collected 10 min post-histones for assessment of circulating platelets and RBC and splenic to haemoglobin (Hb). c, Impact of CBS and MTS on a mouse model of histone-induced DVT (n=7-10 mice/group). Data mean s.e.m. *P5_0.05, **P<0.01, *"P<0.001, ****P<0.0001 (one way ANOVA with Dunnett's multiple comparisons test).
Figure 7 SPAs inhibit a range of pathologies involving extracellular IS histones. a, Survival of rats (n=8/group) subjected to caecal ligation and puncture (CLP) and receiving saline (Control), CBS or MTS. P values obtained with Log rank (Mantel-Cox) test. b, Kidney and liver damage in CLP rats, as measured by ALT and creatinine blood levels. c, Effect of CBS and MTS (n=6-12/group) on cardiac IRI in rats, with ischemic zone (IZ) in left ventricle (LV), 20 microvascular obstruction (MVO) and infarct territory being measured. d, Effect of mCBS and MTS on a skin flap model of IRI in mice (n=3-5/group), with representative photos shown. Statistical analysis of (b-d) as for Fig. 6.
Figure 8 HMEC-1 proliferation is a highly sensitive assay for both determining histone cytotoxicity and detecting inhibitors of this 25 cytotoxicity. a, Sub-confluent HMEC-1 monolayers were exposed to increasing concentrations of histones for 3 h and then 3H-thymidine added and HMEC-1 proliferation measured by 3H-thymidine incorporation over the next 24 h, with HMEC-1 proliferation being inhibited, in a highly concentration-dependent manner, by histones. b, The SPAs mCBS and MTS (100 pg m1-1) completely 30 neutralized the anti-proliferative effect of histones (400 pg m1-1) on HMEC-1 AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 monolayers. Data are mean s.e.m. (n=3 biological replicates). ****/3<0.0001 (one way ANOVA with Dunnett's multiple comparisons test).
Figure 9 Serum from sepsis patients is toxic for endothelial cells, an effect neutralized by DNase I, anti-histone antibodies and SPAs. a, Correlation (Spearman's r value) of APACHE II scores with anti-proliferative effect of sepsis patients sera on HMEC-1 (n=20 patients). b, Correlation of APACHE II scores with extracellular DNA content of sepsis patients sera. c, Effect of DNase I
or pAbs against histone 3 (aH3) and histone 4 (aH4) (n=4 biological replicates/treatment) on anti-proliferative effect of serum from sepsis patient 5 (red circle, panel a). d, Ability of SPAs mCBS and MTS to neutralize the anti-proliferative effect of septic patient sera (SS)(n=10 patients). Statistical analysis as for Fig. 6.
DETAILED DESCRIPTION OF THE PREFERED EMBODIMENTS
[0052] The present invention is directed to the use of modified sulfated cellobioside compounds, that have high chemical stability, in the treatment or prevention of NET
mediated ailments (such as, for example, sepsis, SIRS or IRI) in a subject.
Such compounds can ameliorate or inhibit or prevent the cytotoxic effect of NETs in a subject.
[0053]
For convenience, the following sections generally outline the various meanings of terms used herein. Following this discussion, general exemplary embodiments illustrating the invention are disclosed, followed by specific examples providing more specific illustration of properties of various exemplary embodiments of the invention.
General [0054]
Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described without departing from the spirit and scope of the invention as herein described. The invention includes all such variations and modifications. The invention also includes all the steps, features, compositions and components, referred to or indicated in the specification, individually or collectively, and any and all combinations or any two or more of said steps AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 or features. Functionally equivalent products, compositions of matter and methods are clearly within the scope of the invention as described herein.
[0055] All publications, references, documents, patents and patent applications cited in the herein, whether supra or infra, are hereby incorporated herein by reference in their 5 entirety, which means that those publications, references, documents, patents and patent applications should be read and considered as part of this text. That any publication, reference, document, patent and patent application cited in this text is not repeated in this text is merely for reasons of conciseness. However, publications, references, documents, patents and patent applications mentioned herein are cited for describing and disclosing 10 the protocols, reagents and products that which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants IS and does not constitute any admission as to the correctness of the dates or contents of these documents.
[0056] Any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention.
[0057] Definitions for selected terms used herein may be found within the summary of invention and the detailed description of the invention and apply throughout.
Unless otherwise defined, all other scientific and technical terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the invention belongs. If there is an apparent discrepancy between the usage of a term in the art and its definition provided herein, the definition provided within the specification shall prevail.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 Definitions [0058] Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term "about." For example, the term "about" when used in connection with percentages can mean 10%.
[0059] Unless the context requires otherwise, or the specification specifically states to the contrary, integers, steps, or elements of the invention recited herein as singular integers, steps or elements clearly encompass both singular and plural forms of the recited integers, steps or elements. Throughout this specification, unless stated otherwise or the context requires otherwise, reference to a single step, composition or matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e., one or more) or those steps, compositions or matter, group of steps or group of compositions of matter. Accordingly, as used herein and in the appended claims, the singular forms "a, "an" and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a sulfated cellobioside modified with a small uncharged substituent at its reducing terminus or a pharmaceutically acceptable salt thereof" includes a plurality of such modified sulfated cellobioside compounds or a plurality of salts thereof, and so forth.
[0060] Throughout the specification and claims, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated step or element or integer or group of steps or elements or integers but not the exclusion of any other step or element or integer or group of steps or elements or integers.
[0061] As used herein, the term "including", as well as variations such as "includes"
and "included", will also be understood to be not limiting.
[0062] In this application, the use of "or" means "and/or" unless stated otherwise.
[0063] The invention described herein may include one or more range of values (for example, size, displacement and field strength etc.). A range of values will be understood AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 to include all values within the range, including the values defining the range, and values adjacent to the range that lead to the same or substantially the same outcome as the values immediately adjacent to that value which defines the boundary to the range. For example, a person skilled in the relevant field will understand that a 10%
variation in upper or lower limits of a range can be totally appropriate and is encompassed by the invention.
More particularly, the variation in upper or lower limits of a range will be 5% or as is commonly recognised in the art, whichever is greater.
[0064] As used herein, the term "NET" refers to extracellular complexes of nucleosomes and proteins, e.g. proteins having anti-microbial activity. The nucleosomes may be derived from neutrophils, mast cells, eosinophils, monocytes, or leukocytes.
[0065] As used herein, the phrase "NET associated complication" means, without particular limitation, NET associated:
a. systemic inflammatory responses to: infection (including bacteria, virus, fungal, parasitic infections), sepsis (including bacteria, virus, fungal, parasite, prion induced sepsis); or to non-infectious inducers including non-infectious Systemic inflammatory response syndrome surgery, trauma, haemorrhage, burns, acute pancreatitis, preeclampsia and acute kidney injury;
b. hypoxia at the localised tissue /eve/ e.g. following blockage of an artery due to atherosclerosis, spontaneous rupture of a vessel, traumatic damage to a vessel and including cardiac and transplantation associated IRI; or at the whole body /eve/ following cessation of breathing e.g. due to drowning, gas exposure or cardiorespiratory arrest and includes ailments such as, for example, acute respiratory distress syndrome, ventilator-associated lung injury, chronic obstructive pulmonary disease and drug-mediated tissue injury;
c. haemostasis or vascular obstruction such as, for example, cardiovascular disease or chronic cardiovascular disease, such as atherosclerosis, coagulation and thrombosis (e.g., deep vein thrombosis); Transfusion-related acute lung injury (TRALI);
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 d. fibrosis where functional parenchymal organ tissue is replaced by fibrotic tissue, which can severely diminish organ function such as pulmonary fibrosis, idiopathic pulmonary fibrosi;
e. autoimmune disease states and inflammation disease states such as, for example, multiple sclerosis, tumour associated inflammation, hyper-inflammatory disease states, systemic lupus erythematosus, spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, inflammatory bowel disease, ulcerative colitis, cystic fibrosis (CF), Asthma, glomerulonephritis, chronic lung disease, Crohn's disease, irritable bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) such as granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), characterized by destruction and inflammation of small vessels, familial Mediterranean fever, amyotrophic lateral sclerosis, Cancer, Sjogren's syndrome, early arthritis, viral arthritisõ psoriasis, age-related organ fibrosis, idiopathic pulmonary fibrosis, juvenile diabetes (Type l), diabetes mellitus (Type 2), antiphospholipid syndrome, f. various central nervous system diseases such as Huntington's disease g. cytokine and chemokine induced degradation such as Gout.
[0066] The above cited conditions are associated with increased NETosis, and thus NETs can be targeted for treatment of these disorders.
[0067] As used herein, the terms "ailment", "condition" or "disease" (used interchangeably) means a medical complication associated with the release of NETs.
[0068] As used herein, the term "sepsis" includes within its meaning all stages of a sepsis disease or condition as characterised by standard medical reference texts and/or known to one of skill in the art. For example, sepsis includes severe sepsis, acute and chronic sepsis and septic shock. The term "sepsis" as used herein also includes episodes associated with infection. The term 'SIRS' (systemic immune response syndrome) used AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 herein includes episodes not associated with infection such as, for example, trauma, burns, pancreatitis, organ transplantation, surgery, tumour lysis following therapeutic regimes for cancer, perinatal complications and immunosuppressive prophylaxis for allogeneic grafts.
[0069] As used herein, the terms "medical condition associated with sepsis or SIRS" or "disease associated with sepsis or SIRS" include within their meaning all signs and symptoms directly or indirectly associated with, derived from, caused by or accompanying any or all stages of sepsis or SIRS diseases or conditions as characterised by standard medical reference texts and/or known to one of skill in the art. For example, the medical conditions or diseases associated with sepsis or SIRS include one or more of the following signs or symptoms associated with, derived from, caused by or accompanying any or all stages of sepsis or SIRS diseases or conditions in a subject which may be manifested in the subject with or without infection: arterial hypotension, metabolic acidosis, decreased systemic vascular resistance, increased heart rate (tachycardia), increased breathing rate IS (tachypnoea), general or systemic inflammation, elevated or decreased white blood cell count (leucocytosis or leucopenia), increased NETs in blood, organ dysfunction such as acute organ dysfunction, dysfunction of the circulatory system, multiple organ dysfunction syndrome, disseminated intravascular coagulation (DIC), deposition of fibrin in the microvasculature of one or more organs, fever, confusion, pneumonia, cough with pneumonia, kidney infection, painful urination with a kidney infection, and/or septic shock.
[0070] As used herein, the terms "decrease", "reduced", "reduction", "decrease" or "inhibit" are all used generally to mean a decrease by a statistically significant amount.
However, for avoidance of doubt, "reduced", "reduction" or "decrease" or "inhibit" means a decrease by at least 10% as compared to a reference level, e.g., in the absence of an agent, for example a decrease by at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%.
[0071] As used herein, the terms "improve", "increased", 'increase" or "enhance" or "activate" are all used to generally mean an increase by a statically significant amount;
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 for the avoidance of any doubt, the terms "improve", "increased", "increase"
or "enhance"
or "activate" means an increase of at least 10% as compared to a reference level, e.g., in in the absence of an agent, for example an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%), or at least about 60%, or at 5 least about 70%, or at least about 80%, or at least about a 2-fold, or at least about a 3-fold, or at least about a 4-fold, or at least about a 5-fold or at least about a 10-fold increase, or any increase between 2-fold and 10-fold or greater as compared to a reference level.
[0072] As used herein, the terms "administer", "administered" and "administering"
refers to the placement of a composition into a subject by a method or route which results 10 in at least partial localization of the composition at a desired site such that a desired effect is produced. A compound or composition described herein can be administered by any appropriate route known in the art including, but not limited to, oral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, nasal, rectal, and topical (including buccal and sublingual) administration. In IS certain embodiments, the compound is a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof. Preferably, the small uncharged glycosidically linked substituent that is present at the reducing terminus of the polyanionic sulfated cellobioside, improves the chemical stability of the polyanion, relative to the same 20 polyanion that is sulfated at its reducing terminus. When the above compound is present in a composition such as a therapeutic or a therapeutic composition it will be prepared for parenteral administration, or another other method allowing delivery to a target site.
Some exemplary modes of administration include, but are not limited to, injection, infusion, instillation, inhalation, or ingestion.
[0073] As used herein, the term "Injection" includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, sub capsular, subarachnoid, intraspinal, intracerebro spinal, and intrasternal injection and infusion. In preferred embodiments, the compositions are administered by intravenous infusion or injection.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0074] As used herein, the terms "treat," "treatment," "treating" and the like, in the context of the present invention insofar as it relates to any of the conditions or diseases recited herein means to relieve, alleviate, ameliorate, inhibit, slow down, reverse, or stop the progression, aggravation, deterioration, progression, anticipated progression or severity of at least one symptom or complication associated with such condition or disease. In an embodiment, the symptoms of a condition or disease are alleviated by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%.
[0075] As used herein, the phrases "effective amount" "therapeutically effective amount" or "effective dose" (used interchangeably herein) include within their meaning a sufficient but non-toxic amount of a compound or composition of the invention to provide a desired effect. The exact amount of a compound or composition required will vary from subject to subject depending on factors such as the desired effect, the species being treated, the age and general condition of the subject, the severity of the condition being treated, the agent being administered, the mode of administration, and so forth. Thus, it IS is not possible to specify an exact "effective amount". However, for any given case, an appropriate effective amount (dose) may be determined by one of ordinary skill in the art using only routine experimentation. Generally, a therapeutically effective amount can vary with the subject's history, age, condition, sex, as well as the severity and type of the medical condition in the subject, and administration of other pharmaceutically active agents.
[0076] As used herein, reference to use of a compound or composition in therapeutic or pharmaceutical applications will be understood to be equally applicable to human and non-human, such as veterinary, applications. Hence, it will be understood that, except where otherwise indicated, reference to a "patient", "subject" or "individual"
(used interchangeably herein) means a human or non-human, such as an individual of any species of social, economic or research importance including but not limited to, mammalian, avian, lagomorph, ovine, bovine, equine, porcine, feline, canine, primate and rodent species. More preferably, the patient, subject or individual is an animal belonging to a mammalian species. The mammalian species is desirably a human or non-human primate or a companion animal such as a domesticated dog, cat, horse, monkey, mouse, AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 rat, rabbit, sheep, goat, cow or pig. In one particularly preferred example, the patient, subject or individual is a human.
[0076A] As used herein, the term "small uncharged glycosidically-linked substituent"
refers to a substituent selected from the group consisting of 0-(C1_6)alkyl, S-(C1_6)alkyl, or N-di-(01_6)alkyl, wherein each alkyl may be straight, branched or cyclic, may contain one or more double or triple bonds, and may be substituted with one or more halogen atoms, and wherein the two alkyl groups on N-di-(C1_6)alkyl may together form a ring.
[0077] Definitions for selected terms used herein may be found within the detailed description of the invention and apply throughout. Unless otherwise defined, all other scientific and technical terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the invention belongs.
Illustrative embodiments of the invention [0078] The ensuing detailed description of this invention is included solely for the purposes of illustrating the invention and should not be understood in any way as a restriction on the broad description of the invention, as set out above.
1. Compounds of the Invention [0079] In a first aspect of the invention, there is provided a compound for use in the treatment of a NET mediated complication wherein the compound comprises: a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof. The substituent rendering the molecule high chemical stability, relative to the same polyanion but which is sulfated at its reducing terminus. Preferably, this class of compound should have a high net negative charge.
[0080] Compounds of the invention can ameliorate NET mediated complications (such as sepsis or ischemia reperfusion injuries) both preventatively i.e. as a prophylactic pre-treatment to a medical procedure or therapeutically during treatment after the conditions or disease has occurred.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 [0081] In an embodiment of the invention, the modified polyanionic sulfated cellobioside, has the general structure:
RI
wherein:
R1 is a sulfate group or a small uncharged glycosidically linked substituent, for example, 0- or S-(C1-6)alkyl; and R2 to R8 are each selected from: (i) a small uncharged 0-linked substituent or (ii) a sulfate group.
[0082]
Preferably, R1 is 0- or S-(C1_6)alkyl. When R1 is 0- or S-(C1_6)alkyl, the selected substituent preferably improves the chemical stability of the polyanion, compared to the same polyanion with a sulfate group at R1.
[0083] Preferably, R2 to R8 are each selected from: (a) an unmodified hydroxyl group;
or (b) a sulfate group.
[0084] More preferably, R1 is a methoxy or ethoxy group and R2 to R8 are each a sulfate group.
[0085]
Desirably, the class of compound has a high net negative charge, i.e. it is a polyanion.
[0086] The anomeric configuration of the small uncharged glycoside substituent (R1) can be in either of the a or 13 position. Preferably, the small uncharged substituent is in the 13 configuration.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0087] In a highly-preferred form of the invention, the compound is 13-0-Methyl Cellobioside Sulfate or a pharmaceutically acceptable salt thereof, which is a sulfated 13-0-methyl cellobioside disaccharide. By way of illustration, the compound is the sodium salt of 13-0-Methyl Cellobioside Sulfate.
[0088] mCBS is highly stable relative to CBS and well tolerated at high doses.
[0089] The small uncharged glycosidically linked substituent that is present at the reducing terminus of the polyanionic sulfated cellobioside, improves the chemical stability of the polyanion relative to the same polyanion that is sulfated at its reducing terminus.
[0090] Chemical stability as used herein represents the tendency of the compound of the invention to resist change (in particular decomposition in its natural environment or when exposed to air, heat, light, pressure, or other natural conditions, or due to internal reaction.
[0091] A compound of the invention is "stable" if it is does not significantly decompose, relative to the same polyanion that is sulfated at its reducing terminus, after at least one-IS month storage under conditions of anticipated use or normal environmental conditions.
[0092] A compound of the invention will have decomposed significantly if it has lost 3 or more sulfate groups after at least one-month storage, under conditions of anticipated use or normal environmental conditions. Preferably, a compound of the invention will have decomposed significantly if it has lost 2 sulfate groups after at least one-month storage, under conditions of anticipated use or normal environmental conditions. Most preferably, a compound of the invention will have decomposed significantly if it has lost 1 sulfate group after at least one-month storage, under conditions of anticipated use or normal environmental conditions.
[0093] Preferably, the compound of the invention is chemically stable for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 months when stored in a phosphate formulation buffered to pH 7.5 and stored at 2-8 C. More preferably, stability is measured over a period of 6 months to 2 years with the compound being stored in a phosphate formulation buffered to pH 7.5 and stored at about 2-8 C.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0094] As used herein, the phrase "pharmaceutically acceptable salt(s)"
includes those salts which, within the scope of sound medical judgement, are suitable for use in contact with tissues of humans and lower animals without the undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
5 [0095] Pharmaceutically acceptable salts are well known in the art.
They include, for example, acid addition salts (formed with the free amino groups of the protein) derived from inorganic acids (e.g., hydrochloric or phosphoric acids, or from organic acids (e.g., citric, acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups of the protein can also be derived from inorganic bases (e.g., sodium, potassium, 10 ammonium, calcium, or ferric hydroxides) or from organic bases (e.g., isopropylamine, trimethylamine, histidine, procaine and the like.
[0096] In a preferred form of the invention the modified sulfated cellobioside of the invention, is present as a pharmaceutically acceptable salt. By way of illustration, the compound is the sodium salt of p-O-Methyl Cellobioside Sulfate, viz Sodium p-O-Methyl 15 Cellobioside Sulfate (mCBS.Na).
[0097] Modified sulfated cellobioside compounds or pharmaceutically acceptable salts thereof used in the methods or compositions of the present invention may be prepared by methods known to those skilled in the art. For example, methods for preparing sulfated compounds modified with an uncharged substituent at its reducing termini are generally 20 described in Katrin C Probst and Hans Peter Wessel, 2001, J.
Carbohydrate Chemistry, 20 (7 & 8): 549-560, which is incorporated herein by reference in its entirety.
2. Treatment methods [0098] As compounds of the invention and therapeutic or pharmaceutical compositions including said compounds can ameliorate or prevent the pathological activity of NETs, the 25 present invention provides as a second aspect of the invention, a method of treatment or prevention for NET associated complications, said method comprising the step of:
administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0099] Further, in a third aspect of the invention, there is provided a method for ameliorating NET accumulation in a subject, said method comprising the step of:
administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0100] In an embodiment of the second and third aspects of the invention the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of 13-0-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0101] The present invention as described by the second and third aspects of the invention contemplates treating ameliorating or preventing a variety of different NET
ailments that are caused by the formation of NETs and the resulting toxicity therefrom.
According to these aspects of the invention, the respective methods can be used for the treatment or prevention of NET associated complications in a subject.
[0102] Typically NET associated conditions are attributable to increased NETosis, and thus NETs can be targeted for treatment of these disorders by modifying (preferably reducing) the level or the activity of the NETs to a basal concentration or quantity that is consistent with their normal pathophylsiological levels in a subject.
[0103] The largest group of NET activators are pathogenic Gram-positive and Gram-negative bacteria lipoteichoic acid and LPS, and breakdown products of prokaryotic proteins. Some examples of bacteria that induce NETs include, by way of illustration: S.
aureus, Streptococcus sp., P. aeruginosa, Bordetella pertussis, Mannheimia haemolytica, AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 Aggregatibacter actinomycetemcomitans , Neisseria gonorhoeae, Neisseria meningitidis, Yersinia enterocolitica, Vibrio cholerae, Leptospira species, H. influenzae, K.
pneumoniae, L. monocyto genes, M. tuberculosis, and S. flexneri). Net Activation also arises from: fungal infection (examples include, by way of illustration:
(Aspergillus spp.
such as, A. nidulans, A. fumigatus and Candida spp.such as C. albicans);
protozoan parasite infection (examples include, by way of illustration: L. amazonensis or its surface lipophosphoglycan, Strongyloides stercoralis, Eimeria bovis, Leishmania species, Toxoplasma gondii, Plasmodium falciparum); or viral infection (examples include, by way of illustration: HIV/SIV, Hantaan virus Respiratory Syncytial Virus (RSV), influenza virus).
IO These pathogenis activators are presented only by way of example and do not consistute a defined list of organisms that represent NET activators. Those skilled in the field will be aware of the NET activation ability of an organism.
[0104] The response caused by infection with organisms such as those listed above is generally an inflammatory response causing activation of inflammation pathways, IS however other responses such as autimmune responses, lung diseases, thrombosis or other microbial activity may also be present as a result of NET activation.
Net activation also arises from non-infectious inducers including non-infectious systemic inflammatory response syndrome, surgery, trauma, haemorrhage, burns and kidney injury;
hypoxia at the localised tissue level or at the whole body level; haemostasis or vascular obstruction;
20 fibrosis where functional parenchymal organ tissue is replaced by fibrotic tissue;
autoimmune disease states and inflammation disease, various central nervous system diseases as well as cytokine and chemokine induced degradation.
[0105] In an embodiment of the second or third aspects of the invention, the respective methods may further comprise administering to the subject, at the same time or 25 concomitantly with the compound of the invention, a second therapeutic agent (such as anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents or other forms of medical intervention) that is distinct from the compound of the invention that provides an adjunct treatment for a medical condition that the subject is or may suffer from.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0106] Preferably, as an example of these aspects of the invention, the respective methods provide a means for treating or preventing sepsis or SIRS or a medical condition or disease associated with sepsis or SIRS in a subject.
[0107] As another example of these aspects of the invention the respective methods provide a means for treating or preventing IRI or a medical condition or disease associated with IRI in a subject.
[0108] Preferably, the method ameliorates the condition or a disease state sufficiently to allow a physician to administer other drugs to treat secondary conditions.
Thus, the invention also includes administering a therapeutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof to a subject, for the purposes of ameliorating NET associated complications in the patient.
[0109] In certain exemplary embodiments according to the second or third aspects of the invention, the identified methods can further comprise the step of:
administering to IS the subject, together with or concomitantly with the modified sulfated cellobioside, a therapeutically or pharmaceutically effective amount of a second active agent, compound or composition selected from: one or more of anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents and/or any other form of pharmaceutical composition that treats one or more condition that a subject is afflicted with or at risk of being afflicted with.
[0110] According to this embodiment, the second active agent, compound or composition provides an adjunct treatment to the treatment directed to the NET
associated complication (such as, for example, sepsis, SIRS or IRI) and/or for medical conditions or diseases associated with such complications. Preferably, the second active agent, compound or composition comprises one or more of anti-inflammatory agents.
[0111] Preferably, the second active agent presents a means for medical intervention of a disease that a patient is afflicted with that is related to or distinct from the medical AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 ailment treated by the compounds of this invention, said second active agent providing an adjunct treatment for the patient.
[0112] Therapeutics and/or pharmaceutical compositions of the invention disclosed herein may be administered either therapeutically or preventively. In a therapeutic application, compounds and compositions are administered to a patient already suffering from NET associated complications or an ailment associated with NET associated complications, in an amount sufficient to cure or at least partially arrest its symptoms.
The compound or composition should be provided in a quantity of the active compound sufficient to effectively treat the patient either in a single dose or as part of a treatment regime e.g., a multi-dose treatment regime. In a preventative application, compounds and compositions of the invention are administered to a subject at risk of developing an ailment associated with NET associated complications, in an amount sufficient to at least partially arrest the ailment's symptoms and/or complications.
[0113] In a fourth aspect of the invention, there is provided a method for treating or preventing a medical condition, ailment or disease associated with NET
mediated pathology in a subject, wherein the method comprises the step of:
administering to the subject a therapeutically or pharmaceutically effective amount of: a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0114] In an embodiment of the fourth aspects of the invention the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0115] In one preferred example, the method is used to treat NETs that (i) are cytotoxic towards the endothelium in a subject, or (ii) contribute to endothelial dysfunction in a AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 subject, or (iii) initiate coagulation by activating platelets in a subject, or (iv) induce red cell fragility and resultant anaemia in a subject.
[0116] Patients suffering from an infection of the type caused by one or more of the above identified organisms have increased levels of NETs present in their blood.
5 [0117] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated sepsis in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged 10 glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof. Preferably, the small uncharged glycosidically linked substituent that is present at the reducing terminus of the polyanionic sulfated cellobioside improves the chemical stability of the polyanion relative to the same polyanion that is sulfated at its reducing terminus. More preferably, the modified sulfated cellobioside is mCBS
or more 15 particularly is a pharmaceutically acceptable salt thereof such as mCBS.Na.
[0118] As demonstrated herein, compounds of the invention in particular mCBS
block the toxic effects of NETs and thereby are useful as a treatment for sepsis.
[0119] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic 20 activity of NET proteins in sepsis, including both pre- treatment (in the case of a medical procedure) and treatment after sepsis has occurred.
[0120] In a highly preferred exemplary form of the invention, according to any aspect, embodiment or example describes herein, the compound of the invention is used to treat or prevent one or more of the following discussed ailments or conditions.
25 A. Sepsis [0121] Sepsis (including septic shock) is a systemic reaction to infection characterized by arterial hypotension, metabolic acidosis, decreased systemic vascular resistance, AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 tachypnoea and organ dysfunction. Sepsis (including septic shock) is also a systemic inflammatory response to infection associated with and mediated by the activation of a number of host defence mechanisms including the cytokine network, leukocytes, and the complement and coagulation fibrinolysis systems. Disseminated intravascular .. coagulation (DIC) with widespread deposition of fibrin in the microvasculature of various organs may be an early manifestation of sepsis. DIC is an important mediator in the development of the multiple organ failure syndrome and contributes to the poor prognosis of patients with septic shock.
[0122] The immunological response that causes sepsis is a systemic inflammatory response causing widespread activation of inflammation and coagulation pathways. This may progress to dysfunction of the circulatory system and, even under optimal treatment, may result in the multiple organ dysfunction syndrome and eventually death.
[0123] Symptoms of sepsis are often related to an underlying infectious process and if left untreated can manifest as severe sepsis (sepsis with acute organ dysfunction) or .. septic shock (sepsis with refractory arterial hypotension). When two or more of the systemic inflammatory response syndrome criteria (e.g., general inflammation, fever, elevated white blood cell count (leukocytosis), and raised heart rate (tachycardia) and breathing rate (tachypnoea)) are met without evidence of infection, patients may be diagnosed simply with "SIRS", which is a septic inflammatory state affecting the whole body.
[0124] Many patients with sepsis exhibit a rapid decline over a 24-48 hour period.
Rapid treatment is essential for effective sepsis treatment. Unfortunately, diagnosis of type of infection requires microbiological analysis to identify the pathogen which may take several days. Therefore, therapy to eliminate a pathogen (e.g. antibiotic therapy) must .. be initiated without knowledge of the type and species of the pathogen, and with no means of knowing the extent of the infection. The present invention provides such a method.
[0125] Patients suffering from sepsis have increased levels of NETs present in their blood. NETs have been implicated as important mediators of sepsis pathology.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0126] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated sepsis in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0127] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated 6-0-methyl cellobioside disaccharide or a sodium salt ofp-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0128] As demonstrated herein, compounds of the invention in particular mCBS
block the toxic effects of NETs and thereby are useful as a treatment for sepsis.
[0129] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in sepsis, including both pre- treatment (in the case of a medical procedure) and treatment after sepsis has occurred.
B. Non-Infectious SIRS
[0130] Non-infectious Systemic inflammatory response syndrome (SIRS) is an inflammatory state affecting the whole body. It is the body's response to non-infectious insult. Although the definition of SIRS refers to it as an "inflammatory"
response, it actually has pro- and anti-inflammatory components.
[0131] SIRS is a serious condition related to systemic inflammation, organ dysfunction, and organ failure. It is a subset of cytokine storm, in which there is abnormal regulation of various cytokines. SIRS is also closely related to sepsis, in which patients satisfy AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 criteria for SIRS and have a suspected or proven infection. Causes of non-infection SIRS
include, for example: trauma, from surgery, traumatic haemorrhage, burns and acute pancreatitis, by way of illustration.
[0132] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated non-infectious SIRS in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0133] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated 13-0-methyl cellobioside disaccharide or a sodium salt of 6-0-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0134] As demonstrated herein, compounds of the invention in particular mCBS
block the toxic effects of NETs and thereby are useful as a treatment for non-infectious SIRS.
[0135] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in non-infectious SIRS, including both pre- treatment (in the case of a medical procedure) and treatment after non-infectious SIRS has occurred.
B.1 Trauma [0136] Physical trauma is a serious and body-altering physical injury, such as the crushing or amputation of a limb.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0137] Blunt force trauma, a type of physical trauma caused by impact or other force applied from or with a blunt object, whereas penetrating trauma is a type of physical trauma in which the skin or tissues are pierced by an object. Trauma can also be described as both unplanned, such as an accident, or planned, in the case of surgery.
Both can be characterized by mild to severe tissue damage, blood loss and/or shock, and both may lead to SIRS, but also significantly increase the risk of subsequent infection and sepsis.
[0138] NETs are released following trauma or severe cellular stress in the absence of infection. Patients suffering from trauma can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of trauma pathology.
[0139] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated trauma in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0140] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated 13-0-methyl cellobioside disaccharide or a sodium salt of P-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0141] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in trauma patients.
[0142] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 activity of NETs in trauma, including both pre- treatment (in the case of a medical procedure) and treatment after trauma injury has occurred.
8.2. Surgery [0143] Surgery uses operative manual and instrumental techniques on a patient to 5 .. investigate and/or treat a pathological condition such as disease or injury, to help improve bodily function or appearance, or sometimes for some other reason. The present invention can address trauma resulting from surgeries, as defined further below.
[0144] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
10 .. associated surgical trauma in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
15 [0145] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is 20 mCBS it is a sulfated 6-0-methyl cellobioside disaccharide or a sodium salt of -O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0146] As a rule, a procedure is considered surgical when it involves cutting of a patient's tissues or closure of a previously sustained wound. Other procedures that do not necessarily fall under this rubric, such as angioplasty or endoscopy, may be 25 considered surgery if they involve common surgical procedure or settings, such as use of a sterile environment, anaesthesia, antiseptic conditions, typical surgical instruments, and suturing or stapling. All forms of surgery are considered invasive procedures;
so-called non-invasive surgery usually refers to an excision that does not penetrate the structure AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 being addressed (e.g., laser ablation of the cornea) or to a radio-surgical procedure (e.g., irradiation of a tumour).
[0147] As compounds of the invention and therapeutic or pharmaceutical compositions including said compounds, can ameliorate the cytotoxic activity of NETs, the present invention provides a treatment for use in surgical trauma, including both pre-treatment (in the case of a medical procedure) and treatment after surgical injury has occurred.
8.3. Traumatic Haemorrhage [0148] Traumatic haemorrhage accounts for much of the wide-ranging international impact of injury, causing a large proportion of deaths and creating great morbidity in the injured. Despite differences in pre-hospital care, the acute management of traumatic haemorrhage is similar around the world and follows well accepted published guidelines.
A critically injured patient's care occurs as four, often overlapping segments: the resuscitative, operative, and critical care phases. The diagnosis and control of bleeding should be a high priority during all the phases of trauma care and is especially important in the patient who is in haemorrhagic shock. Early attempts at haemorrhage control include direct control of visible sources of severe bleeding with direct pressure, pressure dressings, or tourniquets; stabilization of long bone and pelvic fractures;
and keeping the patient warm. During the resuscitative phase, warmed intravenous fluids, hypotensive resuscitation prior to surgical control of haemorrhage, and appropriate transfusion of blood and blood products are provided. In the operative phase, surgical control of the haemorrhage and any other injury, and additional transfusion is provided.
Finally, the critical care phase provides for post-operative support and tissue perfusion).
[0149] As compounds of the invention and therapeutic or pharmaceutical compositions including said compounds, can ameliorate the cytotoxic activity of NETs, the present invention provides to treatment for use in traumatic haemorrhage, including both pre-treatment (in the case of a medical procedure) and treatment after traumatic haemorrhage has occurred.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 BA. Burns [0150] A burn can be an injury caused by heat, cold, electricity, chemicals, friction or radiation. First-degree burns are usually limited to redness (erythema), a white plaque, and minor pain at the site of injury. These burns usually extend only into the epidermis.
Second-degree burns additionally fill with clear fluid, have superficial blistering of the skin, and can involve more or less pain depending on the level of nerve involvement.
Second-degree burns involve the superficial (papillary) dermis and may also involve the deep (reticular) dermis layer. Third-degree burns additionally have charring of the skin, and produce hard, leather-like eschars. An eschar is a scab that has separated from the .. unaffected part of the body. Frequently, there is also purple fluid. These types of burns are often painless, because nerve endings have been destroyed in the burned areas.
Serious burns, especially if they cover large areas of the body, can cause death; any hint of burn injury to the lungs (e.g., through smoke inhalation) is a medical emergency.
[0151] Burns that injure the tissues underlying the skin, such as the muscles or bones, are sometimes categorized as fourth-degree burns. These burns are broken down into three additional degrees: fourth-degree burns result in the skin being irretrievably lost, fifth-degree burns result in muscle being irretrievably lost, and sixth-degree burns result in bone being charred.
[0152] Various burns lead to an increase in the levels of NETs which in turn are associated with toxicity. To the extent that the NETs toxicity is present, the present invention seeks to reduce this toxicity using the pharmaceutical compositions of the present invention, thereby reducing or alleviating discomfort on the part of the patient, as well as permitting higher doses of the therapy.
[0153] Patients suffering from burns can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of burns pathology.
[0154] In an embodiment of the second or third aspect of the invention, there is provided a method of ameliorating NET induced cytotoxicity caused by burns to a subject, said method comprising the step of: administering to the subject a therapeutically or AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0155] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated 6-0-methyl cellobioside disaccharide or a sodium salt of 6-0-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0156] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in burns patients.
[0157] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic IS activity of NETs in a burn in a subject.
B.5. Acute Pancreatitis [0158] Acute pancreatitis is characterized as rapidly-onset inflammation of the pancreas by sterile inflammation and acinar cell death, including necrosis and apoptosis.
[0159] Depending on its severity, acute pancreatitis can have severe complications and high mortality despite treatment. While mild cases are often successfully treated with conservative measures or laparoscopy, severe cases require invasive surgery (often more than one intervention) to contain the disease process.
[0160] Patients suffering from acute pancreatitis can have increased levels of NETs present in their blood. NETS have been implicated as important mediators of acute pancreatitis pathology.
[0161] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 associated acute pancreatitis in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0162] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0163] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in acute pancreatitis patients.
IS [0164] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NET.s in acute pancreatitis, including both pre-treatment (in the case of a medical procedure) and treatment after acute pancreatitis has occurred.
C. Ischemia-Reperfusion Injury [0165] Ischemia reperfusion injuries (including transplantation associated Ischemia reperfusion injuries) and drug-mediated tissue injury result in sterile inflammation, a process occurring in the absence of microorganisms.
[0166] lschemia is a restriction in blood supply to tissues, causing a shortage of oxygen that is needed for cellular metabolism. In prolonged ischemia (60 min or more), hypoxanthine is formed as a breakdown product of ATP metabolism. The enzyme xanthine dehydrogenase is converted to xanthine oxidase as a result of the higher availability of oxygen. This oxidation results in molecular oxygen being converted into highly reactive superoxide and hydroxyl radicals. Xanthine oxidase also produces uric AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 acid, which may act as both a prooxidant and as a scavenger of reactive species such as peroxinitrite. Excessive nitric oxide produced during reperfusion reacts with superoxide to produce the potent reactive species peroxynitrite. Such radicals and reactive oxygen species attack cell membrane lipids, proteins, and glycosaminoglycans, causing further 5 damage. They may also initiate specific biological processes by redox signalling.
[0167] Reperfusion injury refers to damage due in part to the inflammatory response of damaged tissues. White blood cells carried to the area by the newly returning blood release a host of inflammatory factors such as interleukins as well as free radicals in response to tissue damage. The restored blood flow reintroduces oxygen within cells that 10 damages cellular proteins, DNA, and the plasma membrane. Damage to the cell's membrane can in turn cause the release of more free radicals. Such reactive species act indirectly in redox signalling to turn on apoptosis. Leukocytes also build up in small capillaries, obstructing them and leading to more ischemia.
[0168] Reperfusion injury also plays a part in the brain's ischemic cascade, which is 15 involved in stroke and brain trauma. Repeated bouts of ischemia and reperfusion injury also are thought to be a factor leading to the formation and failure to heal of chronic wounds such as pressure sores and diabetic foot ulcers. Continuous pressure limits blood supply and causes ischemia, and the inflammation occurs during reperfusion. As this process is repeated, it eventually damages tissue enough to cause a wound.
20 [0169] NET levels are elevated in animal lschemia reperfusion models with liver, kidney, lung, and brain injury, suggesting an important role of NETs in the regulation of sterile inflammation.
[0170] NETs mediate not only liver, but also acute kidney injury or ischemic stroke through direct toxicity or pro-inflammatory effects. Inhibition of NET
formation and activity 25 presents a therapeutic strategy for tissue injury.
[0171] Patients suffering from ischemia reperfusion injuries (including transplantation associated ischemia reperfusion injuries) and drug-mediated tissue injury have increased AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 levels of NETs present in their blood. NETs have been implicated as important mediators of ischemia/reperfusion and drug-mediated tissue injury pathology.
[0172] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated IRI and/or drug-mediated tissue injury in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0173] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated 13-0-methyl cellobioside disaccharide or a sodium salt of 13-0-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0174] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in ischemia/reperfusion and drug-mediated tissue injury patients.
[0175] Thus, compounds of the invention and therapeutic or pharmaceutical .. compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in ischemia/reperfusion and drug-mediated tissue injury, including both pre-treatment (in the case of a medical procedure) and treatment after ischemia/reperfusion and drug-mediated tissue injury has occurred.
D. Coagulation and Thrombosis [0176] Coagulation is the biological process by which blood forms clots. A
precise regulation mechanism prevents aberrant coagulation that results in an increased risk of bleeding (haemorrhage) or obstructive clotting (thrombosis).
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0177] Patients suffering from coagulation and or thrombosis can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of coagulation and or thrombosis pathology.
[0178] In an embodiment of the second or third aspect of the invention, there is provided a method of treating coagulation and or thrombosis in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof. .
[0179] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated -O-methyl cellobioside disaccharide or a sodium salt of -O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0180] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in coagulation and or thrombosis patients.
[0181] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in coagulation and or thrombosis, including both pre-treatment (in the case of a medical procedure) and treatment after coagulation or thrombosis has occurred.
E. Autoimmune/Inflammatory Disease [0182] The present invention contemplates the treatment of a variety of autoimmune and/or inflammatory disease states such as multiple sclerosis, spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, ulcerative colitis, Crohn's disease, irritable bowel disease, rheumatoid arthritis, juvenile AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 rheumatoid arthritis, familial Mediterranean fever, amyotrophic lateral sclerosis, Sjogren's syndrome, early arthritis, viral arthritis, or psoriasis. The diagnosis and treatment of these diseases are well documented in the literature.
[0183] Patients suffering from autoimmune and/or inflammatory disease have increased levels of NETs present in their blood. NETs have been implicated as important mediators of autoimmune and/or inflammatory disease pathology.
[0184] In an embodiment of the second or third aspect of the invention, there is provided a method of treating autoimmune and/or inflammatory disease in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of:
administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0185] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0186] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in autoimmune and/or inflammatory disease patients.
[0187] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in autoimmune and/or inflammatory disease, including both pre-treatment (in the case of a medical procedure) and treatment after autoimmune and/or inflammatory disease has occurred.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 F. Acute Respiratory Distress Syndrome [0188] Acute respiratory distress syndrome (ARDS), also known as respiratory distress syndrome (RDS) or adult respiratory distress syndrome (in contrast with IRDS) is a serious reaction to various forms of injuries to the lung. This is the most important disorder resulting in increased permeability pulmonary oedema.
[0189] ARDS is caused by a variety of direct and indirect insults. It is characterized by inflammation of the lung parenchyma leading to impaired gas exchange with concomitant systemic release of inflammatory mediators causing inflammation, hypoxemia and frequently resulting in multiple organ failure. This condition is life threatening and often lethal, usually requiring mechanical ventilation and admission to an intensive care unit. A
less severe form is called acute lung injury (ALI) including transfusion-related acute lung injury (TRALI).
[0190] ARDS can occur within 24 to 48 hours of an injury or attack of acute illness. In such a case the patient usually presents with shortness of breath, tachypnoea, and symptoms related to the underlying cause, i.e., shock. Long term illnesses can also trigger it, such as malaria. The ARDS may then occur sometime after the onset of a particularly acute case of the infection.
[0191] Patients suffering from ARDS can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of ARDS pathology.
[0192] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated acute respiratory distress syndrome in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0193] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0194] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in ARDS patients.
[0195] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic 10 activity of NETs in ARDS, including both pre-treatment (in the case of a medical procedure) and treatment after ARDS has occurred.
G. Cardiovascular Disease [0196] Cardiovascular disease refers to the class of diseases that involve the heart or blood vessels (arteries and veins). While the term technically refers to any disease that 15 affects the cardiovascular system, it is usually used to refer to those related to atherosclerosis (arterial disease). These conditions have similar causes, mechanisms, and treatments.
[0197] Treatment of cardiovascular disease depends on the specific form of the disease in each patient, but effective treatment always includes preventive lifestyle 20 changes discussed above. Medications, such as blood pressure reducing medications, aspirin and the statin cholesterol-lowering drugs may be helpful. In some circumstances, surgery or angioplasty may be warranted to reopen, repair, or replace damaged blood vessels [0198] Various forms of cardiovascular disease include aneurysms, angina, 25 arrhythmia, atherosclerosis, cardiomyopathy, cerebrovascular disease, congenital heart disease, congestive heart failure, myocarditis, valve disease, coronary artery disease, dilated cardiomyopathy, diastolic dysfunction, endocarditis, high blood pressure AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 (hypertension), hypertrophic cardiomyopathy, nitral valve prolapse, myocardial infarction, and venous thromboembolism.
[0199] Patients suffering from NET associated cardiovascular disease have increased levels of NETs present in their blood, which have been implicated as important mediators of NET associated cardiovascular disease pathology.
[0200] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated cardiovascular disease in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0201] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked .. substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0202] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in NET associated cardiovascular disease patients.
[0203] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NET proteins in NET associated cardiovascular disease, including both pre-treatment (in the case of a medical procedure) and treatment after NET
associated cardiovascular disease has occurred.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 H. Fibrosis [0204] Patients suffering from fibrosis have increased levels of NETs present in their blood. NETs have been implicated as important mediators of fibrosis pathology.
[0205] In an embodiment of the second or third aspect of the invention, there is provided a method of ameliorating NET induced cytotoxicity caused fibrosis in a subject, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0206] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0207] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in fibrosis patients.
[0208] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in fibrosis in a subject, including both pre-treatment (in the case of a medical procedure) and treatment after fibrosis has occurred.
I. Diabetes [0209] Patients suffering from diabetes can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of diabetes pathology.
[0210] The invention provides methods for treating NET associated complications in diabetes (e.g inflammation and delayed wound healing). The methods comprise AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 administering a therapeutically effective amount of at least one compound of the invention to a subject diagnosed with Type 1, Type 1.5 or Type 2 diabetes.
[0211] In an embodiment of the second or third aspect of the invention, there is provided a method of ameliorating diabetes in a subject, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0212] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated 13-0-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0213] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in diabetes patients.
[0214] In certain embodiments, the symptom of diabetes having NET involvement is inflammation. Reduction in inflammation can be monitored by physical examination, as well as the reduction in the presence of inflammatory markers.
[0215] In certain embodiments, a method for treatment of diabetes is provided, that comprises the administration of a therapeutically effective amount of an agent used to treat diabetes and at least one compound of the invention. The agent used to treat diabetes can be insulin or another agents selected from the following Biguanides, Metformin (Glucophage), Metformin liquid (Riomet), Metformin extended release (Glucophage XR, Fortamet, Glumetza), Sulfonylureas, Glimepiride (Amaryl), Glyburide (Diabeta, Micronase), Glipizide (Glucotrol, Glucotrol XL), Micronized glyburide (Glynase), Meglitinides, Repaglinide (Prandin), D-Phenylalanine Derivatives, Nateglinide (Starlix), AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 Thiazolidinediones, Pioglitazone (TZDs), Pioglitazone, (Actos), DPP-4 Inhibitor, Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin ( Tradjenta), Alpha-glucosidase, Acarbose (Precose), Miglitol (Glyset), Bile Acid Sequestrants, Colesevelam (Welchol), Pioglitazone & metformin (Actoplus Met), Glyburide & metformin (Glucovance), Glipizide & metformin (Metaglip), Sitagliptin & metformin (Janumet), Saxagliptin &
metformin (kombiglyze ), Repaglinide & metformin (Prandimet) and Pioglitazone &
glimepiride (Duetact).
[0216] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in diabetes in a subject. As such the present invention provides a treatment for diabetes in a subject, including both pre-treatment (in the case of a medical procedure) and treatment after diabetes has occurred.
J. Chemotherapy, Radiotherapy and Cytokine Therapy Toxicity [0217] Various forms of cancer therapy, including chemotherapy, radiation, and cytokines, are associated with toxicity, sometimes severe, in the cancer patient. To the extent that the toxicity is caused at least in part by the actions of NETs, the present invention seeks to reduce this toxicity using the pharmaceutical compositions of the present invention, thereby reducing or alleviating discomfort on the part of the patient, as well as permitting higher doses of the therapy.
[0218] Patients suffering from the side effects of various forms of cancer therapy, including chemotherapy, radiation, and cytokine therapy can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of these side effects.
[0219] In an embodiment of the second or third aspect of the invention, there is provided a method of ameliorating the side effects of various forms of cancer therapy, including chemotherapy, radiation, and cytokine therapy in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0220] According to this embodiment the selected compound is prefereably a 5 polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl 10 Cellobioside Sulfate, viz mCBS.Na.
[0221] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment for the side effects of various forms of cancer therapy, including chemotherapy, radiation, and cytokine therapy.
[0222] In a highly preferred form of the invention the compound used in treating the IS side effects of various forms of cancer therapy, including chemotherapy, radiation, and cytokine therapy in the patients undergoing such therapy is the compound [3-0-Methyl Cellobioside Sulphate or a pharmaceutically acceptable salt thereof. For example, the compound used in the method is Sodium p-O-Methyl Cellobioside Sulphate.
[0223] Thus, compounds of the invention and therapeutic or pharmaceutical 20 compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in the side effects of various forms of cancer therapy, including chemotherapy, radiation, and cytokine therapy, including both pre-treatment (in the case of a medical procedure) and treatment after these therapies have occurred.
K. Wound healing 25 [0224] Also provided are methods for use in wound healing. As used herein "wound healing" refers to the intricate process where the skin (or another organ-tissue) repairs itself after injury. The classic model of wound healing is divided into three or four sequential, yet overlapping, phases: (1) haemostasis, when clot stops bleeding, (2) AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 inflammation, (3) proliferation and (4) remodelling. Upon injury to the skin, a set of complex biochemical events takes place in a closely orchestrated cascade to repair the damage. During the inflammation phase, bacteria and cell debris are phagocytosed and removed from the wound by white blood cells. Platelet-derived growth factors (stored in the alpha granules of the platelets) are released into the wound that cause the migration and division of cells during the proliferative phase. The proliferation phase is characterized by angiogenesis, collagen deposition, granulation tissue formation, epithelialization, and wound contraction. New blood vessels are formed and fibroblasts grow and form a new, provisional extracellular matrix (ECM) by excreting collagen and fibronectin. Concurrently, re-epithelialization of the epidermis occurs, in which epithelial cells proliferate and 'crawl' atop the wound bed, providing cover for the new tissue.
[0225] Patients suffering from wound healing difficulties can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of wound healing pathology.
[0226] In an embodiment of the second or third aspect of the invention, there is provided a method of ameliorating NET induced cytotoxicity caused during wound healing in a subject, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0227] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0228] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in patients suffering from wound healing difficulties.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0229] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in treating wounds in a subject.
L. Central Nervous System Disease [0230] Patients suffering from central nervous system disease can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of central nervous system disease pathology. For example, Huntington's disease is an autosomal dominant neurodegenerative disorder caused by a polyglutamine repeat expansion, resulting in an expanded polyglutamine track in the huntington protein.
[0231] In an embodiment of the second or third aspect of the invention, there is provided a method of ameliorating NET induced central nervous system disease in a subject, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked IS substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0232] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0233] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in central nervous system disease.
[0234] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in central nervous system disease in a subject, including both pre-AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 treatment (in the case of a medical procedure) and treatment after central nervous system disease has occurred.
3. Therapeutic and Pharmaceutical Forms [0235]
In a fifth aspect of the invention, there is provided a therapeutic or pharmaceutical composition for use in treating an NET associated complication comprising: at least a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a therapeutically or pharmaceutically acceptable salt thereof.
Preferably, the composition includes a therapeutically or pharmaceutically acceptable carrier, excipient and/or diluent. The .. compound in the therapeutic or pharmaceutic may be in a neutral free base form or salt form. Preferably, the compound is the sodium salt of 8-0-Methyl Cellobioside Sulfate.
[0236] As used here, the terms "pharmaceutically acceptable" or "therapeutically effective" refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
[0237] Methods for preparing administrable compositions are apparent to those skilled in the art, and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pa., hereby incorporated by reference in its entirety.
[0238] As used here, the term "pharmaceutically-acceptable carrier" or "a pharmaceutically acceptable excipient" or "pharmaceutically acceptable diluent"
"therapeutically-acceptable carrier" or "a therapeutically acceptable excipient" or "therapeutically acceptable diluent" means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 another organ, or portion of the body. Each carrier, diluent and excipient must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. It is a material that is not biologically or otherwise undesirable i.e., the material can be applied to an individual along with the active agent without causing unacceptable biological effects or interacting in a deleterious manner with any one or more of the components of the composition in which it is contained.
Some examples of materials that can serve as pharmaceutically-acceptable carriers, diluents and excipients include, but are not limited to: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar;
(14) buffering agents, such as magnesium hydroxide and aluminum hydroxide;
(15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or .. polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; (22) C2-012 alcohols, such as ethanol;
and (23) other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, binding agents, fillers, lubricants, colouring agents, disintegrants, release agents, coating agents, sweetening agents, flavouring agents, perfuming agents, preservative, water, salt solutions, alcohols, antioxidants, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like can also be present in the formulation. The terms such as "excipient", "carrier", "diluent" and "pharmaceutically acceptable carrier" or the like are used interchangeably herein.
[0239] Examples of therapeutically or pharmaceutically acceptable carriers, excipients or diluents are demineralised or distilled water; saline solution; vegetable based oils such AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oil, arachis oil or coconut oil;
silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysolpoxane; volatile silicones; mineral oils such as liquid paraffin, 5 soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethyl-cellulose; lower alkanols, for example ethanol or iso-propanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols, for example polyethylene glycol, polypropylene glycol, ethylene glycol, propylene glycol, 1,3- butylene glycol or glycerin;
10 fatty acid esters such as isopropyl palmitate, isopropyl myristate or ethyl oleate;
polyvinylpyrridone; agar; carrageenan; gum tragacanth or gum acacia, and petroleum jelly. Typically, the carrier or carriers will form from 10% to 99.9% by weight of the compositions.
[0240] The compositions described herein can additionally contain other adjunct IS components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions can contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anaesthetics or anti-inflammatory agents. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions 20 described herein.
[0241] As described in detail below, the therapeutically or pharmaceutical acceptable compositions described herein can be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or nonaqueous solutions or suspensions), lozenges, dragees, 25 capsules, pills, tablets (e.g., those targeted for buccal, sublingual, and systemic absorption), boluses, powders, granules, pastes for application to the tongue;
(2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) injection directly into the organ needing treatment such as by 30 intraparenchymal (into the brain), intrathecal, intraventricular or intrahepatic AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 administration; (4) topical application, for example, as a cream, lotion, gel, ointment, or a controlled-release patch or spray applied to the skin; (5) in an aerosol form suitable for administration by inhalation, such as by intranasal inhalation or oral inhalation, (6) intravaginally or intrarectally, for example, as a pessary, cream, suppository or foam; (7) sublingually; (8) ocularly as an eye drop; (9) transdermally; (10) transmucosally; or (11) nasally.
[0242] In one embodiment, the composition of the invention is administered by injection such as by parenteral injection (such as by subcutaneous, intramuscular or intravenous injection) or locally to tissues and organs such as by intraparenchymal (into the brain), .. intrathecal, intraventricular or intrahepatic administration.
[0243] Pharmaceutical compositions suitable for injection include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
Ideally, the composition is stable under the conditions of manufacture and storage and may include a preservative to stabilise the composition against the contaminating action of microorganisms such as bacteria and fungi.
[0244] Sterile injectable solutions can be prepared by incorporating the pharmaceutical composition of the invention in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilisation. By way of illustration, a single dose may be dissolved in 1 ml of isotonic NaCI solution and either added to 1000 ml of fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580).
[0245] In the case of injectable solutions, the carrier can be a solvent or dispersion medium containing, for example, water, Ringer's solution, isotonic saline, phosphate buffered saline, ethanol, polyol (for example, glycerol, propylene glycol (eg 1,2 propylene glycol), and liquid polyetheylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 [0246] The proper fluidity can be maintained, for example, using a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and using surfactants. Prevention of the action of microorganisms can be achieved by including various anti-bacterial and or anti-fungal agents. Suitable agents are well known to those skilled in the art and include, for example, parabens, chlorobutanol, phenol, benzyl alcohol, ascorbic acid, thiomerosal, and the like. In many cases, it may be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminium monostearate and gelatin.
[0247] In a second embodiment, the composition of the invention is administered orally, for example, with an inert diluent or an assimilable edible carrier. For oral therapeutic administration, the pharmaceutical composition may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
[0248] Some examples of suitable carriers, diluents, excipients and adjuvants for oral use include peanut oil, liquid paraffin, sodium carboxymethylcellulose, methylcellulose, sodium alginate, gum acacia, gum tragacanth, dextrose, sucrose, sorbitol, mannitol, gelatine and lecithin. In addition, these oral formulations may contain suitable flavouring and colourings agents.
[0249] When used in capsule form the capsules may be coated with compounds such as glyceryl monostearate or glyceryl distearate which delay disintegration.
Tablets, troches, pills, capsules and the like can also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; an .. additional disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0250] When the dosage unit form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier. Various other materials can be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules can be coated with shellac, sugar or both.
[0251] Liquid forms for oral administration (such as a syrup or elixir) can contain, in addition to the above agents, a liquid carrier, a sweetening agent (e.g.
sucrose), a preservative (eg methyl and propylparabens), a dye and flavouring such as cherry or orange flavour. Suitable liquid carriers include water, oils such as olive oil, peanut oil, sesame oil, sunflower oil, safflower oil, arachis oil, coconut oil, liquid paraffin, ethylene glycol, propylene glycol, polyethylene glycol, ethanol, propanol, isopropanol, glycerol, fatty alcohols, triglycerides or mixtures thereof.
[0252] Suspensions for oral administration may further comprise dispersing agents and/or suspending agents. Suitable suspending agents include sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, poly-vinyl-pyrrolidone, sodium alginate or acetyl alcohol. Suitable dispersing agents include lecithin, polyoxyethylene esters of fatty acids such as stearic acid, polyoxyethylene sorbitol mono-or di-oleate, -stearate or - laurate, polyoxyethylene sorbitan mono- or di-oleate, -stearate or -laurate and the like. The emulsions for oral administration may further comprise one or more emulsifying agents. Suitable emulsifying agents include dispersing agents as exemplified above or natural gums such as guar gum, gum acacia or gum tragacanth.
[0253] In a third exemplary embodiment, the composition of the invention is administered directly to the airways of a subject in the form of an aerosol or by nebulization. For use as aerosols, solution or suspension of the pharmaceutical acceptable compositions of the invention can be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants. Such compositions can also be administered in a non-pressurized form such as in a nebulizer or atomizer.
[0254] Aerosols for the delivery to the respiratory tract are known in the art: see, for example, Adjei, A. and Garren, J. Pharm. Res., 1: 565-569 (1990); Zanen, P.
and Lamm, AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 J - W. J. Int. J. Pharm., 114: 111-115 (1995); Gonda, I. "Aerosols for delivery of therapeutic an diagnostic agents to the respiratory tract," in Critical Reviews in Therapeutic Drug Carrier Systems, 6:273-313 (1990); Anderson et al., Am. Rev.
Respir.
Dis., 140: 1317-1324 (1989)).
[0255] In a fourth exemplary embodiment, the composition may be administered in the form of liposomes. Liposomes are generally derived from phospholipids or other lipid substances, and are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolisable lipid capable of forming liposomes can be used. The compositions in liposome form may contain stabilisers, preservatives, excipients and the like.
The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art, and in relation to this specific reference is made to: Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq., the contents of which are IS incorporated herein by reference.
[0256] In addition, the therapeutic or pharmaceutical acceptable composition of the invention according to any aspect, embodiment or example described hereof, can be incorporated into sustained-release preparations and formulations. Such therapeutic or pharmaceutical compositions may further include a suitable buffer to minimise acid hydrolysis. Suitable buffer agent agents are well known to those skilled in the art and include, but are not limited to, phosphates, citrates, carbonates and mixtures thereof.
[0257] Compounds of the invention may also be administered in the form of a "prodrug". A prodrug is an inactive form of a compound which is transformed in vivo to the active form. Suitable prodrugs include esters, phosphonate esters etc, of the active form of the compound.
[0258] Additionally, compositions of the invention can be implanted into a patient or injected using a drug delivery system. Coated delivery devices can also be useful. See, for example, Urquhart, etal. (1984), Ann. Rev. Pharmacol. Toxicol. 24: 199-236; Lewis, AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 ed. "Controlled Release of Pesticides and Pharmaceuticals" (Plenum Press, New York, 1981); U.S. Pat. No. 3,773,919; U.S. Pat. No. 6,747,014; and U.S. Pat. No. 35 3,270,960.
[0259] In certain embodiments, the compositions are delivered using a device, or bandage, used for example in the process of treatment of a wound.
5 [0260] The therapeutically effective amount of a pharmaceutical compositions disclosed herein for any particular subject will depend upon a variety of factors including:
the toxicity and therapeutic efficacy of the pharmaceutical composition; the severity of the ailment; the age, body weight, general health, sex and diet of the patient;
the time of administration; the route of administration; the rate of sequestration of the compositions;
10 the duration of the treatment; drugs used in combination or coincidental with the treatment, together with other related factors well known in medicine.
[0261] Toxicity and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 15 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD5o/ED5o. Compositions that exhibit large therapeutic indices, are preferred.
[0262] Data obtained from the cell culture assays and animal models described herein can be used in formulating a range of therapeutically effective dosages for use in humans.
20 The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized.
[0263] The amount of compound of the invention described herein which can be 25 combined with a carrier material to produce a dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.1% to 99% of compound, preferably from about 5% to about 70%, most preferably from 10% to about 30%.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0264] The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. By way of illustration only the compositions may be administered so that the pharmaceutical acceptable compositions is given at a dose from 1 pg/kg to 150 mg/kg, 1 pg/kg to 100 mg/kg, 1 pg/kg to 50 mg/kg, 1 pg/kg to 20 mg/kg, 1pg/kg to 10 mg/kg, 1 pg/kg to 1 mg/kg, 100 pg/kg to 100 mg/kg, 100 pg/kg to 50 mg/kg, 100 pg/kg to 20 mg/kg, 100 pg/kg to 10 mg/kg, 100pg/kg to 1 mg/kg, 1 mg/kg to 100 mg/kg, 1 mg/kg to 50 mg/kg, 1 mg/kg to 20 mg/kg, 1 mg/kg to 10 mg/kg, 10 mg/kg to 100 mg/kg, 10 mg/kg to 50 mg/kg, or 10 mg/kg to 20 mg/kg. It is to be understood that ranges given here include all intermediate ranges, for example, the range 1 mg/kg to 10 mg/kg includes 1 mg/kg to 2 mg/kg, 1 mg/kg to 3 mg/kg, 1 mg/kg to 4 mg/kg, 1 mg/kg to 5 mg/kg, 1 mg/kg to 6 mg/kg, 1 mg/kg to 7 mg/kg, 1 mg/kg to 8 mg/kg, 1 mg/kg to 9 mg/kg, 2 mg/kg to 10 mg/kg, 3 mg/kg to 10 mg/kg, 4mg/kg to 10 mg/kg, 5 mg/kg to 10 mg/kg, 6 mg/kg to 10 mg/kg, 7 mg/kg to 10 mg/kg, 8 mg/kg to 10 mg/kg, 9 mg/kg to 10 mg/kg etc...
It is to be further understood that the ranges intermediate to the given above are also within the scope of the methods and compositions described herein, for example, in the range 1 mg/kg to 10 mg/kg, dose ranges such as 2 mg/kg to 8 mg/kg, 3 mg/kg to 7 mg/kg, 4 mg/kg to 6 mg/kg etc.
[0265] Where the compound of the invention is CBS, mCBS or mCBS.Na the dosage may be from 10 to 800 pg/ml. Preferably, it is in the range of 50 to 500 pg/ml. More preferably the dosage is 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790 or 800 pg/ml when administered to a human subject.
[0266] In certain examples of the invention an effective amount of the modified sulfated cellobioside compound is given as a single dose of administration. In certain examples, the dose is given repeatedly. That is treatment regimens will vary depending on the severity and type of disease, the overall health and age of the patient, and various other conditions to be considered by the treating physician. With respect to duration and AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 frequency of treatment, it is typical for skilled clinicians to monitor subjects to determine when a treatment is providing therapeutic benefit, and to determine whether to increase or decrease dosage, increase or decrease administration frequency, discontinue treatment, resume treatment or make other alteration to treatment regimen.
[0267] Therapeutics or pharmaceutical acceptable compositions of the invention according to any aspect, embodiment or example described hereof, may be provided in a single bolus administration or in multiple doses or treatments and may also be applied by "continuous" therapy where a small amount of the therapeutic composition is provided continually over an extended time period.
[0268] Where multiple dosing is used in the treatment (including continuous therapy) the therapeutics or pharmaceutical composition will be administered by a dosing schedule that can vary from once a week to daily depending on several clinical factors, such as the subject's sensitivity to the modified sulfated cellobioside compound used in the therapeutic or pharmaceutical composition. The desired dose to be administered in such a regime can be delivered as a single dose at one time or divided into sub-doses, e.g., 2-4 sub-doses and administered over a time period, e.g., at appropriate intervals through the day or other appropriate schedule. Such sub-doses can be administered as unit dosage forms.
[0269] In some embodiments, administration is chronic, e.g., one or more doses daily over a period of weeks or months. Examples of dosing schedules are administration daily, twice daily, three times daily or four or more times daily over a period of 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more.
[0270] The desired dose can be administered using continuous infusion or delivery through a controlled release formulation. In that case, the pharmaceutical composition contained in each sub-dose must be correspondingly smaller to achieve the total daily dosage.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0271] The dosage unit can also be compounded for delivery over several days, e.g., using a conventional sustained release formulation which provides sustained release of the pharmaceutical composition over a several day period. Sustained release formulations are well known in the art and are particularly useful for delivery of agents at a site, such as could be used with the agents described herein. In this embodiment, the dosage unit contains a corresponding multiple of the daily dose.
4. Combination regimes [0272] In certain exemplary embodiments, according to the fifth aspect of the invention, the identified composition may also comprise a second active agent, compound or composition selected from: one or more of anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents and/or any other form of therapeutic or pharmaceutical compound that treats one or more conditions that the subject is afflicted with. According to this embodiment, the second active agent, compound or composition desirably provides an adjunct therapy for sepsis, SIRS and IRI or for a medical condition or disease associated with sepsis, SIRS and IRI. Preferably, the second active agent, compound or composition comprises one or more of anti-inflammatory agents.
[0273] Therapeutic advantages may be realised through combination regimens. In certain embodiments of the invention, the described methods may further comprise the step of: administering to a subject, at the same time or concomitantly with the inventive treatment, a second active agent that is an adjunct treatment for the sepsis, SIRS and IRI
or the medical condition or disease associated with sepsis, SIRS and IRI that the patient is having or suffering from or is at risk of having or suffering from when delivered preventatively.
[0274] The second active agent may include, without limitation, anti-inflammatory .. agents, antibiotic agents, antiviral agents, antifungal agents or other forms of medical intervention that is distinct from the compound of the invention.
[0275] By way of illustration, when the method or treatment is directed to treating or ameliorating a septic or non-septic disease state involving NET mediated pathology in a AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 subject the method may also comprise administering to a subject at the same time or concomitantly, a second anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents or other forms of medical intervention that is distinct from the compound of the invention, which provides an adjunct treatment for a medical condition involving NET mediated pathology.
[0276] In one example, the second active agent provides an adjunct treatment or prevention for sepsis, SIRS or IRI or the medical condition or disease associated with the sepsis, SIRS or IRI such as a sepsis, SIRS or IRI or a medical condition or disease associated with the sepsis, SIRS or IRI involving NET mediated pathology in a subject.
[0277] In another example, the second active agent provides an adjunct treatment or prevention for a medical condition involving NET cytotoxicity.
[0278] By way of illustration, when the method of treatment is directed to treating or ameliorating a septic or non-septic disease state associated with sepsis, SIRS
or IRI
involving NET mediated pathology in a subject, the method may also comprise administering to a subject at the same time or concomitantly, a second anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents or other forms of medical intervention that is distinct from the compound of the invention, which provides an adjunct treatment for a medical condition involving NET mediated pathology.
[0279] In some examples, the additional agent administered is an anti-inflammatory agent such as a steroid, corticosteroids, COX-2 inhibitor, non-steroidal anti-inflammatory agent (NSAIDs), aspirin or any combination thereof. More particularly, the additional agent administered may be an anti-inflammatory agent, selected from the group consisting of Alclofenac; Alclometasone Dipropionate; Algestone Acetonide;
Alpha Amylase; Amcinafal; Amcinafide; Amfenac Sodium; Amiprilose Hydrochloride;
Anakinra;
Anirolac; Anitrazafen; Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen;
Benzydamine Hydrochloride; Bromelains; Broperamole; Budesonide; Carprofen;
Cicloprofen; Cintazone; Cliprofen; Clobetasol Propionate; Clobetasone Butyrate;
Clopirac; Cloticasone Propionate; Cormethasone Acetate; Cortodoxone;
Deflazacort;
Desonide; Desoximetasone; Dexamethasone Dipropionate; Diclofenac Potassium;
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 Diclofenac Sodium; Diflorasone Diacetate; Diflumidone Sodium; Diflunisal;
Difluprednate;
Diftalone, Dimethyl Sulfoxide; Drocinonide; Endrysone; Enlimomab; Enolicam Sodium;
Epirizole; Etodolac; Etofenamate; Felbinac; Fenamole; Fenbufen; Fenclofenac;
Fenclorac; Fendosal; Fenpipalone; Fentiazac; Flazalone; Fluazacort; Flufenamic Acid;
5 Flumizole; Flunisolide Acetate; Flunixin; Flunixin Meglumine; Fluocortin Butyl;
Fluorometholone Acetate; Fluquazone; Flurbiprofen; Fluretofen; Fluticasone Propionate;
Furaprofen; Furobufen; Halcinonide; Halobetasol Propionate; Halopredone Acetate;
Ibufenac; Ibuprofen; Ibuprofen Aluminum; Ibuprofen Piconol; llonidap;
Indomethacin;
Indomethacin Sodium; Indoprofen; Indoxole; Intrazole; Isoflupredone Acetate;
Isoxepac;
10 Isoxicam; Ketoprofen; Lofemizole Hydrochloride; Lomoxicam; Loteprednol Etabonate;
Meclofenamate Sodium; Meclofenamic Acid; Meclorisone Dibutyrate; Mefenamic Acid;
Mesalamine; Meseclazone; Methylprednisolone Suleptanate; Morniflumate;
Nabumetone; Naproxen; Naproxen Sodium; Naproxol; Nimazone; Olsalazine Sodium;
Orgotein; Orpanoxin; Oxaprozin; Oxyphenbutazone; Paranyline Hydrochloride;
Pentosan 15 Polysulfate Sodium; Phenbutazone Sodium Glycerate; Pirfenidone;
Piroxicam; Piroxicam Cinnamate; Piroxicam Olamine; Pirprofen; Prednazate; Prifelone; Prodolic Acid;
Proquazone; Proxazole; Proxazole Citrate; Rimexolone; Romazarit; Salcolex;
Salnacedin; Salsalate; Salycilates; Sanguinarium Chloride; Seclazone;
Sermetacin;
Sudoxicam; Sulindac; Suprofen; Talmetacin; Talniflumate; Talosalate;
Tebufelone;
20 Tenidap; Tenidap Sodium; Tenoxicam; Tesicam; Tesimide; Tetrydamine;
Tiopinac;
Tixocortol Pivalate; Tolmetin; Tolmetin Sodium; Triclonide; Triflumidate;
Zidometacin;
Glucocorticoids; Zomepirac Sodium, and combinations thereof.
[0280] In some examples, the additional agent administered is an antibiotic agent such as kanamycin, actinomycin D, doxorubicin, bleomycin, mithramycin, aminoglycosides, 25 ansamycins, carbacephems, carbapenems, cephalosporins, glycopeptides, lincosamides, macrolides, monobactams, penicillins, polypeptides, quinolones sulfonamides and/or tetracyclines.
[0281] In some examples, the additional agent administered is an antiviral agent such as a non-nucleoside reverse transcriptase inhibitor, nucleoside reverse transcriptase AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 inhibitor (e.g. nucleoside analogues), protease inhibitor and/or a nucleotide analogue reverse transcriptase inhibitor.
[0282] In some examples, the additional agent administered is an antifungal agent such as an imidazole, triazole, thiazole, allylamine, and/or echinocandin compound.
[0283] In some examples, the additional agent administered is an agent to treat diabetes. Such agents include those agents known in the art for treatment of diabetes and or for having anti-hyperglycemic activities, for example, inhibitors of dipeptidyl peptidase 4 (DPP-4) (e.g., Alogliptin, Linagliptin, Saxagliptin, Sitagliptin, Vildagliptin, and Berberine), biguanides (e.g., Metformin, Buformin and Phenfornnin), peroxisome proliferator-activated receptor (PPAR) modulators such as thiazolidinediones (TZDs) (e.g., Pioglitazone, Rivoglitazone, Rosiglitazone and Troglitazone), dual PPAR
agonists (e.g., Aleglitazar, Muraglitazar and Tesaglitazar), sulfonylureas (e.g., Acetohexamide, Carbutamide, Chlorpropamide, Gliclazide, Tolbutamide, Tolazamide, Glibenclamide (Glyburide), Glipizide, Gliquidone, Glyclopyramide, and Glimepiride), meglitinides ("glinides") (e.g., Nateglinide, Repaglinide and Mitiglinide), glucagon-like peptide- 1 (GLP-1) and analogs (e.g., Exendin-4, Exenatide, Liraglutide, Albiglutide), insulin and insulin analogs (e.g., Insulin lispro, Insulin aspart, lnsluin glulisine, Insulin glargine, Insulin detemir, Exubera and NPH insulin), alpha-glucosidase inhibitors (e.g., Acarbose, Miglitol and Voglibose), amylin analogs (e.g. Pramlintide), Sodium-dependent glucose cotransporter T2 (SGLT T2) inhibitors (e.g., Dapgliflozin, Remogliflozin and Sergliflozin) and others (e.g. Benfluorex and Tolrestat).
[0284] Those skilled in the art will appreciate that the compositions according to any aspect, embodiment or example described hereof may be administered as part of a combination therapy approach to the treatment of sepsis, SIRS or IRI or a disease or condition associated with sepsis, SIRS or IRI. In combination therapy, the respective agents may be administered simultaneously, or sequentially in any order. When administered sequentially, it may be preferred that the components be administered by the same route.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 [0285] In some examples where the two agents are applied separately, one would generally ensure that a significant time period did not expire between the time of each delivery, such that both agents would still be able to exert an advantageously combined effect. In such instances, it is contemplated that one would typically administer both modalities within about 12-24 hours of each other and, more preferably, within about 6-12 hours of each other, with a delay time of only about 12 hours being most preferred, in some situations, it may be desirable to extend the time for treatment significantly, however, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations. It also is conceivable that more than one administration of a drug will be desired.
[0286] When compositions of the invention, and a second active agent are administered in different compositions, routes of administration may be different. For example, the composition of the invention is administered by any appropriate route known in the art including, but not limited to oral or parenteral routes, including intravenous, IS intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, nasal, rectal, and topical (including buccal and sublingual) administration, and the second pharmaceutically active agent is administration by a different route, e.g. a route commonly used in the art for administration of said pharmaceutically active agent. In a non-limiting example, the compositions of the invention can be administered by injection, while the second active agent can be administrated orally.
5. Manufacture of a medicament [0287] In a sixth aspect of the invention, there is provided a use of a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a medical condition, ailment or disease involving NETs.
[0288] Prefereably in this aspect of the invention the selected compound is a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated [3-0-methyl cellobioside disaccharide or a sodium salt of 6-0-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0289] For example, in an embodiment of the sixth aspect of the invention, there is provided a use of a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of sepsis or an IRI or a medical condition or disease associated with sepsis, SIRS or IRI in a subject. Preferably, the modified sulfated cellobioside is mCBS or more particularly is a pharmaceutically acceptable salt thereof such as mCBS.Na.
[0290] In one embodiment of such use, the medicament is for the treatment of sepsis or SIRS or of a medical condition or disease associated with sepsis or SIRS in a subject, wherein said treatment ameliorates or inhibits said sepsis or SIRS or said condition or disease associated with said sepsis or SIRS.
[0291] In another embodiment of such use, the medicament is for the treatment of an IRI or of a medical condition or disease associated with an IRI in a subject, wherein said treatment ameliorates or inhibits said the IRI or said condition or disease associated with said injury.
[0292] In yet another embodiment of such use, the medicament is used to neutralise NETs that (i) are cytotoxic towards the endothelium in a subject, or (ii) contribute to endothelial dysfunction in a subject, or (iii) initiate coagulation by activating platelets in a subject, or (iv) induce red cell fragility and resultant anaemia in a subject.
[0293] In yet another embodiment, the manufactured medicament may also include a therapeutic or pharmaceutically effective amount of a second active agent, compound or composition. According to this embodiment, the second active agent, compound or composition provides an adjunct therapy for treating a medical condition, ailment or AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 disease involving NETs. Desirably, the second active agent, compound or composition provides an adjunct therapy for the treatment of sepsis, SIRS or IRI or for a medical condition or disease associated with sepsis, SIRS or IRI. Preferably, the second active agent is selected from: one or more of anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents and/or any other form of therapeutic or pharmaceutical compound that treats one or more conditions that the subject is afflicted with. More preferably, the second active agent, compound or composition comprises one or more of anti-inflammatory agents.
[0294] When the modified sulfated cellobioside compound is used in any of the methods of the invention the compound can be administered or formulated for administration to the subject in need thereof, in a single dose of formulation. In certain alternative embodiments, the modified sulfated cellobioside compound is administered, or formulated for administration to the subject in need thereof, as a multi-dose formulation.
[0295] Preferably, for administration to a subject, the therapeutic or pharmaceutical composition is provided as a pharmaceutically acceptable composition. When in this form, (1) the composition will be pharmaceutical formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents and/or excipients and (2) the modified sulfated cellobioside compound in the composition may be formulated in a neutral or salt form.
EXAMPLES
[0296] The present invention is described further in the following non-limiting example which is provided by way of illustration only, and should not be construed as limiting the generality of the disclosure of the description throughout this specification.
Example 1: Method for the preparation of mCBS-Na .. [0297] [3-0-methyl cellobioside is prepared as described by Jon K
Fairweather et al., 2004, Aust J. Chem., 57: 197-205.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0298] 13-0-methyl cellobioside sulfate (mCBS) and sodium 13-0-methyl cellobioside sulfate (mCBS.Na) compounds were prepared as described by Katrin C Probst and Hans Peter Wessel, 2001, J. Carbohydrate Chemistry, 20 (7 & 8): 549-560, the disclosure of which is hereby incorporated herein by reference in its entirety.
5 [0299] (3-0-methyl cellobioside sulfate (mCBS) was prepared according to the following schematic:
/
= \
x.
X =
X =
I
X =
X
X =
[0300] Step 1: To the mixture of a-D-cellobiose 1 (116 g, 338 mmol) and glacial acetic acid (1.6 L) was added acetyl bromide (300 mL, 500.0 g, 4065 mmol, 12.0 equiv) at room 10 temperature. The resulting creamy mixture was heated at 6000 for 45 - 55 mins until the reaction mixture turn to be a clear solution which indicate the completion of reaction.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 [0301] Carefully pour the hot solution into the beaker (10 L) containing the cracked ice (4 kg). Stir the mixture until the white solid precipitated (-10 min). Add another portion of cold water (1 L) and keep on stirring for 10 min.
[0302] Filter with sinter funnel and washed the solid with cold water (700 mL
x 3). The resulting solid in the funnel was dissolved in DCM (1 L) and washed the funnel with DCM
(300 mL x2). The combined DCM layer was washed with brine (1 .5 L) and back extracted with DCM (0.5 L). The final DCM layer was dried over Na2SO4, filtered and concentrated under reduce pressure at < 35 C within 2 h to obtain the target bromide 2 (172.5 g, 74.3%
yield) which was directly used for the following glycosylation.
[0303] Step 2: To the mixture of per-O-acetylated cellobiosyl bromide 2 (171 g, 250 mmol), anhydrous DCM (800 mL), anhydrous Me0H (800 mL), activated 3A molecular sieves (70 g) was added silver carbonate (Ag2CO3, 75 g, 275 mmol, 1.1 equiv).
The resulting mixture was stirred in the absence of light for 16 h. The mixture was purified through a plug of silica and eluted with Et0Ac. The collected fractions were concentrated to give the crude product as the brown solid which was directly used for the next step.
The Rf of compound 3 = 0.28 (Et0Ac-Hexane, 1:1).
[0304] Step 3: To the mixture of the crude product obtained from step 2 and anhydrous Me0H (1 L) was added a small piece of Na (1.72 g, 0.3 equiv, 75 mmol) at room temperature. Shortly afterwards, a white solid began to precipitate from solution. The resulting mixture was stirred overnight in order to ensure the completion of de-acetylation.
The final suspension was filtered and washed with Me0H (300 mL x 2). The white solid was collected and dried under vacuum for overnight to obtain the final cellobioside 4 (72.5 g, 81.4% over 2 steps).
. =
, .
=
5. = =
=
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 Synthetic and purification procedure for step 4:
[0305] Step 4 The mixture of compound 4 (84.0 g, 236 mmol), S03.TMA (367.4 g, 2.64 mol, 11.2 equiv), anhydrous DMF (3140 mL) and anhydrous DOE (767 mL) was degassed under Ar for three times and heated at 80-90 C for 2 h. (Reaction monitoring:
After heating for 10 min, the creamy mixture turned to be a clear solution. After 30 min, the solution became cloudy again. After 50 min, the aggregated solid was observed on the surface of flask.) Upon cooling, the resulting mixture was moved to the cold room (-5 C) and settled overnight which allows the solid to completely aggregate from the solvent.
The complete conversion from compound 4 into 5 was confirmed with 1H-NMR.
Decant the solution into the drain. The crude solid was filtered and washed with DCM
for a couple of times. The resulting solid was dissolved in de-ionized water and directly subjected to ion-exchange column [Na form of DOWEX 50Wx8: 3 kg of resin (H+ form) was pre-packed in glass gravity column, regenerated by elution of 1M NaOH (-6 L) and neutralized with de-ionized water (-12 L)]. The collected fractions were concentrated to yield the final sulfated cellobioside 6(232.1 g, 92.0%) as the glassy solid.
Examples 2 to 6: Comparison of CBS, mCBS and MTS
[0306] In the following studies, the inventors examined 3 SPAs, namely cellobiose per-0-sulfate (CBS), methyl f3-cellobioside per-0-sulfate (mCBS) and maltotriose per-0-sulfate (MTS) (structures in Figure 1). The methodologies used in Examples 2 to 6 are set out below.
Method and materials for the following examples (2 ¨ 6) [0307] Heparin (porcine mucosa - PM) was purchased from Sigma-Aldrich.
[0308] Human subjects. All human-related research was approved by the ACT
Health Human Research Ethics Committee. Healthy adult donors were used as a source of erythrocytes and platelets for in vitro studies. Consenting patients admitted to The Canberra Hospital Intensive Care Unit with an APACHE II mortality score (Knaus, W.
A., Draper, E. A., Wagner, D. P. & Zimmerman, J. E. APACHE II: a severity of disease AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 classification system. Crit care med 13, 818-829 (1985)) on arrival in the ICU
and a diagnosis of sepsis were included in our study.
[0309] Sepsis was diagnosed based upon the following criteria (Mayr, F. B., Yende, S.
& Angus, D. C. Epidemiology of severe sepsis. Virulence 5, 4-11 (2014); and Bone, R. C.
et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101, 1644-(1992)):
a. At least two of the following:
i. Tachypnea > 24 bpm, or blood gas P002 < 32 mm Hg ii. White blood cells count (WCC) either <4,000 cell/mm3 or >12,000 cells/mm3 iii. Heart rate (HR) > 100 bpm iv. Temperature (fever) > 38.0 C or (hypothermia) < 36.0 C.
IS b.
No alternative cause for Systemic Inflammatory Response Syndrome (SIRS) identified c. Evidence of sepsis including positive blood culture, signs of pneumonia on chest x-ray or other imaging d. Evidence of end-organ dysfunction: renal failure, liver dysfunction, changes in Glasgow Coma Score (not attributable to other causes) or raised serum lactate.
e. Refractory hypotension requiring inotropic support.
[0310] Animals. All animal experiments were approved by the Australian National University Animal Experimentation Ethics Committee. Pathogen free male and female 057BL/6 mice (6-8 weeks of age), female BALB/c mice (5-6 weeks of age) and male Wistar rats (weighing between 250-350g) were obtained from the Australian Phenomics Facility at the Australian National University.
[0311]
Cell line and cell culture conditions. Human microvascular endothelial cells-1 (HMEC-1), carrying the type 0 blood group and thus not reactive with anti-blood group AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 antibodies in human sera, were supplied by ATCC and were cultured in MCDB 131 medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 IU m1-1 penicillin, 100 pg m1-1 streptomycin, 10 ng m1-1 EGF
and 1 pg ml -1 hydrocortisone. The cells were incubated in 5% CO2 and ambient 02 at 37 C
and were repeatedly tested for mycoplasma using a MycoAlert Assay kit (Lonza).
[0312] Histone-mediated cytotoxicity assays. To determine the cytotoxicity of calf thymus histones (Sigma-Aldrich), various concentrations of histones (100-800 pg m1-1) were added to suspensions of HMEC-1 or HUVEC (1 x 106 m1-1) in 96 well plates and incubated for 1 h at 37 C. Cells were then incubated for 5 min at 37 C with propidium iodide (PI; 2.5 pg m1-1) (ThermoFisher Scientific), to detect dead cells, and Calcein-AM
(0.04 pM) (ThermoFisher Scientific), to detect viable cells, placed on ice and the percentage of dead and viable cells determined by flow cytometry using gating strategies.
In inhibition assays, HMEC-1 were incubated with histones (400 pg m1-1) for 1 h at 37 C
in the presence of different concentrations of compounds (12.5-400 pg m1-1) prior to the IS .. addition of PI and Calcein-AM. HMEC-1 cytotoxicity at each compound concentration was then determined based on the formula:
Cytotoxicity (%) = Dead (compound & histones) - Dead (cells alone) x 100 Dead (histones alone) - Dead (cells alone) and the 1050 value for each polyanion then determined based on the line of best fit (nonlinear regression analysis) using Prism Software (Graphpad Software). In all assays MTS (I050 30 pg m1-1) was included as a standard to compensate for experimental variation, with data being adjusted in each assay to MTS having an I050 of 30 pg m1-1.
[0313] Lipid bilayer assays. Artificial lipid bilayers, prepared as previously described (Rebbeck, R. T. etal. The beta(1a) subunit of the skeletal DHPR binds to skeletal RyR1 and activates the channel via its 35-residue C-terminal tail. Biophys J 100, (2011).), separated symmetrical 150 mM or 250 mM KCI (pH -5.5) solutions.
Histones (1 pM, 15.2 pg m1-1) were added to bilayers alone or after 0.5-3 h incubation with 10 pM
CBS (3.5 pg m1-1) or 10 pM MTS (5.1 pg m1-1) at -20 C. Current was recorded continuously after histone addition until the bilayers broke or the experiment was AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 terminated.
[0314] Calcium flux studies in endothelial cells. HMEC-1 (2 x 107 m1-1) in RPMI-1640 medium were incubated with Indo-1 AM (5 pM) (ThermoFisher) (Tellam, R. L.
&
Parish, C. R. The effect of sulfated polysaccharides on the free intracellular calcium ion 5 .. concentration of lymphocytes. Biochim Biophys Acta 930, 55-64 (1987); and Weston, S.
A., Tellam, R. L. & Parish, C. R. Dextran sulfate induces changes in the free intracellular calcium ion concentration of a subpopulation of immature thymocytes. Immunol Cell Biol 69, 369-376 (1991)) at 37 C for 60 min. After 3 washes with RPMI-1640 medium supplemented with 5% FCS the cells were resuspended at 4 x 106 m1-1 in ice-chilled 10 HEPES-buffered saline (NaCl 8 g L, KCI 0.4 g L, CaCl2 0.2 g L, MgC12.6H20 0.2 g D-glucose 1.8 g 1-1, pH 7.4) supplemented with 10 mM HEPES. The cell suspension was kept on ice and used within 3 h. Intracellular Ca2+ flux was monitored using flow cytometry.
The cells were pre-equilibrated and maintained at 37 C during analysis using an external sheath connected to a heated water bath. After the exclusion of cellular debris and 15 clumped cells (on the basis of FSC/SSC light scattering) the basal Ca2+
level was monitored for 2 min before histone addition in the presence/absence of novel compounds.
Ca2+ levels were measured at 1, 3 and 9 min post-histone addition with a constant flow rate (-300 events/sec). Ca2+ flux was determined as an increase in the ratio of geometric mean fluorescence intensity (GMFI) of Ca24"-bound over Ca2+-unbound lndo-1.
20 [0315] In vitro erythrocyte microscopy, aggregation, fragility and deformability assays. Histone-mediated aggregation of human erythrocytes and its inhibition by various compounds was detected by flow cytometry, based on either forward and side scatter parameters or erythrocyte auto-fluorescence, as reported by the inventors previously (Kordbacheh, F., O'Meara, C. H., Coupland, L. A., Lelliott, P. M. &
Parish, C.
25 .. R. Extracellular histones induce erythrocyte fragility and anemia. Blood 130, 2884-2888 (2017).) and scanning electron microscopy as described earlier (Yabas, M. et al. Mice deficient in the putative phospholipid flippase ATP11C exhibit altered erythrocyte shape, anemia, and reduced erythrocyte life span. J Biol Chem 289, 19531-19537 (2014)).
Similarly, erythrocyte fragility induced by histones, in the presence or absence of 30 inhibitors, was quantified using a sheer stress assay that we developed recently AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 (Kordbacheh, F., O'Meara, C. H., Coupland, L. A., Lelliott, P. M. & Parish, C.
R.
Extracellular histones induce erythrocyte fragility and anemia. Blood 130, (2017)). Finally, the reduced deformability of erythrocytes in the presence of histones and the effect of inhibitors on this process was assessed by measuring the passage of erythrocytes through an artificial human spleen (Kordbacheh, F., O'Meara, C.
H., Coupland, L. A., Lelliott, P. M. & Parish, C. R. Extracellular histones induce erythrocyte fragility and anemia. Blood 130, 2884-2888 (2017); and Deplaine, G. etal. The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro. Blood 117, e88-95 (2011)).
[0316] In vitro platelet aggregation and degranulation assays. For aggregation studies platelets were isolated from human whole blood collected into Na-citrate vacutainers through 2-step centrifugation at room temperature (200xg for 20 min then the platelet-rich plasma 800xg for 15 min), the platelet pellet resuspended in Hank's balanced salt solution containing calcium and magnesium and histones added and incubated in the IS presence/absence of compounds at the concentrations of each as indicated. Samples were assessed for degree of platelet aggregation after 15 min exposure to histones by flow cytometry using the characteristic log FSC versus log SSC identification of platelets, with increases in the geometric mean of log FSC indicative of platelet aggregation.
[0317] For the platelet activation assay, whole blood collected in Na-citrate vacutainers was monitored for platelet degranulation using the luminescence mode on the Chrono-Log Model 700 with Chrono-Lume reagent (Chrono-Log Corp). Saline (300 pl) was added to pre-warmed blood (420 pl) with a stirrer bar in-situ. Chromo-Lume reagent (100 pl) was then added and incubated for 2 min before histones compounds diluted in water were added in a total volume of 180 pl at the concentrations indicated. Results expressed as ATP release calculated as a percentage of the histone + saline control.
[0318] In-vivo histone toxicity assays. BALB/c female mice (5-6 weeks of age), that are more prone to histone-induced anemia and easier to inject i.v. at this young age than C57BU6 mice, were injected i.p. with test compounds at concentrations indicated 10 min prior to i.v. injection of histones (50 mg kg-1) in phosphate buffered saline.
Retro-orbital AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 bleeds were performed with glass Pasteur pipettes 10 min after histone injection and collected blood added to acid citrate dextrose (ACD), the 10 min blood sample being subjected to hematologic analyses for platelet and erythrocyte content using an AD VIA
2120i Hematology Analyzer. Spleens were also harvested at 10 min post-histone injection and splenic hemoglobin content quantified using a hemoglobin assay kit (Sigma-Aldrich).
In the case of 4 h blood samples, male 057/BL/6 mice (6-8 weeks of age) were injected with test compounds and histones as above and plasma isolated and stored frozen for subsequent biochemical testing, with markers for liver (alanine aminotransferase, ALT), kidney (creatinine, Crea) and general tissue (lactate dehydrogenase, LDH) damage being determined by the Department of Pathology, The Canberra Hospital.
[0319] Murine deep vein thrombosis (DVT) model. The procedure used is largely as previously described (Brill, A. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 10, 136-144 (2012)). Briefly, 8 week old male C57BL/6 mice were anaesthetized, a laparotomy incision made, the intestines exteriorized and then, after gentle separation from the abdominal aorta, the inferior vena cava (IVC) immediately below the renal veins was ligated to ¨10% patency and all associated IVC tributaries were ligated. The peritoneum and skin were closed following which all mice received an i.v. injection of histones via the tail vein (10 mg kg-1) or an equivalent volume of saline followed 5 min later by an i.v. injection of test compounds (50 mg kg-1) or saline. Mice were monitored for 48 h after which they were re-anesthetized, re-opened and any thrombi that had developed distal to the IVC stenosis were removed for analysis. Sham operated control animals received laparotomy and 90%
ligation of the IVC, however the ligation was removed immediately after occlusion of the IVC.
[0320] Rat caecal ligation and puncture (CLP) assay for sepsis. The CLP assay was performed in male Wistar rats as previously described (Hubbard, W. J. et al. Cecal ligation and puncture. Shock 24 Suppl 1, 52-57 (2005)). Test compounds (50 mg kg-1) dissolved in saline or an equivalent volume of saline only (Control cohort) were administered i.p. 5 min pre-CLP and 5, 10 and 15 h post-op until cessation of the experiment at 20 h. Sham-CLP rats underwent the same procedure, however, the caecum was not ligated or punctured and these rats received saline at the same times as AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 above. At the conclusion of the experimental time period (20 h) or when morbidity required ethical euthanasia, the rats were anaesthetized and blood was collected via cardiac puncture into EDTA for subsequent analysis of liver (ALT) and kidney (creatinine) function by the Department of Pathology, The Canberra Hospital. The propensity for clots to form within the blood samples of the saline treated control CLP animals (despite the presence of EDTA) prevented successful analysis of plasma samples from all animals.
[0321] Rat cardiac ischemia reperfusion injury model. The method used is based on a combination of previously published procedures (Takada, Y., Hashimoto, M., Kasahara, J., Aihara, K. & Fukunaga, K. Cytoprotective effect of sodium orthovanadate on ischemia/reperfusion-induced injury in the rat heart involves Akt activation and inhibition of fodrin breakdown and apoptosis. J Pharmacol Exp Ther 311, 1249-(2004); and Hale, S. L., Dae, M. W. & Kloner, R. A. Hypothermia during reperfusion limits 'no-reflow' injury in a rabbit model of acute myocardial infarction.
Cardiovasc Res 59, 715-722 (2003)). Male Wistar rats were anaesthetized with isofluorane, intubated via IS tracheostomy and ventilated with a tidal volume of 1 ml 150 g-1 and a respiratory rate of 65 breaths min-1. Supplemental oxygen was delivered at a Fi02 of -30%. A left hemi-thoracotomy was performed to enable visualization of the left ventricle. The left coronary arterial plexus (LCA) was occluded using an atraumatic snare for 30 min prior to reperfusion for 30 min. lschemia was confirmed by myocardial hyperemia. The test compounds (30 mg kg-1) or an equivalent volume (200 pl) of saline were injected into the lumen of the left ventricle (confirmed with aspiration) 5 min prior to the release of the snare for the reperfusion phase.
[0322] At the conclusion of reperfusion (30 min), Thioflavin S (1 ml 200 g-1 of body weight) was slowly injected into the lumen of the left ventricle, to define the territory of microvascular obstruction (MVO) within the ischemic zone (IZ). The IZ
territory was determined by the re-occlusion of the atraumatic snare and infusion of blue microspheres into the left ventricle (Unisperse Blue, BASF), distributed within solutions via ultrasonication using a CD-6800 (Unisonics) sonicator. The heart was then excised from the thorax, rinsed in isotonic saline and 2 mm sections were cut distal to the atraumatic snare at right angles to the interventricular line. This method produced 4 myocardial AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 sections that were weighed and photographed (Sony Handycam, Zeiss 60x optical zoom) under ultraviolet light (territory of MVO) and bright light (IZ territory), before being incubated in tetrazolium chloride (TTC) to determine the region of necrotic myocardium.
Planimetry (Image J, Freeware) was used to quantify the areas of the IZ, MVO
and necrosis.
[0323] Rat ischemia reperfusion tissue flap model. The procedure employed is largely based on a previously described method (Bone, R. C. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101, 1644-1655 (1992)).
Briefly, male Wistar rats were anaesthetized, locally depilated and a 3 cm by 6 cm fasciocutaneous flap was excised leaving the vascular pedicle intact. The inferior epigastric artery was clamped, a fine rubber sheet was placed under the flap preventing oxygen diffusion from the tissues below and the flap was re-sutured back into place. The clamp was removed IS 10 h post-application permitting returned blood flow to the flap. Test compounds (50 mg kg-1) or saline were administered i.p. 5 min prior to clamp application and 5 min following its removal. The rats were monitored for a total experimental period of 72 h during which rats received additional compound or saline i.p. at 24 and 48 h post-op. The 'Control No Clamp' rats had the tissue flap excised and rubber placed underneath prior to re-suturing, however, the vessel was not clamped and they received saline at the same time points as the other rats. At the end of the experimental period the viability of the flaps was determined by the percentage of black necrotic or reddened areas versus pink viable areas. Despite the application of Elizabethan collars and the use of analgesia as a settling agent, a small number of rats had to be prematurely euthanized when they repeatedly auto-cannibalized their flaps.
[0324] Quantification of DNA in patient sera. Blood from consenting patients with an APACHE II score >12 upon arrival at ICU was collected from venous access lines into a serum-separator tube, the tubes centrifuged at 2300xg for 10 min and the serum harvested and stored at -80 C. To quantify DNA content serum from septic patients (5 pl) was incubated with 95 pl of 5 pM Sytox Green at 37 C for 10 min in a 96-well flat AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 bottom culture plate. Fluorescence intensity was then measured in a fluorescence plate reader (Tecan Infinite M200 Pro) with excitation set at 504 nm and emission at 523 nm.
[0325] Detection and analysis of cytotoxicity of septic patient sera for endothelial cells. To measure the cytotoxic activity of septic patients sera for endothelial cells in-vitro, HMEC-1 were seeded into 96-well plates at 2.5 x i0 well-1 in medium and grown at 37 C
in 5% CO2 for 48 h prior to the addition of 50 pl of patient serum in the presence/absence of DNase I (10 pg m1-1), anti-human histone 3 and histone 4 rabbit pAbs (200 pg m1-1) (BioVision), or test compounds (200 pg ml-1) and incubated for 3 h. 3H-thymidine (0.5 pCi, MP Biomedical) was then added to each culture well in 20 pl of HMEC-1 medium 10 and incubated for a further 24 h. At the conclusion of the incubation period plates were subjected to 3 freeze/thaw cycles (-70 C for 30 min, then 37 0.5 C for 30 min) prior to harvesting and measurement of 3H-thymidine incorporation. Using a Filtermate harvester (Packard Bioscience), cell cultures were harvested onto glass fiber filters (EasyTabTm-C Self Aligning Filters; Packard Bioscience). Filters were dried at 80 C and 15 placed in Omnifilter plates (Perkin Elmer) then 20 pl of Microscint-O
scintillation fluid (Perkin Elmer) was added to each well and the plate sealed with TopSeal-A
adhesive film (Perkin Elmer). 3H-thymidine incorporation was measured using a TopCount NXTTm Microplate Scintillation and Luminescence Counter (Packard Bioscience).
Results expressed as a percentage of the proliferation of HMEC-1 not exposed to patient sera.
20 [0326] Statistical analysis. Prism software (Graphpad Software) was used to perform statistical tests and to generate graphs, with details of the test used included in Figure legends.
In-vitro evidence of the biological effects of mCBS
[0327] The following Examples 2 to 6 provide in vitro evidence of the biological effect 25 of mCBS in neutralising free histones and NETs.
[0328] Example 2: mCBS protects endothelial cells from histone toxicity and erythrocytes from histone-induced fragility and aggregation [0329] Each of CBS, mCBS and MTS (collectively called Small Polyanions or SPAs) AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 have histone-inhibitory activity similar to heparin, unlike sulfated monosaccharides that are much less active, when histone cytotoxicity for endothelial cells (Figure 2a) or induction of erythrocyte (RBC) fragility (Figure 2b) was measured.
[0330] This Example investigates whether mCBS and MTS promote erythrocyte aggregation and reduce erythrocyte deformability. Based on flow cytometry FSC
and SSC, histones very efficiently aggregate erythrocytes, this effect being completely inhibited by mCBS (Figure. 3a), a result confirmed by scanning EM (Figure.
3b). The inventors also used erythrocyte auto-fluorescence to quantify the number of erythrocytes present in histone-induced aggregates. At high histone concentrations (400 pg m1-1) there were -35 erythrocytes/aggregate, but mCBS and MTS prevented aggregation in a concentration dependent manner, with MTS being -2-fold more effective than mCBS
(Figure. 3c). Finally, erythrocytes exposed to histone concentrations that do not induce erythrocyte aggregation (<50 pg m1-1) (Figure. 3d) showed significantly reduced passage through an artificial spleen, this assay measuring erythrocyte deformability/rigidity (Deplaine, G. etal. The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro. Blood 117, e88-95 (2011)). The addition of mCBS and MTS, however, totally restored the ability of erythrocytes to passage through an artificial spleen (Figure. 3d), indicating that SPAs, as well as protecting erythrocytes from histone-mediated aggregation and fragility, prevent histone-induced rigidity.
Example 3: SPAs inhibit platelet activation by histones [0331] Histones are known to induce platelet activation thus, to investigate the capacity of SPAs to inhibit this process, isolated, washed human platelets were incubated with histones and platelet aggregation measured by flow cytometry. Additionally, ATP release, due to platelet degranulation, was measured following exposure of whole blood to histones. Both platelet aggregation and degranulation were histone-concentration dependent (Figure. 4a, c), the difference in histone sensitivity of platelets between the two assays being attributed to the presence of plasma proteins and erythrocytes in the ATP release assay that also bind histones. Histone-induced platelet aggregation was completely inhibited by CBS, mCBS and MTS, with MTS being the most active (Figure.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 4b). Unsulfated CB, included as a negative control, was non-inhibitory (Figure. 4b).
Similar results were obtained with histone-induced ATP release (Figure. 4d).
Thus, CBS, mCBS and MTS are effective in inhibiting the platelet-activating properties of histones.
Example 4: SPAs prevent lipid bilayer disruption [0332] We next investigated how histones mediate their cytotoxicity and, consequently, how SPAs protect cells from histone-mediated damage. Histones are known to interact with and damage lipid bilayers (Kleine, T. J., Lewis, P. N. & Lewis, S. A.
Histone-induced damage of a mammalian epithelium: the role of protein and membrane structure.
Am J
Physiol 273, 01925-1936 (1997)) and act as cell penetrating proteins (Rosenbluh, J. et al. Translocation of histone proteins across lipid bilayers and Mycoplasma membranes. J
Mol Biol 345, 387-400 (2005)). Thus, we investigated whether histones mediate their cytotoxicity by directly disrupting lipid bilayers. To examine this possibility artificial lipid bilayers were prepared and their susceptibility to histone rupture detected by changes in current across the bilayers. Lipid bilayers have a finite lifetime, normally ¨30 to 120 min (Rebbeck, R. T. etal. The beta(1a) subunit of the skeletal DHPR binds to skeletal RyR1 and activates the channel via its 35-residue C-terminal tail. Biophys J 100, (2011)). In inventors experiments, control lipid bilayers containing ryanodine receptor 1 (RyR1) ion channel protein had an average lifetime of 46 4 min, addition of histones (1 .IM) markedly reducing the lifetime to 5.7 1.2 min (Fig. 3a). In fact, 13/47 bilayers (28%) broke within 0.3-0.5 min of histone addition whereas only 2/125 control bilayers (1.6%) ruptured in the same time period, with higher histone concentrations (50 OA) resulting in rapid rupture of most bilayers (not shown). Bilayers were less prone to rupture by histones when CBS or MTS was present, the average bilayer lifetime increasing significantly to 18 4 min and 36 5 min for CBS and MTS, respectively (Figure.
5a).
Furthermore, bilayer lifetimes with MTS were not significantly different from the control lifetimes. Similarly, compared with histones alone (28%), the incidence of rapid bilayer rupture decreased to 3/52 bilayers (5.8%) for CBS and 1/40 bilayers (2.5%) for MTS.
[0333] Earlier studies demonstrated that histones can induce non-selective Ca2+
channels in cells and plasma membrane depolarisation. These findings further support AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 the concept that histones directly interact with cell surface phospholipids and disrupt membrane integrity. To investigate whether CBS, mCBS and MTS protect cells against histone-induced Ca2+ flux, HMEC-1 were loaded with the Ca2+ sensitive dye, Indo-1, challenged with histones in the presence or absence of CBS or MTS, and Ca2+
uptake measured by flow cytometry (Figure. 5b). Histones induced an over 8-fold increase in the population of cells exhibiting high intracellular Ca2+ levels, this response plateauing 1 to 3 min after histone addition. The presence of MTS totally ablated the Ca2+
response and CBS substantially inhibited the response (Figure. 5c). Collectively inventors findings indicate that histones damage cell membranes by directly disrupting the lipid bilayer of .. cells, with CBS, mCBS and MTS SPAs neutralising this undesirable property of histones.
Example 5: Effect of CBS, mCBS and MTS on in vivo histone-associated pathologies [0334] The Inventors next assessed the ability of the CBS, mCBS and MTS to inhibit histone-mediated pathologies in vivo. Injection of histones intravenously into mice results in a sepsis-like syndrome involving liver damage, generalised tissue injury and kidney failure, as measured by circulating ALT, LDH and creatinine levels.
Administration of CBS, mCBS and MTS protected animals from each of these tissue-specific pathologies in a concentration-dependent manner, with MTS being the most potent, CBS and mCBS
being equally active and unsulfated CB being inactive (Figure. 6a). Systemic histones also induce thrombocytopenia and anaemia that was prevented by mCBS and MTS
treatment (Figure. 6b). To examine whether CBS, mCBS and MTS influence the localised vascular effects of histones, a histone-mediated model of DVT (Brill, A. et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 117, 1400-1407(2011)) was established that revealed this to be almost totally inhibited by both CBS and MTS (Figure. 6c), consistent with both systemic and localised pathologies mediated by free histones being amenable to inhibition by CBS, mCBS and MTS.
[0335] The inventors next examined the efficacy of CBS, mCBS and MTS in a rat caecal ligation puncture (CLP) model of sepsis. There was no mortality in the CBS
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 treatment group, an effect that was highly significant compared with PBS
controls, and only one death occurred in the MTS group, which approached significance (Figure. 7a).
Importantly, high ALT and creatinine levels detected in the untreated group, indicative of extensive liver and kidney damage, were not seen in the CBS treated animals but were only partially reduced in the MTS treatment group (Figure. 7b). This finding is somewhat paradoxical as in vitro and in vivo MTS was consistently a more potent neutraliser of DNA-free extracellular histones than mCBS/CBS.
[0336] To further investigate this paradox, CBS and MTS were tested for their efficacy in a rat cardiac ischemia reperfusion injury (IRI) model, previous studies having demonstrated that cardiac IRI is highly NET-dependent (Savchenko, A. S. et al.
VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice. Blood 123, 141-148, (2014);
and Ge, L.
et al. Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of DNase-based reperfusion strategy. Am J
Physiol Heart Circ Physiol 308, H500-509, (2015)). Remarkably, in this model MTS was totally ineffectual whereas CBS treatment significantly reduced the area of microvascular obstruction and myocardial necrosis in the ischemic zone by 50% (Figure. 7c).
This unexpected finding was largely confirmed in a rat skin flap IRI model where mCBS
consistently and significantly increased the viable area of the skin flap, whereas the results with MTS treatment were highly variable (Figure. 7d).
Example 6: Comparison of the ability of CBS, mCBS and MTS to inhibit NETs in sepsis patient sera [0337] Based on the in vivo efficacy data discussed above, we hypothesised that mCBS/CBS inhibit pathologies mediated by both DNA-free and NET-associated histones whereas MTS preferentially inhibits the damaging effects of DNA-free histones.
Support for this interpretation was obtained using sera from sepsis patients that, we discovered, inhibited HMEC-1 proliferation, as measured by 3H-thymidine incorporation (Figure. 8a, b), at a level that highly correlated with their APACHE II scores (Figure.
9a). This correlation was stronger than that observed between APACHE II scores and circulating AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 DNA levels (Figure. 9b). Further analysis of highly inhibitory serum from patient 5 revealed that this cytotoxic activity was DNase I sensitive and also was totally inhibited by polyclonal antibodies specific for histones 3 and 4 (Figure. 9c). Such data are consistent with NETs mediating the anti-proliferative effects of the septic patient's sera.
5 Finally, the inventors found that CBS significantly overrode the anti-proliferative activity of the 10 most inhibitory septic patient sera, whereas MIS did not (Figure.
9d). Thus, these results are entirely consistent with MIS being a free histone inhibitor and mCBS/CBS inhibiting pathologies mediated by both DNA-free and NET-associated histones.
AMENDED SHEET
IPEA/AU
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of sepsis, SIRS or an IRI or a medical condition or disease associated with sepsis, SIRS or an IRI in a subject. Preferably, the modified sulfated cellobioside is mCBS
or more particularly is a pharmaceutically acceptable salt thereof such as mCBS.Na.
5 [0045] In one embodiment of such use, the medicament is for the treatment of sepsis, or SIRS or a medical condition or disease associated with sepsis or SIRS in a subject, wherein said treatment ameliorates or inhibits said sepsis or SIRS or said condition or disease associated with said sepsis or SIRS.
[0046] In another embodiment of such use, the medicament is for the treatment of an 10 IRI or of a medical condition or disease associated with an IRI in a subject, wherein said treatment ameliorates or inhibits said IRI or said condition or disease associated with said injury.
[0047] In yet another embodiment of such use, the medicament is used to neutralise NETs that (i) are cytotoxic towards the endothelium in a subject, or (ii) contribute to endothelial dysfunction in a subject, or (iii) initiate coagulation by activating platelets in a subject, or (iv) induce red cell fragility and resultant anaemia in a subject.
[0048] In yet another embodiment, the manufactured medicament may also include a therapeutic or pharmaceutically effective amount of a second active agent, compound or composition. According to this embodiment, the second active agent, compound or composition provides an adjunct therapy for treating a medical condition, ailment or disease involving NETs. Desirably, the second active agent, compound or composition provides an adjunct therapy for the treatment of sepsis, SIRS or an IRI or for a medical condition or disease associated with sepsis, SIRS or an IRI. Preferably, the second active agent is selected from: one or more of anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents and/or any other form of therapeutic or pharmaceutical compound that treats one or more conditions that the subject is afflicted with. More preferably, the second active agent, compound or composition comprises one or more of anti-inflammatory agents.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 [0049] When the modified sulfated cellobioside compound is used in any of the methods of the invention the compound can be administered or formulated for administration to the subject in need thereof, in a single dose of formulation. In certain alternative embodiments, the modified sulfated cellobioside compound is administered, or formulated for administration to the subject in need thereof, as a multi-dose formulation.
[0050] Additional objectives, advantages and novel features will be set forth in the description which follows or will become apparent to those skilled in the art upon examination of the drawings and the ensuing detailed description of several non-limiting embodiments which follows.
.. BRIEF DESCRIPTION OF THE DRAWINGS
[0051]
The disclosure will provide details in the following description of preferred embodiments with reference to the following figures wherein:
Figure 1 Chemical structures of compounds selected.
Figure 2 Minimal structural requirements for polyanions to be as potent as heparin at inhibiting histone-mediated pathologies. a, Inhibition curves showing that the sulfated disaccharide, mCBS, and the sulfated trisaccharide, MTS, are as effective as heparin at inhibiting histone-mediated cytotoxicity for HMEC-1, whereas the sulfated monosaccharides, glucose per-O-sulfate and methyl p-glucoside per-O-sulfate, exhibit little or no inhibitory activity. b, Similar results obtained when examining inhibition of histone-induced erythrocyte fragility. Data are mean s.e.m. (n=3 biological replicates).
Figure 3 Histones promote erythrocyte aggregation and reduce erythrocyte deformability, processes that are completely inhibited by SPAs. Human erythrocytes (RBC) were incubated for 1 h at 37 C alone (Saline' control) or in the presence of histones (400 1.1g m1-1) with or without mCBS (200 pg m1-1).
a, Percentage of RBC aggregation measured by flow cytometry based on forward (FSC) and side (SSC) scatter parameters and an appropriate gating strategy to discriminate aggregated from normal (non-aggregated) RBC. b, Scanning AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 electron micrographs depicting level of RBC aggregation at low and high magnification following the three treatments depicted in (a). c, Concentration dependent inhibition of histone-mediated RBC aggregation by mCBS and MTS, in this case RBC aggregation being calculated by flow cytometry as fold increase in RBC auto-fluorescence relative to RBC in the absence of histones. The fold increase values also provide an estimate of the number of RBC in each aggregate. d, Retention of RBC in an artificial spleen that measures RBC
deformability. RBC were incubated with increasing concentrations of histones for 1 h and, at the highest concentration used (400 jig m1-1), also incubated with either mCBS or MTS (100 and 200 jig m1-1), prior to passage through the artificial spleen. Data are mean s.e.m. (n=3 biological replicates). ***P<0.001, ****P<0.0001 (one way ANOVA with Dunnett's multiple comparisons test).
Figure 4 SPAs inhibit histone-induced platelet aggregation and degranulation. a, Histone-induced aggregation of isolated platelets. b, SPA
inhibition of histone (HIS)(150 pg/mL) induced platelet aggregation. c, Histone-induced degranulation of platelets in whole blood, as measured by ATP release.
Dotted line ATP release from thrombin-activated platelets. d, SPA inhibition of histone-induced platelet degranulation. Data in (a,b) are mean s.e.m (n=3 biological replicates). Data in (c,d) representative of one of three experiments.
Figure 5 Histones disrupt lipid bilayers and induce a cellular Ca2+ flux, processes blocked by SPAs. a, Lifetime of artificial lipid bilayers exposed to histones (HIS)(1 pm) alone (n=47) or in the presence of the SPAs CBS (n=52) or MTS (n=40)(10 pM). Control bilayers (n=125) contained the R7R1 ion channel protein (n=biological replicates). Data are mean s.e.m. P values calculated using non-parametric Kruskal-Wallis test. b, Representative flow cytometry plots, using Ca2+ sensitive dye lndo-1, showing Ca2+ fluxing HMEC-1 1 min following histone addition (100 jig m1-1). c, Time course of effect of CBS and MTS (100 jig m1-1) on histone-induced Ca2+ flux by HMEC-1. Data in (c) from one of two separate experiments and mean of two biological replicates.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 Figure 6 In Vivo SPAs inhibit histone-induced tissue injury, thrombocytopenia, anaemia and DVT. a, Mice (n=5-28/group), injected i.p. with SPA doses (as indicated) 10 min prior to i.v. injection of histones (50 mg kg-1), had their blood collected 4 h post-histones for assessment of liver (alanine aminotransferase, ALT), kidney (creatinine, Crea) and general tissue (lactate dehydrogenase, LDH) damage. Data pooled from 10 separate experiments, with n=5-28 mice/treatment. b, Mice (n=5/group), treated as above but receiving one SPA dosage (100 mg kg-1), had their blood and spleens collected 10 min post-histones for assessment of circulating platelets and RBC and splenic to haemoglobin (Hb). c, Impact of CBS and MTS on a mouse model of histone-induced DVT (n=7-10 mice/group). Data mean s.e.m. *P5_0.05, **P<0.01, *"P<0.001, ****P<0.0001 (one way ANOVA with Dunnett's multiple comparisons test).
Figure 7 SPAs inhibit a range of pathologies involving extracellular IS histones. a, Survival of rats (n=8/group) subjected to caecal ligation and puncture (CLP) and receiving saline (Control), CBS or MTS. P values obtained with Log rank (Mantel-Cox) test. b, Kidney and liver damage in CLP rats, as measured by ALT and creatinine blood levels. c, Effect of CBS and MTS (n=6-12/group) on cardiac IRI in rats, with ischemic zone (IZ) in left ventricle (LV), 20 microvascular obstruction (MVO) and infarct territory being measured. d, Effect of mCBS and MTS on a skin flap model of IRI in mice (n=3-5/group), with representative photos shown. Statistical analysis of (b-d) as for Fig. 6.
Figure 8 HMEC-1 proliferation is a highly sensitive assay for both determining histone cytotoxicity and detecting inhibitors of this 25 cytotoxicity. a, Sub-confluent HMEC-1 monolayers were exposed to increasing concentrations of histones for 3 h and then 3H-thymidine added and HMEC-1 proliferation measured by 3H-thymidine incorporation over the next 24 h, with HMEC-1 proliferation being inhibited, in a highly concentration-dependent manner, by histones. b, The SPAs mCBS and MTS (100 pg m1-1) completely 30 neutralized the anti-proliferative effect of histones (400 pg m1-1) on HMEC-1 AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 monolayers. Data are mean s.e.m. (n=3 biological replicates). ****/3<0.0001 (one way ANOVA with Dunnett's multiple comparisons test).
Figure 9 Serum from sepsis patients is toxic for endothelial cells, an effect neutralized by DNase I, anti-histone antibodies and SPAs. a, Correlation (Spearman's r value) of APACHE II scores with anti-proliferative effect of sepsis patients sera on HMEC-1 (n=20 patients). b, Correlation of APACHE II scores with extracellular DNA content of sepsis patients sera. c, Effect of DNase I
or pAbs against histone 3 (aH3) and histone 4 (aH4) (n=4 biological replicates/treatment) on anti-proliferative effect of serum from sepsis patient 5 (red circle, panel a). d, Ability of SPAs mCBS and MTS to neutralize the anti-proliferative effect of septic patient sera (SS)(n=10 patients). Statistical analysis as for Fig. 6.
DETAILED DESCRIPTION OF THE PREFERED EMBODIMENTS
[0052] The present invention is directed to the use of modified sulfated cellobioside compounds, that have high chemical stability, in the treatment or prevention of NET
mediated ailments (such as, for example, sepsis, SIRS or IRI) in a subject.
Such compounds can ameliorate or inhibit or prevent the cytotoxic effect of NETs in a subject.
[0053]
For convenience, the following sections generally outline the various meanings of terms used herein. Following this discussion, general exemplary embodiments illustrating the invention are disclosed, followed by specific examples providing more specific illustration of properties of various exemplary embodiments of the invention.
General [0054]
Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described without departing from the spirit and scope of the invention as herein described. The invention includes all such variations and modifications. The invention also includes all the steps, features, compositions and components, referred to or indicated in the specification, individually or collectively, and any and all combinations or any two or more of said steps AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 or features. Functionally equivalent products, compositions of matter and methods are clearly within the scope of the invention as described herein.
[0055] All publications, references, documents, patents and patent applications cited in the herein, whether supra or infra, are hereby incorporated herein by reference in their 5 entirety, which means that those publications, references, documents, patents and patent applications should be read and considered as part of this text. That any publication, reference, document, patent and patent application cited in this text is not repeated in this text is merely for reasons of conciseness. However, publications, references, documents, patents and patent applications mentioned herein are cited for describing and disclosing 10 the protocols, reagents and products that which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants IS and does not constitute any admission as to the correctness of the dates or contents of these documents.
[0056] Any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention.
[0057] Definitions for selected terms used herein may be found within the summary of invention and the detailed description of the invention and apply throughout.
Unless otherwise defined, all other scientific and technical terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the invention belongs. If there is an apparent discrepancy between the usage of a term in the art and its definition provided herein, the definition provided within the specification shall prevail.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 Definitions [0058] Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term "about." For example, the term "about" when used in connection with percentages can mean 10%.
[0059] Unless the context requires otherwise, or the specification specifically states to the contrary, integers, steps, or elements of the invention recited herein as singular integers, steps or elements clearly encompass both singular and plural forms of the recited integers, steps or elements. Throughout this specification, unless stated otherwise or the context requires otherwise, reference to a single step, composition or matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e., one or more) or those steps, compositions or matter, group of steps or group of compositions of matter. Accordingly, as used herein and in the appended claims, the singular forms "a, "an" and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a sulfated cellobioside modified with a small uncharged substituent at its reducing terminus or a pharmaceutically acceptable salt thereof" includes a plurality of such modified sulfated cellobioside compounds or a plurality of salts thereof, and so forth.
[0060] Throughout the specification and claims, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated step or element or integer or group of steps or elements or integers but not the exclusion of any other step or element or integer or group of steps or elements or integers.
[0061] As used herein, the term "including", as well as variations such as "includes"
and "included", will also be understood to be not limiting.
[0062] In this application, the use of "or" means "and/or" unless stated otherwise.
[0063] The invention described herein may include one or more range of values (for example, size, displacement and field strength etc.). A range of values will be understood AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 to include all values within the range, including the values defining the range, and values adjacent to the range that lead to the same or substantially the same outcome as the values immediately adjacent to that value which defines the boundary to the range. For example, a person skilled in the relevant field will understand that a 10%
variation in upper or lower limits of a range can be totally appropriate and is encompassed by the invention.
More particularly, the variation in upper or lower limits of a range will be 5% or as is commonly recognised in the art, whichever is greater.
[0064] As used herein, the term "NET" refers to extracellular complexes of nucleosomes and proteins, e.g. proteins having anti-microbial activity. The nucleosomes may be derived from neutrophils, mast cells, eosinophils, monocytes, or leukocytes.
[0065] As used herein, the phrase "NET associated complication" means, without particular limitation, NET associated:
a. systemic inflammatory responses to: infection (including bacteria, virus, fungal, parasitic infections), sepsis (including bacteria, virus, fungal, parasite, prion induced sepsis); or to non-infectious inducers including non-infectious Systemic inflammatory response syndrome surgery, trauma, haemorrhage, burns, acute pancreatitis, preeclampsia and acute kidney injury;
b. hypoxia at the localised tissue /eve/ e.g. following blockage of an artery due to atherosclerosis, spontaneous rupture of a vessel, traumatic damage to a vessel and including cardiac and transplantation associated IRI; or at the whole body /eve/ following cessation of breathing e.g. due to drowning, gas exposure or cardiorespiratory arrest and includes ailments such as, for example, acute respiratory distress syndrome, ventilator-associated lung injury, chronic obstructive pulmonary disease and drug-mediated tissue injury;
c. haemostasis or vascular obstruction such as, for example, cardiovascular disease or chronic cardiovascular disease, such as atherosclerosis, coagulation and thrombosis (e.g., deep vein thrombosis); Transfusion-related acute lung injury (TRALI);
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 d. fibrosis where functional parenchymal organ tissue is replaced by fibrotic tissue, which can severely diminish organ function such as pulmonary fibrosis, idiopathic pulmonary fibrosi;
e. autoimmune disease states and inflammation disease states such as, for example, multiple sclerosis, tumour associated inflammation, hyper-inflammatory disease states, systemic lupus erythematosus, spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, inflammatory bowel disease, ulcerative colitis, cystic fibrosis (CF), Asthma, glomerulonephritis, chronic lung disease, Crohn's disease, irritable bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) such as granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), characterized by destruction and inflammation of small vessels, familial Mediterranean fever, amyotrophic lateral sclerosis, Cancer, Sjogren's syndrome, early arthritis, viral arthritisõ psoriasis, age-related organ fibrosis, idiopathic pulmonary fibrosis, juvenile diabetes (Type l), diabetes mellitus (Type 2), antiphospholipid syndrome, f. various central nervous system diseases such as Huntington's disease g. cytokine and chemokine induced degradation such as Gout.
[0066] The above cited conditions are associated with increased NETosis, and thus NETs can be targeted for treatment of these disorders.
[0067] As used herein, the terms "ailment", "condition" or "disease" (used interchangeably) means a medical complication associated with the release of NETs.
[0068] As used herein, the term "sepsis" includes within its meaning all stages of a sepsis disease or condition as characterised by standard medical reference texts and/or known to one of skill in the art. For example, sepsis includes severe sepsis, acute and chronic sepsis and septic shock. The term "sepsis" as used herein also includes episodes associated with infection. The term 'SIRS' (systemic immune response syndrome) used AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 herein includes episodes not associated with infection such as, for example, trauma, burns, pancreatitis, organ transplantation, surgery, tumour lysis following therapeutic regimes for cancer, perinatal complications and immunosuppressive prophylaxis for allogeneic grafts.
[0069] As used herein, the terms "medical condition associated with sepsis or SIRS" or "disease associated with sepsis or SIRS" include within their meaning all signs and symptoms directly or indirectly associated with, derived from, caused by or accompanying any or all stages of sepsis or SIRS diseases or conditions as characterised by standard medical reference texts and/or known to one of skill in the art. For example, the medical conditions or diseases associated with sepsis or SIRS include one or more of the following signs or symptoms associated with, derived from, caused by or accompanying any or all stages of sepsis or SIRS diseases or conditions in a subject which may be manifested in the subject with or without infection: arterial hypotension, metabolic acidosis, decreased systemic vascular resistance, increased heart rate (tachycardia), increased breathing rate IS (tachypnoea), general or systemic inflammation, elevated or decreased white blood cell count (leucocytosis or leucopenia), increased NETs in blood, organ dysfunction such as acute organ dysfunction, dysfunction of the circulatory system, multiple organ dysfunction syndrome, disseminated intravascular coagulation (DIC), deposition of fibrin in the microvasculature of one or more organs, fever, confusion, pneumonia, cough with pneumonia, kidney infection, painful urination with a kidney infection, and/or septic shock.
[0070] As used herein, the terms "decrease", "reduced", "reduction", "decrease" or "inhibit" are all used generally to mean a decrease by a statistically significant amount.
However, for avoidance of doubt, "reduced", "reduction" or "decrease" or "inhibit" means a decrease by at least 10% as compared to a reference level, e.g., in the absence of an agent, for example a decrease by at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%.
[0071] As used herein, the terms "improve", "increased", 'increase" or "enhance" or "activate" are all used to generally mean an increase by a statically significant amount;
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 for the avoidance of any doubt, the terms "improve", "increased", "increase"
or "enhance"
or "activate" means an increase of at least 10% as compared to a reference level, e.g., in in the absence of an agent, for example an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%), or at least about 60%, or at 5 least about 70%, or at least about 80%, or at least about a 2-fold, or at least about a 3-fold, or at least about a 4-fold, or at least about a 5-fold or at least about a 10-fold increase, or any increase between 2-fold and 10-fold or greater as compared to a reference level.
[0072] As used herein, the terms "administer", "administered" and "administering"
refers to the placement of a composition into a subject by a method or route which results 10 in at least partial localization of the composition at a desired site such that a desired effect is produced. A compound or composition described herein can be administered by any appropriate route known in the art including, but not limited to, oral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, nasal, rectal, and topical (including buccal and sublingual) administration. In IS certain embodiments, the compound is a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof. Preferably, the small uncharged glycosidically linked substituent that is present at the reducing terminus of the polyanionic sulfated cellobioside, improves the chemical stability of the polyanion, relative to the same 20 polyanion that is sulfated at its reducing terminus. When the above compound is present in a composition such as a therapeutic or a therapeutic composition it will be prepared for parenteral administration, or another other method allowing delivery to a target site.
Some exemplary modes of administration include, but are not limited to, injection, infusion, instillation, inhalation, or ingestion.
[0073] As used herein, the term "Injection" includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, sub capsular, subarachnoid, intraspinal, intracerebro spinal, and intrasternal injection and infusion. In preferred embodiments, the compositions are administered by intravenous infusion or injection.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0074] As used herein, the terms "treat," "treatment," "treating" and the like, in the context of the present invention insofar as it relates to any of the conditions or diseases recited herein means to relieve, alleviate, ameliorate, inhibit, slow down, reverse, or stop the progression, aggravation, deterioration, progression, anticipated progression or severity of at least one symptom or complication associated with such condition or disease. In an embodiment, the symptoms of a condition or disease are alleviated by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%.
[0075] As used herein, the phrases "effective amount" "therapeutically effective amount" or "effective dose" (used interchangeably herein) include within their meaning a sufficient but non-toxic amount of a compound or composition of the invention to provide a desired effect. The exact amount of a compound or composition required will vary from subject to subject depending on factors such as the desired effect, the species being treated, the age and general condition of the subject, the severity of the condition being treated, the agent being administered, the mode of administration, and so forth. Thus, it IS is not possible to specify an exact "effective amount". However, for any given case, an appropriate effective amount (dose) may be determined by one of ordinary skill in the art using only routine experimentation. Generally, a therapeutically effective amount can vary with the subject's history, age, condition, sex, as well as the severity and type of the medical condition in the subject, and administration of other pharmaceutically active agents.
[0076] As used herein, reference to use of a compound or composition in therapeutic or pharmaceutical applications will be understood to be equally applicable to human and non-human, such as veterinary, applications. Hence, it will be understood that, except where otherwise indicated, reference to a "patient", "subject" or "individual"
(used interchangeably herein) means a human or non-human, such as an individual of any species of social, economic or research importance including but not limited to, mammalian, avian, lagomorph, ovine, bovine, equine, porcine, feline, canine, primate and rodent species. More preferably, the patient, subject or individual is an animal belonging to a mammalian species. The mammalian species is desirably a human or non-human primate or a companion animal such as a domesticated dog, cat, horse, monkey, mouse, AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 rat, rabbit, sheep, goat, cow or pig. In one particularly preferred example, the patient, subject or individual is a human.
[0076A] As used herein, the term "small uncharged glycosidically-linked substituent"
refers to a substituent selected from the group consisting of 0-(C1_6)alkyl, S-(C1_6)alkyl, or N-di-(01_6)alkyl, wherein each alkyl may be straight, branched or cyclic, may contain one or more double or triple bonds, and may be substituted with one or more halogen atoms, and wherein the two alkyl groups on N-di-(C1_6)alkyl may together form a ring.
[0077] Definitions for selected terms used herein may be found within the detailed description of the invention and apply throughout. Unless otherwise defined, all other scientific and technical terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the invention belongs.
Illustrative embodiments of the invention [0078] The ensuing detailed description of this invention is included solely for the purposes of illustrating the invention and should not be understood in any way as a restriction on the broad description of the invention, as set out above.
1. Compounds of the Invention [0079] In a first aspect of the invention, there is provided a compound for use in the treatment of a NET mediated complication wherein the compound comprises: a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof. The substituent rendering the molecule high chemical stability, relative to the same polyanion but which is sulfated at its reducing terminus. Preferably, this class of compound should have a high net negative charge.
[0080] Compounds of the invention can ameliorate NET mediated complications (such as sepsis or ischemia reperfusion injuries) both preventatively i.e. as a prophylactic pre-treatment to a medical procedure or therapeutically during treatment after the conditions or disease has occurred.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 [0081] In an embodiment of the invention, the modified polyanionic sulfated cellobioside, has the general structure:
RI
wherein:
R1 is a sulfate group or a small uncharged glycosidically linked substituent, for example, 0- or S-(C1-6)alkyl; and R2 to R8 are each selected from: (i) a small uncharged 0-linked substituent or (ii) a sulfate group.
[0082]
Preferably, R1 is 0- or S-(C1_6)alkyl. When R1 is 0- or S-(C1_6)alkyl, the selected substituent preferably improves the chemical stability of the polyanion, compared to the same polyanion with a sulfate group at R1.
[0083] Preferably, R2 to R8 are each selected from: (a) an unmodified hydroxyl group;
or (b) a sulfate group.
[0084] More preferably, R1 is a methoxy or ethoxy group and R2 to R8 are each a sulfate group.
[0085]
Desirably, the class of compound has a high net negative charge, i.e. it is a polyanion.
[0086] The anomeric configuration of the small uncharged glycoside substituent (R1) can be in either of the a or 13 position. Preferably, the small uncharged substituent is in the 13 configuration.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0087] In a highly-preferred form of the invention, the compound is 13-0-Methyl Cellobioside Sulfate or a pharmaceutically acceptable salt thereof, which is a sulfated 13-0-methyl cellobioside disaccharide. By way of illustration, the compound is the sodium salt of 13-0-Methyl Cellobioside Sulfate.
[0088] mCBS is highly stable relative to CBS and well tolerated at high doses.
[0089] The small uncharged glycosidically linked substituent that is present at the reducing terminus of the polyanionic sulfated cellobioside, improves the chemical stability of the polyanion relative to the same polyanion that is sulfated at its reducing terminus.
[0090] Chemical stability as used herein represents the tendency of the compound of the invention to resist change (in particular decomposition in its natural environment or when exposed to air, heat, light, pressure, or other natural conditions, or due to internal reaction.
[0091] A compound of the invention is "stable" if it is does not significantly decompose, relative to the same polyanion that is sulfated at its reducing terminus, after at least one-IS month storage under conditions of anticipated use or normal environmental conditions.
[0092] A compound of the invention will have decomposed significantly if it has lost 3 or more sulfate groups after at least one-month storage, under conditions of anticipated use or normal environmental conditions. Preferably, a compound of the invention will have decomposed significantly if it has lost 2 sulfate groups after at least one-month storage, under conditions of anticipated use or normal environmental conditions. Most preferably, a compound of the invention will have decomposed significantly if it has lost 1 sulfate group after at least one-month storage, under conditions of anticipated use or normal environmental conditions.
[0093] Preferably, the compound of the invention is chemically stable for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 months when stored in a phosphate formulation buffered to pH 7.5 and stored at 2-8 C. More preferably, stability is measured over a period of 6 months to 2 years with the compound being stored in a phosphate formulation buffered to pH 7.5 and stored at about 2-8 C.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0094] As used herein, the phrase "pharmaceutically acceptable salt(s)"
includes those salts which, within the scope of sound medical judgement, are suitable for use in contact with tissues of humans and lower animals without the undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
5 [0095] Pharmaceutically acceptable salts are well known in the art.
They include, for example, acid addition salts (formed with the free amino groups of the protein) derived from inorganic acids (e.g., hydrochloric or phosphoric acids, or from organic acids (e.g., citric, acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups of the protein can also be derived from inorganic bases (e.g., sodium, potassium, 10 ammonium, calcium, or ferric hydroxides) or from organic bases (e.g., isopropylamine, trimethylamine, histidine, procaine and the like.
[0096] In a preferred form of the invention the modified sulfated cellobioside of the invention, is present as a pharmaceutically acceptable salt. By way of illustration, the compound is the sodium salt of p-O-Methyl Cellobioside Sulfate, viz Sodium p-O-Methyl 15 Cellobioside Sulfate (mCBS.Na).
[0097] Modified sulfated cellobioside compounds or pharmaceutically acceptable salts thereof used in the methods or compositions of the present invention may be prepared by methods known to those skilled in the art. For example, methods for preparing sulfated compounds modified with an uncharged substituent at its reducing termini are generally 20 described in Katrin C Probst and Hans Peter Wessel, 2001, J.
Carbohydrate Chemistry, 20 (7 & 8): 549-560, which is incorporated herein by reference in its entirety.
2. Treatment methods [0098] As compounds of the invention and therapeutic or pharmaceutical compositions including said compounds can ameliorate or prevent the pathological activity of NETs, the 25 present invention provides as a second aspect of the invention, a method of treatment or prevention for NET associated complications, said method comprising the step of:
administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0099] Further, in a third aspect of the invention, there is provided a method for ameliorating NET accumulation in a subject, said method comprising the step of:
administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0100] In an embodiment of the second and third aspects of the invention the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of 13-0-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0101] The present invention as described by the second and third aspects of the invention contemplates treating ameliorating or preventing a variety of different NET
ailments that are caused by the formation of NETs and the resulting toxicity therefrom.
According to these aspects of the invention, the respective methods can be used for the treatment or prevention of NET associated complications in a subject.
[0102] Typically NET associated conditions are attributable to increased NETosis, and thus NETs can be targeted for treatment of these disorders by modifying (preferably reducing) the level or the activity of the NETs to a basal concentration or quantity that is consistent with their normal pathophylsiological levels in a subject.
[0103] The largest group of NET activators are pathogenic Gram-positive and Gram-negative bacteria lipoteichoic acid and LPS, and breakdown products of prokaryotic proteins. Some examples of bacteria that induce NETs include, by way of illustration: S.
aureus, Streptococcus sp., P. aeruginosa, Bordetella pertussis, Mannheimia haemolytica, AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 Aggregatibacter actinomycetemcomitans , Neisseria gonorhoeae, Neisseria meningitidis, Yersinia enterocolitica, Vibrio cholerae, Leptospira species, H. influenzae, K.
pneumoniae, L. monocyto genes, M. tuberculosis, and S. flexneri). Net Activation also arises from: fungal infection (examples include, by way of illustration:
(Aspergillus spp.
such as, A. nidulans, A. fumigatus and Candida spp.such as C. albicans);
protozoan parasite infection (examples include, by way of illustration: L. amazonensis or its surface lipophosphoglycan, Strongyloides stercoralis, Eimeria bovis, Leishmania species, Toxoplasma gondii, Plasmodium falciparum); or viral infection (examples include, by way of illustration: HIV/SIV, Hantaan virus Respiratory Syncytial Virus (RSV), influenza virus).
IO These pathogenis activators are presented only by way of example and do not consistute a defined list of organisms that represent NET activators. Those skilled in the field will be aware of the NET activation ability of an organism.
[0104] The response caused by infection with organisms such as those listed above is generally an inflammatory response causing activation of inflammation pathways, IS however other responses such as autimmune responses, lung diseases, thrombosis or other microbial activity may also be present as a result of NET activation.
Net activation also arises from non-infectious inducers including non-infectious systemic inflammatory response syndrome, surgery, trauma, haemorrhage, burns and kidney injury;
hypoxia at the localised tissue level or at the whole body level; haemostasis or vascular obstruction;
20 fibrosis where functional parenchymal organ tissue is replaced by fibrotic tissue;
autoimmune disease states and inflammation disease, various central nervous system diseases as well as cytokine and chemokine induced degradation.
[0105] In an embodiment of the second or third aspects of the invention, the respective methods may further comprise administering to the subject, at the same time or 25 concomitantly with the compound of the invention, a second therapeutic agent (such as anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents or other forms of medical intervention) that is distinct from the compound of the invention that provides an adjunct treatment for a medical condition that the subject is or may suffer from.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0106] Preferably, as an example of these aspects of the invention, the respective methods provide a means for treating or preventing sepsis or SIRS or a medical condition or disease associated with sepsis or SIRS in a subject.
[0107] As another example of these aspects of the invention the respective methods provide a means for treating or preventing IRI or a medical condition or disease associated with IRI in a subject.
[0108] Preferably, the method ameliorates the condition or a disease state sufficiently to allow a physician to administer other drugs to treat secondary conditions.
Thus, the invention also includes administering a therapeutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof to a subject, for the purposes of ameliorating NET associated complications in the patient.
[0109] In certain exemplary embodiments according to the second or third aspects of the invention, the identified methods can further comprise the step of:
administering to IS the subject, together with or concomitantly with the modified sulfated cellobioside, a therapeutically or pharmaceutically effective amount of a second active agent, compound or composition selected from: one or more of anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents and/or any other form of pharmaceutical composition that treats one or more condition that a subject is afflicted with or at risk of being afflicted with.
[0110] According to this embodiment, the second active agent, compound or composition provides an adjunct treatment to the treatment directed to the NET
associated complication (such as, for example, sepsis, SIRS or IRI) and/or for medical conditions or diseases associated with such complications. Preferably, the second active agent, compound or composition comprises one or more of anti-inflammatory agents.
[0111] Preferably, the second active agent presents a means for medical intervention of a disease that a patient is afflicted with that is related to or distinct from the medical AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 ailment treated by the compounds of this invention, said second active agent providing an adjunct treatment for the patient.
[0112] Therapeutics and/or pharmaceutical compositions of the invention disclosed herein may be administered either therapeutically or preventively. In a therapeutic application, compounds and compositions are administered to a patient already suffering from NET associated complications or an ailment associated with NET associated complications, in an amount sufficient to cure or at least partially arrest its symptoms.
The compound or composition should be provided in a quantity of the active compound sufficient to effectively treat the patient either in a single dose or as part of a treatment regime e.g., a multi-dose treatment regime. In a preventative application, compounds and compositions of the invention are administered to a subject at risk of developing an ailment associated with NET associated complications, in an amount sufficient to at least partially arrest the ailment's symptoms and/or complications.
[0113] In a fourth aspect of the invention, there is provided a method for treating or preventing a medical condition, ailment or disease associated with NET
mediated pathology in a subject, wherein the method comprises the step of:
administering to the subject a therapeutically or pharmaceutically effective amount of: a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0114] In an embodiment of the fourth aspects of the invention the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0115] In one preferred example, the method is used to treat NETs that (i) are cytotoxic towards the endothelium in a subject, or (ii) contribute to endothelial dysfunction in a AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 subject, or (iii) initiate coagulation by activating platelets in a subject, or (iv) induce red cell fragility and resultant anaemia in a subject.
[0116] Patients suffering from an infection of the type caused by one or more of the above identified organisms have increased levels of NETs present in their blood.
5 [0117] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated sepsis in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged 10 glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof. Preferably, the small uncharged glycosidically linked substituent that is present at the reducing terminus of the polyanionic sulfated cellobioside improves the chemical stability of the polyanion relative to the same polyanion that is sulfated at its reducing terminus. More preferably, the modified sulfated cellobioside is mCBS
or more 15 particularly is a pharmaceutically acceptable salt thereof such as mCBS.Na.
[0118] As demonstrated herein, compounds of the invention in particular mCBS
block the toxic effects of NETs and thereby are useful as a treatment for sepsis.
[0119] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic 20 activity of NET proteins in sepsis, including both pre- treatment (in the case of a medical procedure) and treatment after sepsis has occurred.
[0120] In a highly preferred exemplary form of the invention, according to any aspect, embodiment or example describes herein, the compound of the invention is used to treat or prevent one or more of the following discussed ailments or conditions.
25 A. Sepsis [0121] Sepsis (including septic shock) is a systemic reaction to infection characterized by arterial hypotension, metabolic acidosis, decreased systemic vascular resistance, AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 tachypnoea and organ dysfunction. Sepsis (including septic shock) is also a systemic inflammatory response to infection associated with and mediated by the activation of a number of host defence mechanisms including the cytokine network, leukocytes, and the complement and coagulation fibrinolysis systems. Disseminated intravascular .. coagulation (DIC) with widespread deposition of fibrin in the microvasculature of various organs may be an early manifestation of sepsis. DIC is an important mediator in the development of the multiple organ failure syndrome and contributes to the poor prognosis of patients with septic shock.
[0122] The immunological response that causes sepsis is a systemic inflammatory response causing widespread activation of inflammation and coagulation pathways. This may progress to dysfunction of the circulatory system and, even under optimal treatment, may result in the multiple organ dysfunction syndrome and eventually death.
[0123] Symptoms of sepsis are often related to an underlying infectious process and if left untreated can manifest as severe sepsis (sepsis with acute organ dysfunction) or .. septic shock (sepsis with refractory arterial hypotension). When two or more of the systemic inflammatory response syndrome criteria (e.g., general inflammation, fever, elevated white blood cell count (leukocytosis), and raised heart rate (tachycardia) and breathing rate (tachypnoea)) are met without evidence of infection, patients may be diagnosed simply with "SIRS", which is a septic inflammatory state affecting the whole body.
[0124] Many patients with sepsis exhibit a rapid decline over a 24-48 hour period.
Rapid treatment is essential for effective sepsis treatment. Unfortunately, diagnosis of type of infection requires microbiological analysis to identify the pathogen which may take several days. Therefore, therapy to eliminate a pathogen (e.g. antibiotic therapy) must .. be initiated without knowledge of the type and species of the pathogen, and with no means of knowing the extent of the infection. The present invention provides such a method.
[0125] Patients suffering from sepsis have increased levels of NETs present in their blood. NETs have been implicated as important mediators of sepsis pathology.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0126] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated sepsis in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0127] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated 6-0-methyl cellobioside disaccharide or a sodium salt ofp-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0128] As demonstrated herein, compounds of the invention in particular mCBS
block the toxic effects of NETs and thereby are useful as a treatment for sepsis.
[0129] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in sepsis, including both pre- treatment (in the case of a medical procedure) and treatment after sepsis has occurred.
B. Non-Infectious SIRS
[0130] Non-infectious Systemic inflammatory response syndrome (SIRS) is an inflammatory state affecting the whole body. It is the body's response to non-infectious insult. Although the definition of SIRS refers to it as an "inflammatory"
response, it actually has pro- and anti-inflammatory components.
[0131] SIRS is a serious condition related to systemic inflammation, organ dysfunction, and organ failure. It is a subset of cytokine storm, in which there is abnormal regulation of various cytokines. SIRS is also closely related to sepsis, in which patients satisfy AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 criteria for SIRS and have a suspected or proven infection. Causes of non-infection SIRS
include, for example: trauma, from surgery, traumatic haemorrhage, burns and acute pancreatitis, by way of illustration.
[0132] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated non-infectious SIRS in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0133] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated 13-0-methyl cellobioside disaccharide or a sodium salt of 6-0-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0134] As demonstrated herein, compounds of the invention in particular mCBS
block the toxic effects of NETs and thereby are useful as a treatment for non-infectious SIRS.
[0135] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in non-infectious SIRS, including both pre- treatment (in the case of a medical procedure) and treatment after non-infectious SIRS has occurred.
B.1 Trauma [0136] Physical trauma is a serious and body-altering physical injury, such as the crushing or amputation of a limb.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0137] Blunt force trauma, a type of physical trauma caused by impact or other force applied from or with a blunt object, whereas penetrating trauma is a type of physical trauma in which the skin or tissues are pierced by an object. Trauma can also be described as both unplanned, such as an accident, or planned, in the case of surgery.
Both can be characterized by mild to severe tissue damage, blood loss and/or shock, and both may lead to SIRS, but also significantly increase the risk of subsequent infection and sepsis.
[0138] NETs are released following trauma or severe cellular stress in the absence of infection. Patients suffering from trauma can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of trauma pathology.
[0139] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated trauma in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0140] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated 13-0-methyl cellobioside disaccharide or a sodium salt of P-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0141] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in trauma patients.
[0142] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 activity of NETs in trauma, including both pre- treatment (in the case of a medical procedure) and treatment after trauma injury has occurred.
8.2. Surgery [0143] Surgery uses operative manual and instrumental techniques on a patient to 5 .. investigate and/or treat a pathological condition such as disease or injury, to help improve bodily function or appearance, or sometimes for some other reason. The present invention can address trauma resulting from surgeries, as defined further below.
[0144] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
10 .. associated surgical trauma in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
15 [0145] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is 20 mCBS it is a sulfated 6-0-methyl cellobioside disaccharide or a sodium salt of -O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0146] As a rule, a procedure is considered surgical when it involves cutting of a patient's tissues or closure of a previously sustained wound. Other procedures that do not necessarily fall under this rubric, such as angioplasty or endoscopy, may be 25 considered surgery if they involve common surgical procedure or settings, such as use of a sterile environment, anaesthesia, antiseptic conditions, typical surgical instruments, and suturing or stapling. All forms of surgery are considered invasive procedures;
so-called non-invasive surgery usually refers to an excision that does not penetrate the structure AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 being addressed (e.g., laser ablation of the cornea) or to a radio-surgical procedure (e.g., irradiation of a tumour).
[0147] As compounds of the invention and therapeutic or pharmaceutical compositions including said compounds, can ameliorate the cytotoxic activity of NETs, the present invention provides a treatment for use in surgical trauma, including both pre-treatment (in the case of a medical procedure) and treatment after surgical injury has occurred.
8.3. Traumatic Haemorrhage [0148] Traumatic haemorrhage accounts for much of the wide-ranging international impact of injury, causing a large proportion of deaths and creating great morbidity in the injured. Despite differences in pre-hospital care, the acute management of traumatic haemorrhage is similar around the world and follows well accepted published guidelines.
A critically injured patient's care occurs as four, often overlapping segments: the resuscitative, operative, and critical care phases. The diagnosis and control of bleeding should be a high priority during all the phases of trauma care and is especially important in the patient who is in haemorrhagic shock. Early attempts at haemorrhage control include direct control of visible sources of severe bleeding with direct pressure, pressure dressings, or tourniquets; stabilization of long bone and pelvic fractures;
and keeping the patient warm. During the resuscitative phase, warmed intravenous fluids, hypotensive resuscitation prior to surgical control of haemorrhage, and appropriate transfusion of blood and blood products are provided. In the operative phase, surgical control of the haemorrhage and any other injury, and additional transfusion is provided.
Finally, the critical care phase provides for post-operative support and tissue perfusion).
[0149] As compounds of the invention and therapeutic or pharmaceutical compositions including said compounds, can ameliorate the cytotoxic activity of NETs, the present invention provides to treatment for use in traumatic haemorrhage, including both pre-treatment (in the case of a medical procedure) and treatment after traumatic haemorrhage has occurred.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 BA. Burns [0150] A burn can be an injury caused by heat, cold, electricity, chemicals, friction or radiation. First-degree burns are usually limited to redness (erythema), a white plaque, and minor pain at the site of injury. These burns usually extend only into the epidermis.
Second-degree burns additionally fill with clear fluid, have superficial blistering of the skin, and can involve more or less pain depending on the level of nerve involvement.
Second-degree burns involve the superficial (papillary) dermis and may also involve the deep (reticular) dermis layer. Third-degree burns additionally have charring of the skin, and produce hard, leather-like eschars. An eschar is a scab that has separated from the .. unaffected part of the body. Frequently, there is also purple fluid. These types of burns are often painless, because nerve endings have been destroyed in the burned areas.
Serious burns, especially if they cover large areas of the body, can cause death; any hint of burn injury to the lungs (e.g., through smoke inhalation) is a medical emergency.
[0151] Burns that injure the tissues underlying the skin, such as the muscles or bones, are sometimes categorized as fourth-degree burns. These burns are broken down into three additional degrees: fourth-degree burns result in the skin being irretrievably lost, fifth-degree burns result in muscle being irretrievably lost, and sixth-degree burns result in bone being charred.
[0152] Various burns lead to an increase in the levels of NETs which in turn are associated with toxicity. To the extent that the NETs toxicity is present, the present invention seeks to reduce this toxicity using the pharmaceutical compositions of the present invention, thereby reducing or alleviating discomfort on the part of the patient, as well as permitting higher doses of the therapy.
[0153] Patients suffering from burns can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of burns pathology.
[0154] In an embodiment of the second or third aspect of the invention, there is provided a method of ameliorating NET induced cytotoxicity caused by burns to a subject, said method comprising the step of: administering to the subject a therapeutically or AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0155] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated 6-0-methyl cellobioside disaccharide or a sodium salt of 6-0-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0156] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in burns patients.
[0157] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic IS activity of NETs in a burn in a subject.
B.5. Acute Pancreatitis [0158] Acute pancreatitis is characterized as rapidly-onset inflammation of the pancreas by sterile inflammation and acinar cell death, including necrosis and apoptosis.
[0159] Depending on its severity, acute pancreatitis can have severe complications and high mortality despite treatment. While mild cases are often successfully treated with conservative measures or laparoscopy, severe cases require invasive surgery (often more than one intervention) to contain the disease process.
[0160] Patients suffering from acute pancreatitis can have increased levels of NETs present in their blood. NETS have been implicated as important mediators of acute pancreatitis pathology.
[0161] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 associated acute pancreatitis in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0162] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0163] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in acute pancreatitis patients.
IS [0164] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NET.s in acute pancreatitis, including both pre-treatment (in the case of a medical procedure) and treatment after acute pancreatitis has occurred.
C. Ischemia-Reperfusion Injury [0165] Ischemia reperfusion injuries (including transplantation associated Ischemia reperfusion injuries) and drug-mediated tissue injury result in sterile inflammation, a process occurring in the absence of microorganisms.
[0166] lschemia is a restriction in blood supply to tissues, causing a shortage of oxygen that is needed for cellular metabolism. In prolonged ischemia (60 min or more), hypoxanthine is formed as a breakdown product of ATP metabolism. The enzyme xanthine dehydrogenase is converted to xanthine oxidase as a result of the higher availability of oxygen. This oxidation results in molecular oxygen being converted into highly reactive superoxide and hydroxyl radicals. Xanthine oxidase also produces uric AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 acid, which may act as both a prooxidant and as a scavenger of reactive species such as peroxinitrite. Excessive nitric oxide produced during reperfusion reacts with superoxide to produce the potent reactive species peroxynitrite. Such radicals and reactive oxygen species attack cell membrane lipids, proteins, and glycosaminoglycans, causing further 5 damage. They may also initiate specific biological processes by redox signalling.
[0167] Reperfusion injury refers to damage due in part to the inflammatory response of damaged tissues. White blood cells carried to the area by the newly returning blood release a host of inflammatory factors such as interleukins as well as free radicals in response to tissue damage. The restored blood flow reintroduces oxygen within cells that 10 damages cellular proteins, DNA, and the plasma membrane. Damage to the cell's membrane can in turn cause the release of more free radicals. Such reactive species act indirectly in redox signalling to turn on apoptosis. Leukocytes also build up in small capillaries, obstructing them and leading to more ischemia.
[0168] Reperfusion injury also plays a part in the brain's ischemic cascade, which is 15 involved in stroke and brain trauma. Repeated bouts of ischemia and reperfusion injury also are thought to be a factor leading to the formation and failure to heal of chronic wounds such as pressure sores and diabetic foot ulcers. Continuous pressure limits blood supply and causes ischemia, and the inflammation occurs during reperfusion. As this process is repeated, it eventually damages tissue enough to cause a wound.
20 [0169] NET levels are elevated in animal lschemia reperfusion models with liver, kidney, lung, and brain injury, suggesting an important role of NETs in the regulation of sterile inflammation.
[0170] NETs mediate not only liver, but also acute kidney injury or ischemic stroke through direct toxicity or pro-inflammatory effects. Inhibition of NET
formation and activity 25 presents a therapeutic strategy for tissue injury.
[0171] Patients suffering from ischemia reperfusion injuries (including transplantation associated ischemia reperfusion injuries) and drug-mediated tissue injury have increased AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 levels of NETs present in their blood. NETs have been implicated as important mediators of ischemia/reperfusion and drug-mediated tissue injury pathology.
[0172] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated IRI and/or drug-mediated tissue injury in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0173] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated 13-0-methyl cellobioside disaccharide or a sodium salt of 13-0-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0174] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in ischemia/reperfusion and drug-mediated tissue injury patients.
[0175] Thus, compounds of the invention and therapeutic or pharmaceutical .. compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in ischemia/reperfusion and drug-mediated tissue injury, including both pre-treatment (in the case of a medical procedure) and treatment after ischemia/reperfusion and drug-mediated tissue injury has occurred.
D. Coagulation and Thrombosis [0176] Coagulation is the biological process by which blood forms clots. A
precise regulation mechanism prevents aberrant coagulation that results in an increased risk of bleeding (haemorrhage) or obstructive clotting (thrombosis).
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0177] Patients suffering from coagulation and or thrombosis can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of coagulation and or thrombosis pathology.
[0178] In an embodiment of the second or third aspect of the invention, there is provided a method of treating coagulation and or thrombosis in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof. .
[0179] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated -O-methyl cellobioside disaccharide or a sodium salt of -O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0180] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in coagulation and or thrombosis patients.
[0181] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in coagulation and or thrombosis, including both pre-treatment (in the case of a medical procedure) and treatment after coagulation or thrombosis has occurred.
E. Autoimmune/Inflammatory Disease [0182] The present invention contemplates the treatment of a variety of autoimmune and/or inflammatory disease states such as multiple sclerosis, spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, ulcerative colitis, Crohn's disease, irritable bowel disease, rheumatoid arthritis, juvenile AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 rheumatoid arthritis, familial Mediterranean fever, amyotrophic lateral sclerosis, Sjogren's syndrome, early arthritis, viral arthritis, or psoriasis. The diagnosis and treatment of these diseases are well documented in the literature.
[0183] Patients suffering from autoimmune and/or inflammatory disease have increased levels of NETs present in their blood. NETs have been implicated as important mediators of autoimmune and/or inflammatory disease pathology.
[0184] In an embodiment of the second or third aspect of the invention, there is provided a method of treating autoimmune and/or inflammatory disease in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of:
administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0185] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0186] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in autoimmune and/or inflammatory disease patients.
[0187] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in autoimmune and/or inflammatory disease, including both pre-treatment (in the case of a medical procedure) and treatment after autoimmune and/or inflammatory disease has occurred.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 F. Acute Respiratory Distress Syndrome [0188] Acute respiratory distress syndrome (ARDS), also known as respiratory distress syndrome (RDS) or adult respiratory distress syndrome (in contrast with IRDS) is a serious reaction to various forms of injuries to the lung. This is the most important disorder resulting in increased permeability pulmonary oedema.
[0189] ARDS is caused by a variety of direct and indirect insults. It is characterized by inflammation of the lung parenchyma leading to impaired gas exchange with concomitant systemic release of inflammatory mediators causing inflammation, hypoxemia and frequently resulting in multiple organ failure. This condition is life threatening and often lethal, usually requiring mechanical ventilation and admission to an intensive care unit. A
less severe form is called acute lung injury (ALI) including transfusion-related acute lung injury (TRALI).
[0190] ARDS can occur within 24 to 48 hours of an injury or attack of acute illness. In such a case the patient usually presents with shortness of breath, tachypnoea, and symptoms related to the underlying cause, i.e., shock. Long term illnesses can also trigger it, such as malaria. The ARDS may then occur sometime after the onset of a particularly acute case of the infection.
[0191] Patients suffering from ARDS can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of ARDS pathology.
[0192] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated acute respiratory distress syndrome in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0193] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0194] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in ARDS patients.
[0195] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic 10 activity of NETs in ARDS, including both pre-treatment (in the case of a medical procedure) and treatment after ARDS has occurred.
G. Cardiovascular Disease [0196] Cardiovascular disease refers to the class of diseases that involve the heart or blood vessels (arteries and veins). While the term technically refers to any disease that 15 affects the cardiovascular system, it is usually used to refer to those related to atherosclerosis (arterial disease). These conditions have similar causes, mechanisms, and treatments.
[0197] Treatment of cardiovascular disease depends on the specific form of the disease in each patient, but effective treatment always includes preventive lifestyle 20 changes discussed above. Medications, such as blood pressure reducing medications, aspirin and the statin cholesterol-lowering drugs may be helpful. In some circumstances, surgery or angioplasty may be warranted to reopen, repair, or replace damaged blood vessels [0198] Various forms of cardiovascular disease include aneurysms, angina, 25 arrhythmia, atherosclerosis, cardiomyopathy, cerebrovascular disease, congenital heart disease, congestive heart failure, myocarditis, valve disease, coronary artery disease, dilated cardiomyopathy, diastolic dysfunction, endocarditis, high blood pressure AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 (hypertension), hypertrophic cardiomyopathy, nitral valve prolapse, myocardial infarction, and venous thromboembolism.
[0199] Patients suffering from NET associated cardiovascular disease have increased levels of NETs present in their blood, which have been implicated as important mediators of NET associated cardiovascular disease pathology.
[0200] In an embodiment of the second, third or fourth aspects of the invention, there is provided a method of treating (either prophylactically or therapeutically) NET
associated cardiovascular disease in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0201] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked .. substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0202] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in NET associated cardiovascular disease patients.
[0203] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NET proteins in NET associated cardiovascular disease, including both pre-treatment (in the case of a medical procedure) and treatment after NET
associated cardiovascular disease has occurred.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 H. Fibrosis [0204] Patients suffering from fibrosis have increased levels of NETs present in their blood. NETs have been implicated as important mediators of fibrosis pathology.
[0205] In an embodiment of the second or third aspect of the invention, there is provided a method of ameliorating NET induced cytotoxicity caused fibrosis in a subject, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0206] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0207] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in fibrosis patients.
[0208] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in fibrosis in a subject, including both pre-treatment (in the case of a medical procedure) and treatment after fibrosis has occurred.
I. Diabetes [0209] Patients suffering from diabetes can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of diabetes pathology.
[0210] The invention provides methods for treating NET associated complications in diabetes (e.g inflammation and delayed wound healing). The methods comprise AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 administering a therapeutically effective amount of at least one compound of the invention to a subject diagnosed with Type 1, Type 1.5 or Type 2 diabetes.
[0211] In an embodiment of the second or third aspect of the invention, there is provided a method of ameliorating diabetes in a subject, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0212] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated 13-0-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0213] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in diabetes patients.
[0214] In certain embodiments, the symptom of diabetes having NET involvement is inflammation. Reduction in inflammation can be monitored by physical examination, as well as the reduction in the presence of inflammatory markers.
[0215] In certain embodiments, a method for treatment of diabetes is provided, that comprises the administration of a therapeutically effective amount of an agent used to treat diabetes and at least one compound of the invention. The agent used to treat diabetes can be insulin or another agents selected from the following Biguanides, Metformin (Glucophage), Metformin liquid (Riomet), Metformin extended release (Glucophage XR, Fortamet, Glumetza), Sulfonylureas, Glimepiride (Amaryl), Glyburide (Diabeta, Micronase), Glipizide (Glucotrol, Glucotrol XL), Micronized glyburide (Glynase), Meglitinides, Repaglinide (Prandin), D-Phenylalanine Derivatives, Nateglinide (Starlix), AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 Thiazolidinediones, Pioglitazone (TZDs), Pioglitazone, (Actos), DPP-4 Inhibitor, Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin ( Tradjenta), Alpha-glucosidase, Acarbose (Precose), Miglitol (Glyset), Bile Acid Sequestrants, Colesevelam (Welchol), Pioglitazone & metformin (Actoplus Met), Glyburide & metformin (Glucovance), Glipizide & metformin (Metaglip), Sitagliptin & metformin (Janumet), Saxagliptin &
metformin (kombiglyze ), Repaglinide & metformin (Prandimet) and Pioglitazone &
glimepiride (Duetact).
[0216] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in diabetes in a subject. As such the present invention provides a treatment for diabetes in a subject, including both pre-treatment (in the case of a medical procedure) and treatment after diabetes has occurred.
J. Chemotherapy, Radiotherapy and Cytokine Therapy Toxicity [0217] Various forms of cancer therapy, including chemotherapy, radiation, and cytokines, are associated with toxicity, sometimes severe, in the cancer patient. To the extent that the toxicity is caused at least in part by the actions of NETs, the present invention seeks to reduce this toxicity using the pharmaceutical compositions of the present invention, thereby reducing or alleviating discomfort on the part of the patient, as well as permitting higher doses of the therapy.
[0218] Patients suffering from the side effects of various forms of cancer therapy, including chemotherapy, radiation, and cytokine therapy can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of these side effects.
[0219] In an embodiment of the second or third aspect of the invention, there is provided a method of ameliorating the side effects of various forms of cancer therapy, including chemotherapy, radiation, and cytokine therapy in a subject by inhibiting the cytotoxic activity of NETs, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0220] According to this embodiment the selected compound is prefereably a 5 polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl 10 Cellobioside Sulfate, viz mCBS.Na.
[0221] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment for the side effects of various forms of cancer therapy, including chemotherapy, radiation, and cytokine therapy.
[0222] In a highly preferred form of the invention the compound used in treating the IS side effects of various forms of cancer therapy, including chemotherapy, radiation, and cytokine therapy in the patients undergoing such therapy is the compound [3-0-Methyl Cellobioside Sulphate or a pharmaceutically acceptable salt thereof. For example, the compound used in the method is Sodium p-O-Methyl Cellobioside Sulphate.
[0223] Thus, compounds of the invention and therapeutic or pharmaceutical 20 compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in the side effects of various forms of cancer therapy, including chemotherapy, radiation, and cytokine therapy, including both pre-treatment (in the case of a medical procedure) and treatment after these therapies have occurred.
K. Wound healing 25 [0224] Also provided are methods for use in wound healing. As used herein "wound healing" refers to the intricate process where the skin (or another organ-tissue) repairs itself after injury. The classic model of wound healing is divided into three or four sequential, yet overlapping, phases: (1) haemostasis, when clot stops bleeding, (2) AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 inflammation, (3) proliferation and (4) remodelling. Upon injury to the skin, a set of complex biochemical events takes place in a closely orchestrated cascade to repair the damage. During the inflammation phase, bacteria and cell debris are phagocytosed and removed from the wound by white blood cells. Platelet-derived growth factors (stored in the alpha granules of the platelets) are released into the wound that cause the migration and division of cells during the proliferative phase. The proliferation phase is characterized by angiogenesis, collagen deposition, granulation tissue formation, epithelialization, and wound contraction. New blood vessels are formed and fibroblasts grow and form a new, provisional extracellular matrix (ECM) by excreting collagen and fibronectin. Concurrently, re-epithelialization of the epidermis occurs, in which epithelial cells proliferate and 'crawl' atop the wound bed, providing cover for the new tissue.
[0225] Patients suffering from wound healing difficulties can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of wound healing pathology.
[0226] In an embodiment of the second or third aspect of the invention, there is provided a method of ameliorating NET induced cytotoxicity caused during wound healing in a subject, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0227] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0228] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in patients suffering from wound healing difficulties.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0229] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in treating wounds in a subject.
L. Central Nervous System Disease [0230] Patients suffering from central nervous system disease can have increased levels of NETs present in their blood. NETs have been implicated as important mediators of central nervous system disease pathology. For example, Huntington's disease is an autosomal dominant neurodegenerative disorder caused by a polyglutamine repeat expansion, resulting in an expanded polyglutamine track in the huntington protein.
[0231] In an embodiment of the second or third aspect of the invention, there is provided a method of ameliorating NET induced central nervous system disease in a subject, said method comprising the step of: administering to the subject a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked IS substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
[0232] According to this embodiment the selected compound is prefereably a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated p-O-methyl cellobioside disaccharide or a sodium salt of p-O-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0233] Compounds such as mCBS can block the toxic effects of NETs and thereby are useful as a treatment in central nervous system disease.
[0234] Thus, compounds of the invention and therapeutic or pharmaceutical compositions including said compounds provide a means for ameliorating the cytotoxic activity of NETs in central nervous system disease in a subject, including both pre-AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 treatment (in the case of a medical procedure) and treatment after central nervous system disease has occurred.
3. Therapeutic and Pharmaceutical Forms [0235]
In a fifth aspect of the invention, there is provided a therapeutic or pharmaceutical composition for use in treating an NET associated complication comprising: at least a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a therapeutically or pharmaceutically acceptable salt thereof.
Preferably, the composition includes a therapeutically or pharmaceutically acceptable carrier, excipient and/or diluent. The .. compound in the therapeutic or pharmaceutic may be in a neutral free base form or salt form. Preferably, the compound is the sodium salt of 8-0-Methyl Cellobioside Sulfate.
[0236] As used here, the terms "pharmaceutically acceptable" or "therapeutically effective" refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
[0237] Methods for preparing administrable compositions are apparent to those skilled in the art, and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pa., hereby incorporated by reference in its entirety.
[0238] As used here, the term "pharmaceutically-acceptable carrier" or "a pharmaceutically acceptable excipient" or "pharmaceutically acceptable diluent"
"therapeutically-acceptable carrier" or "a therapeutically acceptable excipient" or "therapeutically acceptable diluent" means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 another organ, or portion of the body. Each carrier, diluent and excipient must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. It is a material that is not biologically or otherwise undesirable i.e., the material can be applied to an individual along with the active agent without causing unacceptable biological effects or interacting in a deleterious manner with any one or more of the components of the composition in which it is contained.
Some examples of materials that can serve as pharmaceutically-acceptable carriers, diluents and excipients include, but are not limited to: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar;
(14) buffering agents, such as magnesium hydroxide and aluminum hydroxide;
(15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or .. polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; (22) C2-012 alcohols, such as ethanol;
and (23) other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, binding agents, fillers, lubricants, colouring agents, disintegrants, release agents, coating agents, sweetening agents, flavouring agents, perfuming agents, preservative, water, salt solutions, alcohols, antioxidants, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like can also be present in the formulation. The terms such as "excipient", "carrier", "diluent" and "pharmaceutically acceptable carrier" or the like are used interchangeably herein.
[0239] Examples of therapeutically or pharmaceutically acceptable carriers, excipients or diluents are demineralised or distilled water; saline solution; vegetable based oils such AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oil, arachis oil or coconut oil;
silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysolpoxane; volatile silicones; mineral oils such as liquid paraffin, 5 soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethyl-cellulose; lower alkanols, for example ethanol or iso-propanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols, for example polyethylene glycol, polypropylene glycol, ethylene glycol, propylene glycol, 1,3- butylene glycol or glycerin;
10 fatty acid esters such as isopropyl palmitate, isopropyl myristate or ethyl oleate;
polyvinylpyrridone; agar; carrageenan; gum tragacanth or gum acacia, and petroleum jelly. Typically, the carrier or carriers will form from 10% to 99.9% by weight of the compositions.
[0240] The compositions described herein can additionally contain other adjunct IS components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions can contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anaesthetics or anti-inflammatory agents. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions 20 described herein.
[0241] As described in detail below, the therapeutically or pharmaceutical acceptable compositions described herein can be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or nonaqueous solutions or suspensions), lozenges, dragees, 25 capsules, pills, tablets (e.g., those targeted for buccal, sublingual, and systemic absorption), boluses, powders, granules, pastes for application to the tongue;
(2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) injection directly into the organ needing treatment such as by 30 intraparenchymal (into the brain), intrathecal, intraventricular or intrahepatic AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 administration; (4) topical application, for example, as a cream, lotion, gel, ointment, or a controlled-release patch or spray applied to the skin; (5) in an aerosol form suitable for administration by inhalation, such as by intranasal inhalation or oral inhalation, (6) intravaginally or intrarectally, for example, as a pessary, cream, suppository or foam; (7) sublingually; (8) ocularly as an eye drop; (9) transdermally; (10) transmucosally; or (11) nasally.
[0242] In one embodiment, the composition of the invention is administered by injection such as by parenteral injection (such as by subcutaneous, intramuscular or intravenous injection) or locally to tissues and organs such as by intraparenchymal (into the brain), .. intrathecal, intraventricular or intrahepatic administration.
[0243] Pharmaceutical compositions suitable for injection include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
Ideally, the composition is stable under the conditions of manufacture and storage and may include a preservative to stabilise the composition against the contaminating action of microorganisms such as bacteria and fungi.
[0244] Sterile injectable solutions can be prepared by incorporating the pharmaceutical composition of the invention in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilisation. By way of illustration, a single dose may be dissolved in 1 ml of isotonic NaCI solution and either added to 1000 ml of fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580).
[0245] In the case of injectable solutions, the carrier can be a solvent or dispersion medium containing, for example, water, Ringer's solution, isotonic saline, phosphate buffered saline, ethanol, polyol (for example, glycerol, propylene glycol (eg 1,2 propylene glycol), and liquid polyetheylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 [0246] The proper fluidity can be maintained, for example, using a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and using surfactants. Prevention of the action of microorganisms can be achieved by including various anti-bacterial and or anti-fungal agents. Suitable agents are well known to those skilled in the art and include, for example, parabens, chlorobutanol, phenol, benzyl alcohol, ascorbic acid, thiomerosal, and the like. In many cases, it may be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminium monostearate and gelatin.
[0247] In a second embodiment, the composition of the invention is administered orally, for example, with an inert diluent or an assimilable edible carrier. For oral therapeutic administration, the pharmaceutical composition may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
[0248] Some examples of suitable carriers, diluents, excipients and adjuvants for oral use include peanut oil, liquid paraffin, sodium carboxymethylcellulose, methylcellulose, sodium alginate, gum acacia, gum tragacanth, dextrose, sucrose, sorbitol, mannitol, gelatine and lecithin. In addition, these oral formulations may contain suitable flavouring and colourings agents.
[0249] When used in capsule form the capsules may be coated with compounds such as glyceryl monostearate or glyceryl distearate which delay disintegration.
Tablets, troches, pills, capsules and the like can also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; an .. additional disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0250] When the dosage unit form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier. Various other materials can be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules can be coated with shellac, sugar or both.
[0251] Liquid forms for oral administration (such as a syrup or elixir) can contain, in addition to the above agents, a liquid carrier, a sweetening agent (e.g.
sucrose), a preservative (eg methyl and propylparabens), a dye and flavouring such as cherry or orange flavour. Suitable liquid carriers include water, oils such as olive oil, peanut oil, sesame oil, sunflower oil, safflower oil, arachis oil, coconut oil, liquid paraffin, ethylene glycol, propylene glycol, polyethylene glycol, ethanol, propanol, isopropanol, glycerol, fatty alcohols, triglycerides or mixtures thereof.
[0252] Suspensions for oral administration may further comprise dispersing agents and/or suspending agents. Suitable suspending agents include sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, poly-vinyl-pyrrolidone, sodium alginate or acetyl alcohol. Suitable dispersing agents include lecithin, polyoxyethylene esters of fatty acids such as stearic acid, polyoxyethylene sorbitol mono-or di-oleate, -stearate or - laurate, polyoxyethylene sorbitan mono- or di-oleate, -stearate or -laurate and the like. The emulsions for oral administration may further comprise one or more emulsifying agents. Suitable emulsifying agents include dispersing agents as exemplified above or natural gums such as guar gum, gum acacia or gum tragacanth.
[0253] In a third exemplary embodiment, the composition of the invention is administered directly to the airways of a subject in the form of an aerosol or by nebulization. For use as aerosols, solution or suspension of the pharmaceutical acceptable compositions of the invention can be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants. Such compositions can also be administered in a non-pressurized form such as in a nebulizer or atomizer.
[0254] Aerosols for the delivery to the respiratory tract are known in the art: see, for example, Adjei, A. and Garren, J. Pharm. Res., 1: 565-569 (1990); Zanen, P.
and Lamm, AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 J - W. J. Int. J. Pharm., 114: 111-115 (1995); Gonda, I. "Aerosols for delivery of therapeutic an diagnostic agents to the respiratory tract," in Critical Reviews in Therapeutic Drug Carrier Systems, 6:273-313 (1990); Anderson et al., Am. Rev.
Respir.
Dis., 140: 1317-1324 (1989)).
[0255] In a fourth exemplary embodiment, the composition may be administered in the form of liposomes. Liposomes are generally derived from phospholipids or other lipid substances, and are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolisable lipid capable of forming liposomes can be used. The compositions in liposome form may contain stabilisers, preservatives, excipients and the like.
The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art, and in relation to this specific reference is made to: Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq., the contents of which are IS incorporated herein by reference.
[0256] In addition, the therapeutic or pharmaceutical acceptable composition of the invention according to any aspect, embodiment or example described hereof, can be incorporated into sustained-release preparations and formulations. Such therapeutic or pharmaceutical compositions may further include a suitable buffer to minimise acid hydrolysis. Suitable buffer agent agents are well known to those skilled in the art and include, but are not limited to, phosphates, citrates, carbonates and mixtures thereof.
[0257] Compounds of the invention may also be administered in the form of a "prodrug". A prodrug is an inactive form of a compound which is transformed in vivo to the active form. Suitable prodrugs include esters, phosphonate esters etc, of the active form of the compound.
[0258] Additionally, compositions of the invention can be implanted into a patient or injected using a drug delivery system. Coated delivery devices can also be useful. See, for example, Urquhart, etal. (1984), Ann. Rev. Pharmacol. Toxicol. 24: 199-236; Lewis, AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 ed. "Controlled Release of Pesticides and Pharmaceuticals" (Plenum Press, New York, 1981); U.S. Pat. No. 3,773,919; U.S. Pat. No. 6,747,014; and U.S. Pat. No. 35 3,270,960.
[0259] In certain embodiments, the compositions are delivered using a device, or bandage, used for example in the process of treatment of a wound.
5 [0260] The therapeutically effective amount of a pharmaceutical compositions disclosed herein for any particular subject will depend upon a variety of factors including:
the toxicity and therapeutic efficacy of the pharmaceutical composition; the severity of the ailment; the age, body weight, general health, sex and diet of the patient;
the time of administration; the route of administration; the rate of sequestration of the compositions;
10 the duration of the treatment; drugs used in combination or coincidental with the treatment, together with other related factors well known in medicine.
[0261] Toxicity and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 15 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD5o/ED5o. Compositions that exhibit large therapeutic indices, are preferred.
[0262] Data obtained from the cell culture assays and animal models described herein can be used in formulating a range of therapeutically effective dosages for use in humans.
20 The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized.
[0263] The amount of compound of the invention described herein which can be 25 combined with a carrier material to produce a dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.1% to 99% of compound, preferably from about 5% to about 70%, most preferably from 10% to about 30%.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0264] The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. By way of illustration only the compositions may be administered so that the pharmaceutical acceptable compositions is given at a dose from 1 pg/kg to 150 mg/kg, 1 pg/kg to 100 mg/kg, 1 pg/kg to 50 mg/kg, 1 pg/kg to 20 mg/kg, 1pg/kg to 10 mg/kg, 1 pg/kg to 1 mg/kg, 100 pg/kg to 100 mg/kg, 100 pg/kg to 50 mg/kg, 100 pg/kg to 20 mg/kg, 100 pg/kg to 10 mg/kg, 100pg/kg to 1 mg/kg, 1 mg/kg to 100 mg/kg, 1 mg/kg to 50 mg/kg, 1 mg/kg to 20 mg/kg, 1 mg/kg to 10 mg/kg, 10 mg/kg to 100 mg/kg, 10 mg/kg to 50 mg/kg, or 10 mg/kg to 20 mg/kg. It is to be understood that ranges given here include all intermediate ranges, for example, the range 1 mg/kg to 10 mg/kg includes 1 mg/kg to 2 mg/kg, 1 mg/kg to 3 mg/kg, 1 mg/kg to 4 mg/kg, 1 mg/kg to 5 mg/kg, 1 mg/kg to 6 mg/kg, 1 mg/kg to 7 mg/kg, 1 mg/kg to 8 mg/kg, 1 mg/kg to 9 mg/kg, 2 mg/kg to 10 mg/kg, 3 mg/kg to 10 mg/kg, 4mg/kg to 10 mg/kg, 5 mg/kg to 10 mg/kg, 6 mg/kg to 10 mg/kg, 7 mg/kg to 10 mg/kg, 8 mg/kg to 10 mg/kg, 9 mg/kg to 10 mg/kg etc...
It is to be further understood that the ranges intermediate to the given above are also within the scope of the methods and compositions described herein, for example, in the range 1 mg/kg to 10 mg/kg, dose ranges such as 2 mg/kg to 8 mg/kg, 3 mg/kg to 7 mg/kg, 4 mg/kg to 6 mg/kg etc.
[0265] Where the compound of the invention is CBS, mCBS or mCBS.Na the dosage may be from 10 to 800 pg/ml. Preferably, it is in the range of 50 to 500 pg/ml. More preferably the dosage is 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790 or 800 pg/ml when administered to a human subject.
[0266] In certain examples of the invention an effective amount of the modified sulfated cellobioside compound is given as a single dose of administration. In certain examples, the dose is given repeatedly. That is treatment regimens will vary depending on the severity and type of disease, the overall health and age of the patient, and various other conditions to be considered by the treating physician. With respect to duration and AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 frequency of treatment, it is typical for skilled clinicians to monitor subjects to determine when a treatment is providing therapeutic benefit, and to determine whether to increase or decrease dosage, increase or decrease administration frequency, discontinue treatment, resume treatment or make other alteration to treatment regimen.
[0267] Therapeutics or pharmaceutical acceptable compositions of the invention according to any aspect, embodiment or example described hereof, may be provided in a single bolus administration or in multiple doses or treatments and may also be applied by "continuous" therapy where a small amount of the therapeutic composition is provided continually over an extended time period.
[0268] Where multiple dosing is used in the treatment (including continuous therapy) the therapeutics or pharmaceutical composition will be administered by a dosing schedule that can vary from once a week to daily depending on several clinical factors, such as the subject's sensitivity to the modified sulfated cellobioside compound used in the therapeutic or pharmaceutical composition. The desired dose to be administered in such a regime can be delivered as a single dose at one time or divided into sub-doses, e.g., 2-4 sub-doses and administered over a time period, e.g., at appropriate intervals through the day or other appropriate schedule. Such sub-doses can be administered as unit dosage forms.
[0269] In some embodiments, administration is chronic, e.g., one or more doses daily over a period of weeks or months. Examples of dosing schedules are administration daily, twice daily, three times daily or four or more times daily over a period of 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more.
[0270] The desired dose can be administered using continuous infusion or delivery through a controlled release formulation. In that case, the pharmaceutical composition contained in each sub-dose must be correspondingly smaller to achieve the total daily dosage.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0271] The dosage unit can also be compounded for delivery over several days, e.g., using a conventional sustained release formulation which provides sustained release of the pharmaceutical composition over a several day period. Sustained release formulations are well known in the art and are particularly useful for delivery of agents at a site, such as could be used with the agents described herein. In this embodiment, the dosage unit contains a corresponding multiple of the daily dose.
4. Combination regimes [0272] In certain exemplary embodiments, according to the fifth aspect of the invention, the identified composition may also comprise a second active agent, compound or composition selected from: one or more of anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents and/or any other form of therapeutic or pharmaceutical compound that treats one or more conditions that the subject is afflicted with. According to this embodiment, the second active agent, compound or composition desirably provides an adjunct therapy for sepsis, SIRS and IRI or for a medical condition or disease associated with sepsis, SIRS and IRI. Preferably, the second active agent, compound or composition comprises one or more of anti-inflammatory agents.
[0273] Therapeutic advantages may be realised through combination regimens. In certain embodiments of the invention, the described methods may further comprise the step of: administering to a subject, at the same time or concomitantly with the inventive treatment, a second active agent that is an adjunct treatment for the sepsis, SIRS and IRI
or the medical condition or disease associated with sepsis, SIRS and IRI that the patient is having or suffering from or is at risk of having or suffering from when delivered preventatively.
[0274] The second active agent may include, without limitation, anti-inflammatory .. agents, antibiotic agents, antiviral agents, antifungal agents or other forms of medical intervention that is distinct from the compound of the invention.
[0275] By way of illustration, when the method or treatment is directed to treating or ameliorating a septic or non-septic disease state involving NET mediated pathology in a AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 subject the method may also comprise administering to a subject at the same time or concomitantly, a second anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents or other forms of medical intervention that is distinct from the compound of the invention, which provides an adjunct treatment for a medical condition involving NET mediated pathology.
[0276] In one example, the second active agent provides an adjunct treatment or prevention for sepsis, SIRS or IRI or the medical condition or disease associated with the sepsis, SIRS or IRI such as a sepsis, SIRS or IRI or a medical condition or disease associated with the sepsis, SIRS or IRI involving NET mediated pathology in a subject.
[0277] In another example, the second active agent provides an adjunct treatment or prevention for a medical condition involving NET cytotoxicity.
[0278] By way of illustration, when the method of treatment is directed to treating or ameliorating a septic or non-septic disease state associated with sepsis, SIRS
or IRI
involving NET mediated pathology in a subject, the method may also comprise administering to a subject at the same time or concomitantly, a second anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents or other forms of medical intervention that is distinct from the compound of the invention, which provides an adjunct treatment for a medical condition involving NET mediated pathology.
[0279] In some examples, the additional agent administered is an anti-inflammatory agent such as a steroid, corticosteroids, COX-2 inhibitor, non-steroidal anti-inflammatory agent (NSAIDs), aspirin or any combination thereof. More particularly, the additional agent administered may be an anti-inflammatory agent, selected from the group consisting of Alclofenac; Alclometasone Dipropionate; Algestone Acetonide;
Alpha Amylase; Amcinafal; Amcinafide; Amfenac Sodium; Amiprilose Hydrochloride;
Anakinra;
Anirolac; Anitrazafen; Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen;
Benzydamine Hydrochloride; Bromelains; Broperamole; Budesonide; Carprofen;
Cicloprofen; Cintazone; Cliprofen; Clobetasol Propionate; Clobetasone Butyrate;
Clopirac; Cloticasone Propionate; Cormethasone Acetate; Cortodoxone;
Deflazacort;
Desonide; Desoximetasone; Dexamethasone Dipropionate; Diclofenac Potassium;
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 Diclofenac Sodium; Diflorasone Diacetate; Diflumidone Sodium; Diflunisal;
Difluprednate;
Diftalone, Dimethyl Sulfoxide; Drocinonide; Endrysone; Enlimomab; Enolicam Sodium;
Epirizole; Etodolac; Etofenamate; Felbinac; Fenamole; Fenbufen; Fenclofenac;
Fenclorac; Fendosal; Fenpipalone; Fentiazac; Flazalone; Fluazacort; Flufenamic Acid;
5 Flumizole; Flunisolide Acetate; Flunixin; Flunixin Meglumine; Fluocortin Butyl;
Fluorometholone Acetate; Fluquazone; Flurbiprofen; Fluretofen; Fluticasone Propionate;
Furaprofen; Furobufen; Halcinonide; Halobetasol Propionate; Halopredone Acetate;
Ibufenac; Ibuprofen; Ibuprofen Aluminum; Ibuprofen Piconol; llonidap;
Indomethacin;
Indomethacin Sodium; Indoprofen; Indoxole; Intrazole; Isoflupredone Acetate;
Isoxepac;
10 Isoxicam; Ketoprofen; Lofemizole Hydrochloride; Lomoxicam; Loteprednol Etabonate;
Meclofenamate Sodium; Meclofenamic Acid; Meclorisone Dibutyrate; Mefenamic Acid;
Mesalamine; Meseclazone; Methylprednisolone Suleptanate; Morniflumate;
Nabumetone; Naproxen; Naproxen Sodium; Naproxol; Nimazone; Olsalazine Sodium;
Orgotein; Orpanoxin; Oxaprozin; Oxyphenbutazone; Paranyline Hydrochloride;
Pentosan 15 Polysulfate Sodium; Phenbutazone Sodium Glycerate; Pirfenidone;
Piroxicam; Piroxicam Cinnamate; Piroxicam Olamine; Pirprofen; Prednazate; Prifelone; Prodolic Acid;
Proquazone; Proxazole; Proxazole Citrate; Rimexolone; Romazarit; Salcolex;
Salnacedin; Salsalate; Salycilates; Sanguinarium Chloride; Seclazone;
Sermetacin;
Sudoxicam; Sulindac; Suprofen; Talmetacin; Talniflumate; Talosalate;
Tebufelone;
20 Tenidap; Tenidap Sodium; Tenoxicam; Tesicam; Tesimide; Tetrydamine;
Tiopinac;
Tixocortol Pivalate; Tolmetin; Tolmetin Sodium; Triclonide; Triflumidate;
Zidometacin;
Glucocorticoids; Zomepirac Sodium, and combinations thereof.
[0280] In some examples, the additional agent administered is an antibiotic agent such as kanamycin, actinomycin D, doxorubicin, bleomycin, mithramycin, aminoglycosides, 25 ansamycins, carbacephems, carbapenems, cephalosporins, glycopeptides, lincosamides, macrolides, monobactams, penicillins, polypeptides, quinolones sulfonamides and/or tetracyclines.
[0281] In some examples, the additional agent administered is an antiviral agent such as a non-nucleoside reverse transcriptase inhibitor, nucleoside reverse transcriptase AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 inhibitor (e.g. nucleoside analogues), protease inhibitor and/or a nucleotide analogue reverse transcriptase inhibitor.
[0282] In some examples, the additional agent administered is an antifungal agent such as an imidazole, triazole, thiazole, allylamine, and/or echinocandin compound.
[0283] In some examples, the additional agent administered is an agent to treat diabetes. Such agents include those agents known in the art for treatment of diabetes and or for having anti-hyperglycemic activities, for example, inhibitors of dipeptidyl peptidase 4 (DPP-4) (e.g., Alogliptin, Linagliptin, Saxagliptin, Sitagliptin, Vildagliptin, and Berberine), biguanides (e.g., Metformin, Buformin and Phenfornnin), peroxisome proliferator-activated receptor (PPAR) modulators such as thiazolidinediones (TZDs) (e.g., Pioglitazone, Rivoglitazone, Rosiglitazone and Troglitazone), dual PPAR
agonists (e.g., Aleglitazar, Muraglitazar and Tesaglitazar), sulfonylureas (e.g., Acetohexamide, Carbutamide, Chlorpropamide, Gliclazide, Tolbutamide, Tolazamide, Glibenclamide (Glyburide), Glipizide, Gliquidone, Glyclopyramide, and Glimepiride), meglitinides ("glinides") (e.g., Nateglinide, Repaglinide and Mitiglinide), glucagon-like peptide- 1 (GLP-1) and analogs (e.g., Exendin-4, Exenatide, Liraglutide, Albiglutide), insulin and insulin analogs (e.g., Insulin lispro, Insulin aspart, lnsluin glulisine, Insulin glargine, Insulin detemir, Exubera and NPH insulin), alpha-glucosidase inhibitors (e.g., Acarbose, Miglitol and Voglibose), amylin analogs (e.g. Pramlintide), Sodium-dependent glucose cotransporter T2 (SGLT T2) inhibitors (e.g., Dapgliflozin, Remogliflozin and Sergliflozin) and others (e.g. Benfluorex and Tolrestat).
[0284] Those skilled in the art will appreciate that the compositions according to any aspect, embodiment or example described hereof may be administered as part of a combination therapy approach to the treatment of sepsis, SIRS or IRI or a disease or condition associated with sepsis, SIRS or IRI. In combination therapy, the respective agents may be administered simultaneously, or sequentially in any order. When administered sequentially, it may be preferred that the components be administered by the same route.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 [0285] In some examples where the two agents are applied separately, one would generally ensure that a significant time period did not expire between the time of each delivery, such that both agents would still be able to exert an advantageously combined effect. In such instances, it is contemplated that one would typically administer both modalities within about 12-24 hours of each other and, more preferably, within about 6-12 hours of each other, with a delay time of only about 12 hours being most preferred, in some situations, it may be desirable to extend the time for treatment significantly, however, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations. It also is conceivable that more than one administration of a drug will be desired.
[0286] When compositions of the invention, and a second active agent are administered in different compositions, routes of administration may be different. For example, the composition of the invention is administered by any appropriate route known in the art including, but not limited to oral or parenteral routes, including intravenous, IS intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, nasal, rectal, and topical (including buccal and sublingual) administration, and the second pharmaceutically active agent is administration by a different route, e.g. a route commonly used in the art for administration of said pharmaceutically active agent. In a non-limiting example, the compositions of the invention can be administered by injection, while the second active agent can be administrated orally.
5. Manufacture of a medicament [0287] In a sixth aspect of the invention, there is provided a use of a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a medical condition, ailment or disease involving NETs.
[0288] Prefereably in this aspect of the invention the selected compound is a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at the reducing terminus. More preferably, the small uncharged glycosidically AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 linked substituent improves the chemical stability of the polyanion, relative to the same polyanion that is sulfated at its reducing terminus. In particular, when the compound is mCBS it is a sulfated [3-0-methyl cellobioside disaccharide or a sodium salt of 6-0-Methyl Cellobioside Sulfate, viz mCBS.Na.
[0289] For example, in an embodiment of the sixth aspect of the invention, there is provided a use of a therapeutically or pharmaceutically effective amount of a polyanionic sulfated cellobioside or a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of sepsis or an IRI or a medical condition or disease associated with sepsis, SIRS or IRI in a subject. Preferably, the modified sulfated cellobioside is mCBS or more particularly is a pharmaceutically acceptable salt thereof such as mCBS.Na.
[0290] In one embodiment of such use, the medicament is for the treatment of sepsis or SIRS or of a medical condition or disease associated with sepsis or SIRS in a subject, wherein said treatment ameliorates or inhibits said sepsis or SIRS or said condition or disease associated with said sepsis or SIRS.
[0291] In another embodiment of such use, the medicament is for the treatment of an IRI or of a medical condition or disease associated with an IRI in a subject, wherein said treatment ameliorates or inhibits said the IRI or said condition or disease associated with said injury.
[0292] In yet another embodiment of such use, the medicament is used to neutralise NETs that (i) are cytotoxic towards the endothelium in a subject, or (ii) contribute to endothelial dysfunction in a subject, or (iii) initiate coagulation by activating platelets in a subject, or (iv) induce red cell fragility and resultant anaemia in a subject.
[0293] In yet another embodiment, the manufactured medicament may also include a therapeutic or pharmaceutically effective amount of a second active agent, compound or composition. According to this embodiment, the second active agent, compound or composition provides an adjunct therapy for treating a medical condition, ailment or AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 disease involving NETs. Desirably, the second active agent, compound or composition provides an adjunct therapy for the treatment of sepsis, SIRS or IRI or for a medical condition or disease associated with sepsis, SIRS or IRI. Preferably, the second active agent is selected from: one or more of anti-inflammatory agents, antibiotic agents, antiviral agents, antifungal agents and/or any other form of therapeutic or pharmaceutical compound that treats one or more conditions that the subject is afflicted with. More preferably, the second active agent, compound or composition comprises one or more of anti-inflammatory agents.
[0294] When the modified sulfated cellobioside compound is used in any of the methods of the invention the compound can be administered or formulated for administration to the subject in need thereof, in a single dose of formulation. In certain alternative embodiments, the modified sulfated cellobioside compound is administered, or formulated for administration to the subject in need thereof, as a multi-dose formulation.
[0295] Preferably, for administration to a subject, the therapeutic or pharmaceutical composition is provided as a pharmaceutically acceptable composition. When in this form, (1) the composition will be pharmaceutical formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents and/or excipients and (2) the modified sulfated cellobioside compound in the composition may be formulated in a neutral or salt form.
EXAMPLES
[0296] The present invention is described further in the following non-limiting example which is provided by way of illustration only, and should not be construed as limiting the generality of the disclosure of the description throughout this specification.
Example 1: Method for the preparation of mCBS-Na .. [0297] [3-0-methyl cellobioside is prepared as described by Jon K
Fairweather et al., 2004, Aust J. Chem., 57: 197-205.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 [0298] 13-0-methyl cellobioside sulfate (mCBS) and sodium 13-0-methyl cellobioside sulfate (mCBS.Na) compounds were prepared as described by Katrin C Probst and Hans Peter Wessel, 2001, J. Carbohydrate Chemistry, 20 (7 & 8): 549-560, the disclosure of which is hereby incorporated herein by reference in its entirety.
5 [0299] (3-0-methyl cellobioside sulfate (mCBS) was prepared according to the following schematic:
/
= \
x.
X =
X =
I
X =
X
X =
[0300] Step 1: To the mixture of a-D-cellobiose 1 (116 g, 338 mmol) and glacial acetic acid (1.6 L) was added acetyl bromide (300 mL, 500.0 g, 4065 mmol, 12.0 equiv) at room 10 temperature. The resulting creamy mixture was heated at 6000 for 45 - 55 mins until the reaction mixture turn to be a clear solution which indicate the completion of reaction.
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 [0301] Carefully pour the hot solution into the beaker (10 L) containing the cracked ice (4 kg). Stir the mixture until the white solid precipitated (-10 min). Add another portion of cold water (1 L) and keep on stirring for 10 min.
[0302] Filter with sinter funnel and washed the solid with cold water (700 mL
x 3). The resulting solid in the funnel was dissolved in DCM (1 L) and washed the funnel with DCM
(300 mL x2). The combined DCM layer was washed with brine (1 .5 L) and back extracted with DCM (0.5 L). The final DCM layer was dried over Na2SO4, filtered and concentrated under reduce pressure at < 35 C within 2 h to obtain the target bromide 2 (172.5 g, 74.3%
yield) which was directly used for the following glycosylation.
[0303] Step 2: To the mixture of per-O-acetylated cellobiosyl bromide 2 (171 g, 250 mmol), anhydrous DCM (800 mL), anhydrous Me0H (800 mL), activated 3A molecular sieves (70 g) was added silver carbonate (Ag2CO3, 75 g, 275 mmol, 1.1 equiv).
The resulting mixture was stirred in the absence of light for 16 h. The mixture was purified through a plug of silica and eluted with Et0Ac. The collected fractions were concentrated to give the crude product as the brown solid which was directly used for the next step.
The Rf of compound 3 = 0.28 (Et0Ac-Hexane, 1:1).
[0304] Step 3: To the mixture of the crude product obtained from step 2 and anhydrous Me0H (1 L) was added a small piece of Na (1.72 g, 0.3 equiv, 75 mmol) at room temperature. Shortly afterwards, a white solid began to precipitate from solution. The resulting mixture was stirred overnight in order to ensure the completion of de-acetylation.
The final suspension was filtered and washed with Me0H (300 mL x 2). The white solid was collected and dried under vacuum for overnight to obtain the final cellobioside 4 (72.5 g, 81.4% over 2 steps).
. =
, .
=
5. = =
=
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 Synthetic and purification procedure for step 4:
[0305] Step 4 The mixture of compound 4 (84.0 g, 236 mmol), S03.TMA (367.4 g, 2.64 mol, 11.2 equiv), anhydrous DMF (3140 mL) and anhydrous DOE (767 mL) was degassed under Ar for three times and heated at 80-90 C for 2 h. (Reaction monitoring:
After heating for 10 min, the creamy mixture turned to be a clear solution. After 30 min, the solution became cloudy again. After 50 min, the aggregated solid was observed on the surface of flask.) Upon cooling, the resulting mixture was moved to the cold room (-5 C) and settled overnight which allows the solid to completely aggregate from the solvent.
The complete conversion from compound 4 into 5 was confirmed with 1H-NMR.
Decant the solution into the drain. The crude solid was filtered and washed with DCM
for a couple of times. The resulting solid was dissolved in de-ionized water and directly subjected to ion-exchange column [Na form of DOWEX 50Wx8: 3 kg of resin (H+ form) was pre-packed in glass gravity column, regenerated by elution of 1M NaOH (-6 L) and neutralized with de-ionized water (-12 L)]. The collected fractions were concentrated to yield the final sulfated cellobioside 6(232.1 g, 92.0%) as the glassy solid.
Examples 2 to 6: Comparison of CBS, mCBS and MTS
[0306] In the following studies, the inventors examined 3 SPAs, namely cellobiose per-0-sulfate (CBS), methyl f3-cellobioside per-0-sulfate (mCBS) and maltotriose per-0-sulfate (MTS) (structures in Figure 1). The methodologies used in Examples 2 to 6 are set out below.
Method and materials for the following examples (2 ¨ 6) [0307] Heparin (porcine mucosa - PM) was purchased from Sigma-Aldrich.
[0308] Human subjects. All human-related research was approved by the ACT
Health Human Research Ethics Committee. Healthy adult donors were used as a source of erythrocytes and platelets for in vitro studies. Consenting patients admitted to The Canberra Hospital Intensive Care Unit with an APACHE II mortality score (Knaus, W.
A., Draper, E. A., Wagner, D. P. & Zimmerman, J. E. APACHE II: a severity of disease AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 classification system. Crit care med 13, 818-829 (1985)) on arrival in the ICU
and a diagnosis of sepsis were included in our study.
[0309] Sepsis was diagnosed based upon the following criteria (Mayr, F. B., Yende, S.
& Angus, D. C. Epidemiology of severe sepsis. Virulence 5, 4-11 (2014); and Bone, R. C.
et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101, 1644-(1992)):
a. At least two of the following:
i. Tachypnea > 24 bpm, or blood gas P002 < 32 mm Hg ii. White blood cells count (WCC) either <4,000 cell/mm3 or >12,000 cells/mm3 iii. Heart rate (HR) > 100 bpm iv. Temperature (fever) > 38.0 C or (hypothermia) < 36.0 C.
IS b.
No alternative cause for Systemic Inflammatory Response Syndrome (SIRS) identified c. Evidence of sepsis including positive blood culture, signs of pneumonia on chest x-ray or other imaging d. Evidence of end-organ dysfunction: renal failure, liver dysfunction, changes in Glasgow Coma Score (not attributable to other causes) or raised serum lactate.
e. Refractory hypotension requiring inotropic support.
[0310] Animals. All animal experiments were approved by the Australian National University Animal Experimentation Ethics Committee. Pathogen free male and female 057BL/6 mice (6-8 weeks of age), female BALB/c mice (5-6 weeks of age) and male Wistar rats (weighing between 250-350g) were obtained from the Australian Phenomics Facility at the Australian National University.
[0311]
Cell line and cell culture conditions. Human microvascular endothelial cells-1 (HMEC-1), carrying the type 0 blood group and thus not reactive with anti-blood group AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 antibodies in human sera, were supplied by ATCC and were cultured in MCDB 131 medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 IU m1-1 penicillin, 100 pg m1-1 streptomycin, 10 ng m1-1 EGF
and 1 pg ml -1 hydrocortisone. The cells were incubated in 5% CO2 and ambient 02 at 37 C
and were repeatedly tested for mycoplasma using a MycoAlert Assay kit (Lonza).
[0312] Histone-mediated cytotoxicity assays. To determine the cytotoxicity of calf thymus histones (Sigma-Aldrich), various concentrations of histones (100-800 pg m1-1) were added to suspensions of HMEC-1 or HUVEC (1 x 106 m1-1) in 96 well plates and incubated for 1 h at 37 C. Cells were then incubated for 5 min at 37 C with propidium iodide (PI; 2.5 pg m1-1) (ThermoFisher Scientific), to detect dead cells, and Calcein-AM
(0.04 pM) (ThermoFisher Scientific), to detect viable cells, placed on ice and the percentage of dead and viable cells determined by flow cytometry using gating strategies.
In inhibition assays, HMEC-1 were incubated with histones (400 pg m1-1) for 1 h at 37 C
in the presence of different concentrations of compounds (12.5-400 pg m1-1) prior to the IS .. addition of PI and Calcein-AM. HMEC-1 cytotoxicity at each compound concentration was then determined based on the formula:
Cytotoxicity (%) = Dead (compound & histones) - Dead (cells alone) x 100 Dead (histones alone) - Dead (cells alone) and the 1050 value for each polyanion then determined based on the line of best fit (nonlinear regression analysis) using Prism Software (Graphpad Software). In all assays MTS (I050 30 pg m1-1) was included as a standard to compensate for experimental variation, with data being adjusted in each assay to MTS having an I050 of 30 pg m1-1.
[0313] Lipid bilayer assays. Artificial lipid bilayers, prepared as previously described (Rebbeck, R. T. etal. The beta(1a) subunit of the skeletal DHPR binds to skeletal RyR1 and activates the channel via its 35-residue C-terminal tail. Biophys J 100, (2011).), separated symmetrical 150 mM or 250 mM KCI (pH -5.5) solutions.
Histones (1 pM, 15.2 pg m1-1) were added to bilayers alone or after 0.5-3 h incubation with 10 pM
CBS (3.5 pg m1-1) or 10 pM MTS (5.1 pg m1-1) at -20 C. Current was recorded continuously after histone addition until the bilayers broke or the experiment was AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 terminated.
[0314] Calcium flux studies in endothelial cells. HMEC-1 (2 x 107 m1-1) in RPMI-1640 medium were incubated with Indo-1 AM (5 pM) (ThermoFisher) (Tellam, R. L.
&
Parish, C. R. The effect of sulfated polysaccharides on the free intracellular calcium ion 5 .. concentration of lymphocytes. Biochim Biophys Acta 930, 55-64 (1987); and Weston, S.
A., Tellam, R. L. & Parish, C. R. Dextran sulfate induces changes in the free intracellular calcium ion concentration of a subpopulation of immature thymocytes. Immunol Cell Biol 69, 369-376 (1991)) at 37 C for 60 min. After 3 washes with RPMI-1640 medium supplemented with 5% FCS the cells were resuspended at 4 x 106 m1-1 in ice-chilled 10 HEPES-buffered saline (NaCl 8 g L, KCI 0.4 g L, CaCl2 0.2 g L, MgC12.6H20 0.2 g D-glucose 1.8 g 1-1, pH 7.4) supplemented with 10 mM HEPES. The cell suspension was kept on ice and used within 3 h. Intracellular Ca2+ flux was monitored using flow cytometry.
The cells were pre-equilibrated and maintained at 37 C during analysis using an external sheath connected to a heated water bath. After the exclusion of cellular debris and 15 clumped cells (on the basis of FSC/SSC light scattering) the basal Ca2+
level was monitored for 2 min before histone addition in the presence/absence of novel compounds.
Ca2+ levels were measured at 1, 3 and 9 min post-histone addition with a constant flow rate (-300 events/sec). Ca2+ flux was determined as an increase in the ratio of geometric mean fluorescence intensity (GMFI) of Ca24"-bound over Ca2+-unbound lndo-1.
20 [0315] In vitro erythrocyte microscopy, aggregation, fragility and deformability assays. Histone-mediated aggregation of human erythrocytes and its inhibition by various compounds was detected by flow cytometry, based on either forward and side scatter parameters or erythrocyte auto-fluorescence, as reported by the inventors previously (Kordbacheh, F., O'Meara, C. H., Coupland, L. A., Lelliott, P. M. &
Parish, C.
25 .. R. Extracellular histones induce erythrocyte fragility and anemia. Blood 130, 2884-2888 (2017).) and scanning electron microscopy as described earlier (Yabas, M. et al. Mice deficient in the putative phospholipid flippase ATP11C exhibit altered erythrocyte shape, anemia, and reduced erythrocyte life span. J Biol Chem 289, 19531-19537 (2014)).
Similarly, erythrocyte fragility induced by histones, in the presence or absence of 30 inhibitors, was quantified using a sheer stress assay that we developed recently AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 (Kordbacheh, F., O'Meara, C. H., Coupland, L. A., Lelliott, P. M. & Parish, C.
R.
Extracellular histones induce erythrocyte fragility and anemia. Blood 130, (2017)). Finally, the reduced deformability of erythrocytes in the presence of histones and the effect of inhibitors on this process was assessed by measuring the passage of erythrocytes through an artificial human spleen (Kordbacheh, F., O'Meara, C.
H., Coupland, L. A., Lelliott, P. M. & Parish, C. R. Extracellular histones induce erythrocyte fragility and anemia. Blood 130, 2884-2888 (2017); and Deplaine, G. etal. The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro. Blood 117, e88-95 (2011)).
[0316] In vitro platelet aggregation and degranulation assays. For aggregation studies platelets were isolated from human whole blood collected into Na-citrate vacutainers through 2-step centrifugation at room temperature (200xg for 20 min then the platelet-rich plasma 800xg for 15 min), the platelet pellet resuspended in Hank's balanced salt solution containing calcium and magnesium and histones added and incubated in the IS presence/absence of compounds at the concentrations of each as indicated. Samples were assessed for degree of platelet aggregation after 15 min exposure to histones by flow cytometry using the characteristic log FSC versus log SSC identification of platelets, with increases in the geometric mean of log FSC indicative of platelet aggregation.
[0317] For the platelet activation assay, whole blood collected in Na-citrate vacutainers was monitored for platelet degranulation using the luminescence mode on the Chrono-Log Model 700 with Chrono-Lume reagent (Chrono-Log Corp). Saline (300 pl) was added to pre-warmed blood (420 pl) with a stirrer bar in-situ. Chromo-Lume reagent (100 pl) was then added and incubated for 2 min before histones compounds diluted in water were added in a total volume of 180 pl at the concentrations indicated. Results expressed as ATP release calculated as a percentage of the histone + saline control.
[0318] In-vivo histone toxicity assays. BALB/c female mice (5-6 weeks of age), that are more prone to histone-induced anemia and easier to inject i.v. at this young age than C57BU6 mice, were injected i.p. with test compounds at concentrations indicated 10 min prior to i.v. injection of histones (50 mg kg-1) in phosphate buffered saline.
Retro-orbital AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 bleeds were performed with glass Pasteur pipettes 10 min after histone injection and collected blood added to acid citrate dextrose (ACD), the 10 min blood sample being subjected to hematologic analyses for platelet and erythrocyte content using an AD VIA
2120i Hematology Analyzer. Spleens were also harvested at 10 min post-histone injection and splenic hemoglobin content quantified using a hemoglobin assay kit (Sigma-Aldrich).
In the case of 4 h blood samples, male 057/BL/6 mice (6-8 weeks of age) were injected with test compounds and histones as above and plasma isolated and stored frozen for subsequent biochemical testing, with markers for liver (alanine aminotransferase, ALT), kidney (creatinine, Crea) and general tissue (lactate dehydrogenase, LDH) damage being determined by the Department of Pathology, The Canberra Hospital.
[0319] Murine deep vein thrombosis (DVT) model. The procedure used is largely as previously described (Brill, A. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 10, 136-144 (2012)). Briefly, 8 week old male C57BL/6 mice were anaesthetized, a laparotomy incision made, the intestines exteriorized and then, after gentle separation from the abdominal aorta, the inferior vena cava (IVC) immediately below the renal veins was ligated to ¨10% patency and all associated IVC tributaries were ligated. The peritoneum and skin were closed following which all mice received an i.v. injection of histones via the tail vein (10 mg kg-1) or an equivalent volume of saline followed 5 min later by an i.v. injection of test compounds (50 mg kg-1) or saline. Mice were monitored for 48 h after which they were re-anesthetized, re-opened and any thrombi that had developed distal to the IVC stenosis were removed for analysis. Sham operated control animals received laparotomy and 90%
ligation of the IVC, however the ligation was removed immediately after occlusion of the IVC.
[0320] Rat caecal ligation and puncture (CLP) assay for sepsis. The CLP assay was performed in male Wistar rats as previously described (Hubbard, W. J. et al. Cecal ligation and puncture. Shock 24 Suppl 1, 52-57 (2005)). Test compounds (50 mg kg-1) dissolved in saline or an equivalent volume of saline only (Control cohort) were administered i.p. 5 min pre-CLP and 5, 10 and 15 h post-op until cessation of the experiment at 20 h. Sham-CLP rats underwent the same procedure, however, the caecum was not ligated or punctured and these rats received saline at the same times as AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 above. At the conclusion of the experimental time period (20 h) or when morbidity required ethical euthanasia, the rats were anaesthetized and blood was collected via cardiac puncture into EDTA for subsequent analysis of liver (ALT) and kidney (creatinine) function by the Department of Pathology, The Canberra Hospital. The propensity for clots to form within the blood samples of the saline treated control CLP animals (despite the presence of EDTA) prevented successful analysis of plasma samples from all animals.
[0321] Rat cardiac ischemia reperfusion injury model. The method used is based on a combination of previously published procedures (Takada, Y., Hashimoto, M., Kasahara, J., Aihara, K. & Fukunaga, K. Cytoprotective effect of sodium orthovanadate on ischemia/reperfusion-induced injury in the rat heart involves Akt activation and inhibition of fodrin breakdown and apoptosis. J Pharmacol Exp Ther 311, 1249-(2004); and Hale, S. L., Dae, M. W. & Kloner, R. A. Hypothermia during reperfusion limits 'no-reflow' injury in a rabbit model of acute myocardial infarction.
Cardiovasc Res 59, 715-722 (2003)). Male Wistar rats were anaesthetized with isofluorane, intubated via IS tracheostomy and ventilated with a tidal volume of 1 ml 150 g-1 and a respiratory rate of 65 breaths min-1. Supplemental oxygen was delivered at a Fi02 of -30%. A left hemi-thoracotomy was performed to enable visualization of the left ventricle. The left coronary arterial plexus (LCA) was occluded using an atraumatic snare for 30 min prior to reperfusion for 30 min. lschemia was confirmed by myocardial hyperemia. The test compounds (30 mg kg-1) or an equivalent volume (200 pl) of saline were injected into the lumen of the left ventricle (confirmed with aspiration) 5 min prior to the release of the snare for the reperfusion phase.
[0322] At the conclusion of reperfusion (30 min), Thioflavin S (1 ml 200 g-1 of body weight) was slowly injected into the lumen of the left ventricle, to define the territory of microvascular obstruction (MVO) within the ischemic zone (IZ). The IZ
territory was determined by the re-occlusion of the atraumatic snare and infusion of blue microspheres into the left ventricle (Unisperse Blue, BASF), distributed within solutions via ultrasonication using a CD-6800 (Unisonics) sonicator. The heart was then excised from the thorax, rinsed in isotonic saline and 2 mm sections were cut distal to the atraumatic snare at right angles to the interventricular line. This method produced 4 myocardial AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 sections that were weighed and photographed (Sony Handycam, Zeiss 60x optical zoom) under ultraviolet light (territory of MVO) and bright light (IZ territory), before being incubated in tetrazolium chloride (TTC) to determine the region of necrotic myocardium.
Planimetry (Image J, Freeware) was used to quantify the areas of the IZ, MVO
and necrosis.
[0323] Rat ischemia reperfusion tissue flap model. The procedure employed is largely based on a previously described method (Bone, R. C. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101, 1644-1655 (1992)).
Briefly, male Wistar rats were anaesthetized, locally depilated and a 3 cm by 6 cm fasciocutaneous flap was excised leaving the vascular pedicle intact. The inferior epigastric artery was clamped, a fine rubber sheet was placed under the flap preventing oxygen diffusion from the tissues below and the flap was re-sutured back into place. The clamp was removed IS 10 h post-application permitting returned blood flow to the flap. Test compounds (50 mg kg-1) or saline were administered i.p. 5 min prior to clamp application and 5 min following its removal. The rats were monitored for a total experimental period of 72 h during which rats received additional compound or saline i.p. at 24 and 48 h post-op. The 'Control No Clamp' rats had the tissue flap excised and rubber placed underneath prior to re-suturing, however, the vessel was not clamped and they received saline at the same time points as the other rats. At the end of the experimental period the viability of the flaps was determined by the percentage of black necrotic or reddened areas versus pink viable areas. Despite the application of Elizabethan collars and the use of analgesia as a settling agent, a small number of rats had to be prematurely euthanized when they repeatedly auto-cannibalized their flaps.
[0324] Quantification of DNA in patient sera. Blood from consenting patients with an APACHE II score >12 upon arrival at ICU was collected from venous access lines into a serum-separator tube, the tubes centrifuged at 2300xg for 10 min and the serum harvested and stored at -80 C. To quantify DNA content serum from septic patients (5 pl) was incubated with 95 pl of 5 pM Sytox Green at 37 C for 10 min in a 96-well flat AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 bottom culture plate. Fluorescence intensity was then measured in a fluorescence plate reader (Tecan Infinite M200 Pro) with excitation set at 504 nm and emission at 523 nm.
[0325] Detection and analysis of cytotoxicity of septic patient sera for endothelial cells. To measure the cytotoxic activity of septic patients sera for endothelial cells in-vitro, HMEC-1 were seeded into 96-well plates at 2.5 x i0 well-1 in medium and grown at 37 C
in 5% CO2 for 48 h prior to the addition of 50 pl of patient serum in the presence/absence of DNase I (10 pg m1-1), anti-human histone 3 and histone 4 rabbit pAbs (200 pg m1-1) (BioVision), or test compounds (200 pg ml-1) and incubated for 3 h. 3H-thymidine (0.5 pCi, MP Biomedical) was then added to each culture well in 20 pl of HMEC-1 medium 10 and incubated for a further 24 h. At the conclusion of the incubation period plates were subjected to 3 freeze/thaw cycles (-70 C for 30 min, then 37 0.5 C for 30 min) prior to harvesting and measurement of 3H-thymidine incorporation. Using a Filtermate harvester (Packard Bioscience), cell cultures were harvested onto glass fiber filters (EasyTabTm-C Self Aligning Filters; Packard Bioscience). Filters were dried at 80 C and 15 placed in Omnifilter plates (Perkin Elmer) then 20 pl of Microscint-O
scintillation fluid (Perkin Elmer) was added to each well and the plate sealed with TopSeal-A
adhesive film (Perkin Elmer). 3H-thymidine incorporation was measured using a TopCount NXTTm Microplate Scintillation and Luminescence Counter (Packard Bioscience).
Results expressed as a percentage of the proliferation of HMEC-1 not exposed to patient sera.
20 [0326] Statistical analysis. Prism software (Graphpad Software) was used to perform statistical tests and to generate graphs, with details of the test used included in Figure legends.
In-vitro evidence of the biological effects of mCBS
[0327] The following Examples 2 to 6 provide in vitro evidence of the biological effect 25 of mCBS in neutralising free histones and NETs.
[0328] Example 2: mCBS protects endothelial cells from histone toxicity and erythrocytes from histone-induced fragility and aggregation [0329] Each of CBS, mCBS and MTS (collectively called Small Polyanions or SPAs) AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 have histone-inhibitory activity similar to heparin, unlike sulfated monosaccharides that are much less active, when histone cytotoxicity for endothelial cells (Figure 2a) or induction of erythrocyte (RBC) fragility (Figure 2b) was measured.
[0330] This Example investigates whether mCBS and MTS promote erythrocyte aggregation and reduce erythrocyte deformability. Based on flow cytometry FSC
and SSC, histones very efficiently aggregate erythrocytes, this effect being completely inhibited by mCBS (Figure. 3a), a result confirmed by scanning EM (Figure.
3b). The inventors also used erythrocyte auto-fluorescence to quantify the number of erythrocytes present in histone-induced aggregates. At high histone concentrations (400 pg m1-1) there were -35 erythrocytes/aggregate, but mCBS and MTS prevented aggregation in a concentration dependent manner, with MTS being -2-fold more effective than mCBS
(Figure. 3c). Finally, erythrocytes exposed to histone concentrations that do not induce erythrocyte aggregation (<50 pg m1-1) (Figure. 3d) showed significantly reduced passage through an artificial spleen, this assay measuring erythrocyte deformability/rigidity (Deplaine, G. etal. The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro. Blood 117, e88-95 (2011)). The addition of mCBS and MTS, however, totally restored the ability of erythrocytes to passage through an artificial spleen (Figure. 3d), indicating that SPAs, as well as protecting erythrocytes from histone-mediated aggregation and fragility, prevent histone-induced rigidity.
Example 3: SPAs inhibit platelet activation by histones [0331] Histones are known to induce platelet activation thus, to investigate the capacity of SPAs to inhibit this process, isolated, washed human platelets were incubated with histones and platelet aggregation measured by flow cytometry. Additionally, ATP release, due to platelet degranulation, was measured following exposure of whole blood to histones. Both platelet aggregation and degranulation were histone-concentration dependent (Figure. 4a, c), the difference in histone sensitivity of platelets between the two assays being attributed to the presence of plasma proteins and erythrocytes in the ATP release assay that also bind histones. Histone-induced platelet aggregation was completely inhibited by CBS, mCBS and MTS, with MTS being the most active (Figure.
AMENDED SHEET
IPEA/AU
PCT/AU2019: 050156 Received 2402,2021 4b). Unsulfated CB, included as a negative control, was non-inhibitory (Figure. 4b).
Similar results were obtained with histone-induced ATP release (Figure. 4d).
Thus, CBS, mCBS and MTS are effective in inhibiting the platelet-activating properties of histones.
Example 4: SPAs prevent lipid bilayer disruption [0332] We next investigated how histones mediate their cytotoxicity and, consequently, how SPAs protect cells from histone-mediated damage. Histones are known to interact with and damage lipid bilayers (Kleine, T. J., Lewis, P. N. & Lewis, S. A.
Histone-induced damage of a mammalian epithelium: the role of protein and membrane structure.
Am J
Physiol 273, 01925-1936 (1997)) and act as cell penetrating proteins (Rosenbluh, J. et al. Translocation of histone proteins across lipid bilayers and Mycoplasma membranes. J
Mol Biol 345, 387-400 (2005)). Thus, we investigated whether histones mediate their cytotoxicity by directly disrupting lipid bilayers. To examine this possibility artificial lipid bilayers were prepared and their susceptibility to histone rupture detected by changes in current across the bilayers. Lipid bilayers have a finite lifetime, normally ¨30 to 120 min (Rebbeck, R. T. etal. The beta(1a) subunit of the skeletal DHPR binds to skeletal RyR1 and activates the channel via its 35-residue C-terminal tail. Biophys J 100, (2011)). In inventors experiments, control lipid bilayers containing ryanodine receptor 1 (RyR1) ion channel protein had an average lifetime of 46 4 min, addition of histones (1 .IM) markedly reducing the lifetime to 5.7 1.2 min (Fig. 3a). In fact, 13/47 bilayers (28%) broke within 0.3-0.5 min of histone addition whereas only 2/125 control bilayers (1.6%) ruptured in the same time period, with higher histone concentrations (50 OA) resulting in rapid rupture of most bilayers (not shown). Bilayers were less prone to rupture by histones when CBS or MTS was present, the average bilayer lifetime increasing significantly to 18 4 min and 36 5 min for CBS and MTS, respectively (Figure.
5a).
Furthermore, bilayer lifetimes with MTS were not significantly different from the control lifetimes. Similarly, compared with histones alone (28%), the incidence of rapid bilayer rupture decreased to 3/52 bilayers (5.8%) for CBS and 1/40 bilayers (2.5%) for MTS.
[0333] Earlier studies demonstrated that histones can induce non-selective Ca2+
channels in cells and plasma membrane depolarisation. These findings further support AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 the concept that histones directly interact with cell surface phospholipids and disrupt membrane integrity. To investigate whether CBS, mCBS and MTS protect cells against histone-induced Ca2+ flux, HMEC-1 were loaded with the Ca2+ sensitive dye, Indo-1, challenged with histones in the presence or absence of CBS or MTS, and Ca2+
uptake measured by flow cytometry (Figure. 5b). Histones induced an over 8-fold increase in the population of cells exhibiting high intracellular Ca2+ levels, this response plateauing 1 to 3 min after histone addition. The presence of MTS totally ablated the Ca2+
response and CBS substantially inhibited the response (Figure. 5c). Collectively inventors findings indicate that histones damage cell membranes by directly disrupting the lipid bilayer of .. cells, with CBS, mCBS and MTS SPAs neutralising this undesirable property of histones.
Example 5: Effect of CBS, mCBS and MTS on in vivo histone-associated pathologies [0334] The Inventors next assessed the ability of the CBS, mCBS and MTS to inhibit histone-mediated pathologies in vivo. Injection of histones intravenously into mice results in a sepsis-like syndrome involving liver damage, generalised tissue injury and kidney failure, as measured by circulating ALT, LDH and creatinine levels.
Administration of CBS, mCBS and MTS protected animals from each of these tissue-specific pathologies in a concentration-dependent manner, with MTS being the most potent, CBS and mCBS
being equally active and unsulfated CB being inactive (Figure. 6a). Systemic histones also induce thrombocytopenia and anaemia that was prevented by mCBS and MTS
treatment (Figure. 6b). To examine whether CBS, mCBS and MTS influence the localised vascular effects of histones, a histone-mediated model of DVT (Brill, A. et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 117, 1400-1407(2011)) was established that revealed this to be almost totally inhibited by both CBS and MTS (Figure. 6c), consistent with both systemic and localised pathologies mediated by free histones being amenable to inhibition by CBS, mCBS and MTS.
[0335] The inventors next examined the efficacy of CBS, mCBS and MTS in a rat caecal ligation puncture (CLP) model of sepsis. There was no mortality in the CBS
AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 treatment group, an effect that was highly significant compared with PBS
controls, and only one death occurred in the MTS group, which approached significance (Figure. 7a).
Importantly, high ALT and creatinine levels detected in the untreated group, indicative of extensive liver and kidney damage, were not seen in the CBS treated animals but were only partially reduced in the MTS treatment group (Figure. 7b). This finding is somewhat paradoxical as in vitro and in vivo MTS was consistently a more potent neutraliser of DNA-free extracellular histones than mCBS/CBS.
[0336] To further investigate this paradox, CBS and MTS were tested for their efficacy in a rat cardiac ischemia reperfusion injury (IRI) model, previous studies having demonstrated that cardiac IRI is highly NET-dependent (Savchenko, A. S. et al.
VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice. Blood 123, 141-148, (2014);
and Ge, L.
et al. Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of DNase-based reperfusion strategy. Am J
Physiol Heart Circ Physiol 308, H500-509, (2015)). Remarkably, in this model MTS was totally ineffectual whereas CBS treatment significantly reduced the area of microvascular obstruction and myocardial necrosis in the ischemic zone by 50% (Figure. 7c).
This unexpected finding was largely confirmed in a rat skin flap IRI model where mCBS
consistently and significantly increased the viable area of the skin flap, whereas the results with MTS treatment were highly variable (Figure. 7d).
Example 6: Comparison of the ability of CBS, mCBS and MTS to inhibit NETs in sepsis patient sera [0337] Based on the in vivo efficacy data discussed above, we hypothesised that mCBS/CBS inhibit pathologies mediated by both DNA-free and NET-associated histones whereas MTS preferentially inhibits the damaging effects of DNA-free histones.
Support for this interpretation was obtained using sera from sepsis patients that, we discovered, inhibited HMEC-1 proliferation, as measured by 3H-thymidine incorporation (Figure. 8a, b), at a level that highly correlated with their APACHE II scores (Figure.
9a). This correlation was stronger than that observed between APACHE II scores and circulating AMENDED SHEET
IPEA/AU
PCT/AU2019:050156 Received 2402,2021 DNA levels (Figure. 9b). Further analysis of highly inhibitory serum from patient 5 revealed that this cytotoxic activity was DNase I sensitive and also was totally inhibited by polyclonal antibodies specific for histones 3 and 4 (Figure. 9c). Such data are consistent with NETs mediating the anti-proliferative effects of the septic patient's sera.
5 Finally, the inventors found that CBS significantly overrode the anti-proliferative activity of the 10 most inhibitory septic patient sera, whereas MIS did not (Figure.
9d). Thus, these results are entirely consistent with MIS being a free histone inhibitor and mCBS/CBS inhibiting pathologies mediated by both DNA-free and NET-associated histones.
AMENDED SHEET
IPEA/AU
Claims (20)
1. Use of a compound in the treatment or prevention of an NET mediated ailment, wherein the compound comprises a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
2. The use according to claim 1 wherein the NET mediated ailment is selected from the group comprising, but not limited to: (a) systemic inflammatory responses to infection such as, for example, sepsis (including bacteria, virus, fungal, parasite, prion induced sepsis), or to non-infectious inducers including surgery, trauma, haemorrhage, burns, acute pancreatitis and acute kidney injury. (b) hypoxia at the localised tissue /eve/ e.g. following blockage of an artery due to atherosclerosis, spontaneous rupture of a vessel, traumatic damage to a vessel and including cardiac and transplantation associated IRI; or at the whole body /eve/
following cessation of breathing e.g. due to drowning, gas exposure or cardiorespiratory arrest and includes ailments such as, for example, acute respiratory distress syndrome, chronic obstructive pulmonary disease and drug-mediated tissue injury;
(c) haemostasis or vascular obstruction such as, for example, cardiovascular disease or chronic cardiovascular disease, such as atherosclerosis, coagulation and thrombosis (e.g., deep vein thrombosis), (d) autoimmune disease states and inflammation disease states such as, for example, multiple sclerosis, hyper-inflammatory disease states, systemic lupus erythematosus, spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, ulcerative colitis, Crohn's disease, irritable bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) such as granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), characterized by destruction and inflammation of small vessels, familial Mediterranean fever, amyotrophic lateral sclerosis, Sjogren's syndrome, early arthritis, viral arthritis, psoriasis, age-related organ fibrosis, idiopathic pulmonary fibrosis, juvenile diabetes (Type l), diabetes mellitus (Type 2), antiphospholipid syndrome, and Received 24/02/2021 various central nervous system diseases such as Huntington's disease; or wherein the NET mediated ailment is sepsis, SIRS or IRI, or a medical condition or disease associated with sepsis, SIRS or IRI.
following cessation of breathing e.g. due to drowning, gas exposure or cardiorespiratory arrest and includes ailments such as, for example, acute respiratory distress syndrome, chronic obstructive pulmonary disease and drug-mediated tissue injury;
(c) haemostasis or vascular obstruction such as, for example, cardiovascular disease or chronic cardiovascular disease, such as atherosclerosis, coagulation and thrombosis (e.g., deep vein thrombosis), (d) autoimmune disease states and inflammation disease states such as, for example, multiple sclerosis, hyper-inflammatory disease states, systemic lupus erythematosus, spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, ulcerative colitis, Crohn's disease, irritable bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) such as granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), characterized by destruction and inflammation of small vessels, familial Mediterranean fever, amyotrophic lateral sclerosis, Sjogren's syndrome, early arthritis, viral arthritis, psoriasis, age-related organ fibrosis, idiopathic pulmonary fibrosis, juvenile diabetes (Type l), diabetes mellitus (Type 2), antiphospholipid syndrome, and Received 24/02/2021 various central nervous system diseases such as Huntington's disease; or wherein the NET mediated ailment is sepsis, SIRS or IRI, or a medical condition or disease associated with sepsis, SIRS or IRI.
3. The use according to claim 1 or claim 2 wherein, the sulfated cellobioside modified with a small uncharged substituent at its reducing terminus, has the general structure of:
R.3 wherein;
R1 is a small uncharged glycosidically linked substituent or R1 is 0- or S-(C1-6)alkyl or R1 is a methoxy or ethoxy group; and R2 to R8 are each independently selected from a small uncharged 0-linked substituent or a sulfate group, or R2 to R8 are each a sulfate group; or wherein the compound is sulfated p-O-methyl cellobioside disaccharide; or wherein the compound is sodium 13-0-methyl cellobioside sulfate.
R.3 wherein;
R1 is a small uncharged glycosidically linked substituent or R1 is 0- or S-(C1-6)alkyl or R1 is a methoxy or ethoxy group; and R2 to R8 are each independently selected from a small uncharged 0-linked substituent or a sulfate group, or R2 to R8 are each a sulfate group; or wherein the compound is sulfated p-O-methyl cellobioside disaccharide; or wherein the compound is sodium 13-0-methyl cellobioside sulfate.
4. A method of treating or preventing an NET mediated ailment, or of treating or preventing sepsis, SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI, said method comprising administering to the subject a therapeutically effective amount of a polyanionic sulfated cellobioside modified Received 24/02/2021 with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof.
5. The method according to claim 4 wherein the NET mediated ailment is selected from the group comprising, but not limited to: (a) systemic inflammatory responses to infection such as, for example, sepsis (including bacteria, virus, fungal, parasite, prion induced sepsis), or to non-infectious inducers including surgery, trauma, haemorrhage, burns, acute pancreatitis and acute kidney injury. (b) hypoxia at the localised tissue level e.g. following blockage of an artery due to atherosclerosis, spontaneous rupture of a vessel, traumatic damage to a vessel and including cardiac and transplantation associated IRI; or at the whole body /eve/
following cessation of breathing e.g. due to drowning, gas exposure or cardiorespiratory arrest and includes ailments such as, for example, acute respiratory distress syndrome, chronic obstructive pulmonary disease and drug-mediated tissue injury;
(c) haemostasis or vascular obstruction such as, for example, cardiovascular disease or chronic cardiovascular disease, such as atherosclerosis, coagulation and thrombosis (e.g., deep vein thrombosis), (d) autoimmune disease states and inflammation disease states such as, for example, multiple sclerosis, hyper-inflammatory disease states, systemic lupus erythematosus, spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, ulcerative colitis, Crohn's disease, irritable bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) such as granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), characterized by destruction and inflammation of small vessels, familial Mediterranean fever, amyotrophic lateral sclerosis, Sjogren's syndrome, early arthritis, viral arthritis, psoriasis, age-related organ fibrosis, idiopathic pulmonary fibrosis, juvenile diabetes (Type l), diabetes mellitus (Type 2), antiphospholipid syndrome, and various central nervous system diseases such as Huntington's disease; or wherein the sepsis, SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI is caused by and/or mediated by and/or involves and/or Received 24/02/2021 associated with NETs mediated pathology in the subject, and said method comprises administering to the subject a therapeutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof sufficient to treat or prevent said sepsis, SIRS or IRI condition or disease in the subject.
following cessation of breathing e.g. due to drowning, gas exposure or cardiorespiratory arrest and includes ailments such as, for example, acute respiratory distress syndrome, chronic obstructive pulmonary disease and drug-mediated tissue injury;
(c) haemostasis or vascular obstruction such as, for example, cardiovascular disease or chronic cardiovascular disease, such as atherosclerosis, coagulation and thrombosis (e.g., deep vein thrombosis), (d) autoimmune disease states and inflammation disease states such as, for example, multiple sclerosis, hyper-inflammatory disease states, systemic lupus erythematosus, spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, ulcerative colitis, Crohn's disease, irritable bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) such as granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), characterized by destruction and inflammation of small vessels, familial Mediterranean fever, amyotrophic lateral sclerosis, Sjogren's syndrome, early arthritis, viral arthritis, psoriasis, age-related organ fibrosis, idiopathic pulmonary fibrosis, juvenile diabetes (Type l), diabetes mellitus (Type 2), antiphospholipid syndrome, and various central nervous system diseases such as Huntington's disease; or wherein the sepsis, SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI is caused by and/or mediated by and/or involves and/or Received 24/02/2021 associated with NETs mediated pathology in the subject, and said method comprises administering to the subject a therapeutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof sufficient to treat or prevent said sepsis, SIRS or IRI condition or disease in the subject.
6. The method of claim 4 or claim 5, wherein;
a) the medical condition or disease is caused by and/or mediated by and/or involves and/or associated with a release of NETs in the subject; and/or;
b) the therapeutically effective amount of the modified polyanionic sulfated cellobioside is sufficient to reduce, minimize or inhibit NET mediated pathology in the subject; and/or c) the therapeutically effective amount is sufficient to reduce, minimize or inhibit NETs that are (i) are cytotoxic towards the endothelium in a subject, or (ii) contribute to endothelial dysfunction in a subject, or (iii) initiate coagulation by activating platelets in a subject, or (iv) induce red cell fragility and resultant anaemia in a subject.
a) the medical condition or disease is caused by and/or mediated by and/or involves and/or associated with a release of NETs in the subject; and/or;
b) the therapeutically effective amount of the modified polyanionic sulfated cellobioside is sufficient to reduce, minimize or inhibit NET mediated pathology in the subject; and/or c) the therapeutically effective amount is sufficient to reduce, minimize or inhibit NETs that are (i) are cytotoxic towards the endothelium in a subject, or (ii) contribute to endothelial dysfunction in a subject, or (iii) initiate coagulation by activating platelets in a subject, or (iv) induce red cell fragility and resultant anaemia in a subject.
7. The method of any one of claims 4 to 6, comprising;
a) administering the therapeutically affective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or the pharmaceutically acceptable salt thereof in a single dose; or b) administering the therapeutically affective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or the pharmaceutically acceptable salt thereof, in multiple doses; or Received 24/02/2021 c) administering to the subject, at the same time or concomitantly, a second active agent selected from the group consisting of: an anti-inflammatory agent, antibiotic agent, antiviral agent, antifungal agent or another form of medical intervention as an adjunct treatment for the medical condition or disease being treated; and/or wherein the second active agent comprises one or more anti-inflammatory agent(s).
a) administering the therapeutically affective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or the pharmaceutically acceptable salt thereof in a single dose; or b) administering the therapeutically affective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or the pharmaceutically acceptable salt thereof, in multiple doses; or Received 24/02/2021 c) administering to the subject, at the same time or concomitantly, a second active agent selected from the group consisting of: an anti-inflammatory agent, antibiotic agent, antiviral agent, antifungal agent or another form of medical intervention as an adjunct treatment for the medical condition or disease being treated; and/or wherein the second active agent comprises one or more anti-inflammatory agent(s).
8. The method of any one of claims 4 to 7, wherein said method comprises treating or preventing sepsis, SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI in a subject having or suspected of having, or at risk of developing sepsis, SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI.
9. Use of a) a therapeutic composition comprising at least a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof; or b) a pharmaceutical composition comprising at least a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, excipient and/or diluent;
in the treatment or prevention of an NET mediated ailment.
in the treatment or prevention of an NET mediated ailment.
10. Use of a therapeutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of sepsis, SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI in a subject.
Received 24/02/2021
Received 24/02/2021
11. The use of claim 10, wherein the sepsis , SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI is caused by and/or mediated by and/or involves and/or associated with;
a) NET mediated pathology in the subject; and/or b) a release of NETs in the subject; and/or c) a release of NETs following an inflammation or an inflammatory response in the subject.
a) NET mediated pathology in the subject; and/or b) a release of NETs in the subject; and/or c) a release of NETs following an inflammation or an inflammatory response in the subject.
12. The use of claim 10 or claim 11, wherein;
a) the NETs are cytotoxic towards endothelium in the subject and/or contribute to endothelium dysfunction in the subject; and/or b) the medicament reduces, minimizes or inhibits NET mediated pathology in the subject; and/or c) the medicament reduces, minimizes or inhibits NET mediated pathology towards the endothelium in the subject.
a) the NETs are cytotoxic towards endothelium in the subject and/or contribute to endothelium dysfunction in the subject; and/or b) the medicament reduces, minimizes or inhibits NET mediated pathology in the subject; and/or c) the medicament reduces, minimizes or inhibits NET mediated pathology towards the endothelium in the subject.
13. The use of any one of claims 10 to 12, wherein the medicament is;
a) formulated for single dose administration to the subject; or b) formulated for multi-dose administration to the subject; or c) formulated for administration to the subject at the same time or concomitantly, with a second active agent selected from the group consisting of: an anti-inflammatory agent, antibiotic agent, antiviral agent, antifungal agent or another form of medical intervention as an adjunct treatment for the sepsis, SIRS or IRI or the medical condition or disease associated with the sepsis, SIRS or IRI, or wherein the second active agent comprises one or more anti-inflammatory agent(s).
Received 24/02/2021
a) formulated for single dose administration to the subject; or b) formulated for multi-dose administration to the subject; or c) formulated for administration to the subject at the same time or concomitantly, with a second active agent selected from the group consisting of: an anti-inflammatory agent, antibiotic agent, antiviral agent, antifungal agent or another form of medical intervention as an adjunct treatment for the sepsis, SIRS or IRI or the medical condition or disease associated with the sepsis, SIRS or IRI, or wherein the second active agent comprises one or more anti-inflammatory agent(s).
Received 24/02/2021
14. The use of any one of claims 10 to 13, wherein the medicament is for treating or preventing sepsis, SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI in a subject having or suspected of having, or in a subject at risk of developing, sepsis, SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI.
15. Use of a therapeutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof in treatment or prevention of sepsis, SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI in a subject.
16. The use of claim 15, wherein the sepsis, SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI is caused by and/or mediated by and/or involves and/or is associated with;
a) NET mediated pathology in the subject; and/or b) a release of NETs in the subject; and/or c) a release of NETs following an inflammation or an inflammatory response in the subject;
optionally further wherein the NETs are (i) cytotoxic towards the endothelium in a subject, or (ii) contribute to endothelial dysfunction in a subject, or (iii) initiate coagulation by activating platelets in a subject, or (iv) induce red cell fragility and resultant anaemia in a subject.
a) NET mediated pathology in the subject; and/or b) a release of NETs in the subject; and/or c) a release of NETs following an inflammation or an inflammatory response in the subject;
optionally further wherein the NETs are (i) cytotoxic towards the endothelium in a subject, or (ii) contribute to endothelial dysfunction in a subject, or (iii) initiate coagulation by activating platelets in a subject, or (iv) induce red cell fragility and resultant anaemia in a subject.
17. The use of claim 15 or claim 16, wherein the therapeutically affective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or the pharmaceutically acceptable salt thereof is sufficient to reduce, minimize or inhibit NET mediated pathology in the subject, and/or wherein said use reduces, minimizes or inhibits NET mediated Received 24/02/2021 pathology in the subject, and/or wherein said use reduces, minimizes or inhibits NET mediated pathology towards the endothelium in the subject.
18. The use of any one of claims 15 to 17, wherein said use comprises;
a) use of a single dose of the therapeutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or the pharmaceutically acceptable salt thereof, in the treatment or prevention of the sepsis, SIRS or IRI or the medical condition or disease associated with the sepsis, SIRS or IRI in the subject; or b) use of multiple doses of the therapeutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or the pharmaceutically acceptable salt thereof, in the treatment or prevention of the sepsis, SIRS or IRI or the medical condition or disease associated with the sepsis, SIRS or IRI in the subject; or c) use of the therapeutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or the pharmaceutically acceptable salt thereof and an amount of a second active agent selected from the group consisting of: an anti-inflammatory agent, antibiotic agent, antiviral agent, antifungal agent or another form of medical intervention as an adjunct treatment for the sepsis, SIRS or IRI or the medical condition or disease associated with the sepsis, SIRS or IRI, or wherein the second active agent comprises one or more anti-inflammatory agent(s).
a) use of a single dose of the therapeutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or the pharmaceutically acceptable salt thereof, in the treatment or prevention of the sepsis, SIRS or IRI or the medical condition or disease associated with the sepsis, SIRS or IRI in the subject; or b) use of multiple doses of the therapeutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or the pharmaceutically acceptable salt thereof, in the treatment or prevention of the sepsis, SIRS or IRI or the medical condition or disease associated with the sepsis, SIRS or IRI in the subject; or c) use of the therapeutically effective amount of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or the pharmaceutically acceptable salt thereof and an amount of a second active agent selected from the group consisting of: an anti-inflammatory agent, antibiotic agent, antiviral agent, antifungal agent or another form of medical intervention as an adjunct treatment for the sepsis, SIRS or IRI or the medical condition or disease associated with the sepsis, SIRS or IRI, or wherein the second active agent comprises one or more anti-inflammatory agent(s).
19. The use of any one of claims 15 to 18, wherein said use comprises treating or preventing sepsis, SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI in a subject having or suspected of having or at risk of Received 24/02/2021 developing sepsis, SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI.
20. The use according to any one of claims 1 to 3, or 9 to 19, or the method according to any one of claims 4 to 8, wherein the treatment comprises ameliorating or inhibiting sepsis, SIRS or IRI or a medical condition or disease associated with sepsis, SIRS or IRI, or wherein the medical condition or disease associated with sepsis, SIRS or IRI is a non-septic, SIRS or IRI disease state.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/AU2019/050156 WO2020172698A1 (en) | 2019-02-25 | 2019-02-25 | Compounds for treating and preventing net associated complications |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3130405A1 true CA3130405A1 (en) | 2020-09-03 |
Family
ID=72238229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3130405A Pending CA3130405A1 (en) | 2019-02-25 | 2019-02-25 | Compounds for treating and preventing net associated complications |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220168327A1 (en) |
EP (1) | EP3930726A4 (en) |
JP (1) | JP2022530732A (en) |
KR (1) | KR20210132032A (en) |
CN (1) | CN113473992A (en) |
AU (1) | AU2019431212A1 (en) |
BR (1) | BR112021016812A2 (en) |
CA (1) | CA3130405A1 (en) |
EA (1) | EA202192345A1 (en) |
IL (1) | IL285828A (en) |
SG (1) | SG11202109032SA (en) |
WO (1) | WO2020172698A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022116981A1 (en) * | 2020-12-01 | 2022-06-09 | 远大医药(中国)有限公司 | Application of polyanionic cellobioside compound |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1060750B1 (en) * | 1993-03-29 | 2005-12-07 | Queen's University At Kingston | Propane-1,3-disulfonic acid and its pharmaceutically acceptable salts for treating amyloidosis |
CA2159649A1 (en) * | 1993-03-29 | 1994-10-13 | Queen's University At Kingston | Anticoagulant compounds |
JPH09183789A (en) * | 1995-10-31 | 1997-07-15 | Sanwa Kagaku Kenkyusho Co Ltd | New sulfated and phosphated sugar derivative, its production and use |
EP1699806A1 (en) * | 2003-12-23 | 2006-09-13 | Progen Industries Limited | Glycosaminoglycan (gag) mimetics |
CA2557989C (en) * | 2004-03-04 | 2013-04-23 | Progen Industries Limited | Sulfated oligosaccharide derivatives |
ES2710857T3 (en) * | 2010-12-01 | 2019-04-29 | Univ Australian National | Use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis |
JP7359396B2 (en) * | 2017-12-15 | 2023-10-11 | ジ・オーストラリアン・ナショナル・ユニヴァーシティ | Compounds for treating and preventing pathologies mediated by extracellular histones |
WO2022116981A1 (en) * | 2020-12-01 | 2022-06-09 | 远大医药(中国)有限公司 | Application of polyanionic cellobioside compound |
-
2019
- 2019-02-25 SG SG11202109032SA patent/SG11202109032SA/en unknown
- 2019-02-25 AU AU2019431212A patent/AU2019431212A1/en active Pending
- 2019-02-25 KR KR1020217025633A patent/KR20210132032A/en unknown
- 2019-02-25 EP EP19916556.4A patent/EP3930726A4/en not_active Withdrawn
- 2019-02-25 CA CA3130405A patent/CA3130405A1/en active Pending
- 2019-02-25 BR BR112021016812A patent/BR112021016812A2/en unknown
- 2019-02-25 CN CN201980092942.8A patent/CN113473992A/en active Pending
- 2019-02-25 EA EA202192345A patent/EA202192345A1/en unknown
- 2019-02-25 WO PCT/AU2019/050156 patent/WO2020172698A1/en unknown
- 2019-02-25 US US17/430,756 patent/US20220168327A1/en active Pending
- 2019-02-25 JP JP2021549884A patent/JP2022530732A/en active Pending
-
2021
- 2021-08-24 IL IL285828A patent/IL285828A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA202192345A1 (en) | 2021-12-06 |
EP3930726A4 (en) | 2022-10-05 |
CN113473992A (en) | 2021-10-01 |
AU2019431212A1 (en) | 2021-09-16 |
EP3930726A1 (en) | 2022-01-05 |
JP2022530732A (en) | 2022-07-01 |
BR112021016812A2 (en) | 2021-11-16 |
US20220168327A1 (en) | 2022-06-02 |
SG11202109032SA (en) | 2021-09-29 |
WO2020172698A1 (en) | 2020-09-03 |
KR20210132032A (en) | 2021-11-03 |
IL285828A (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230255992A1 (en) | Compounds for treating and preventing extracellular histone mediated pathologies | |
US20200055927A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
AU2008287419A1 (en) | Polymer therapy for the treatment of chronic microvascular diseases | |
US20220168327A1 (en) | Compounds for Treating and Preventing Net Associated Complications | |
EA010650B1 (en) | Tissue protective cytokines for the treatment and preservations of sepsis and the formation of adhesions | |
US5607916A (en) | Method and composition for the treatment of septic shock | |
JP2008505912A (en) | Direct activation method of ATIII in whole blood and plasma | |
EA047197B1 (en) | COMPOUNDS FOR TREATING AND PREVENTING COMPLICATIONS ASSOCIATED WITH NET | |
Wang et al. | Autophagy is involved in stellate ganglion block reversing posthemorrhagic shock mesenteric lymph-mediated vascular hyporeactivity | |
CN1455679A (en) | Use of melagatran for manufacture of medicament for treatment of ischemic disorders | |
US20230210942A1 (en) | Methods and compositions for modulating endothelial cell dysfunction | |
JP7505160B2 (en) | Pharmaceutical compositions for inhibiting inflammatory responses comprising hydroxyurea - Patent Application 20070123333 | |
JP2012532831A (en) | Glycyrrhizin as a restoring agent for the production of antimicrobial peptides | |
WO2023064847A1 (en) | Methods for treating a trauma patient | |
Frye | The Clinical Use of N-Acetylcysteine in Other Medical Disorders | |
Harman et al. | Drug-Induced Pemphigus |